

Inducing labour

Evidence tables for pharmacological and mechanical methods for induction of labour

NICE guideline CG70 (update)

Supplement 3

May 2021

Draft for consultation

This supplement was developed by the National Guideline Alliance which is a part of the Royal College of Obstetricians and Gynaecologists

Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© NICE 2021. All rights reserved. Subject to [Notice of rights](#)

ISBN:

Contents

Evidence tables	5
D1 – Participant and study characteristics	5
D2 – Risk of bias assessment for included studies	78
D3 - No vaginal delivery in 24 hours	105
D4 - Hyperstimulation with fetal heart rate changes	115
D5 - Caesarean birth	140
D6 - Perinatal mortality	201
D7 - Maternal morbidity (uterine rupture) and mortality	209
D8a - Maternal satisfaction – GRADED studies	215
D8b – Maternal satisfaction – Narrative studies	237
D9 - Instrumental birth	241
D10 - NICU admission	261
D11 - Epidural outcome data	279

1 Evidence tables

2

3 D1 – Participant and study characteristics

4

5 **Table 1: Participant and study characteristics**

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Aalami-Harandi 2013	Titrated (low dose) oral misoprostol solution	IV oxytocin				None	Mixed	Some ruptured*	All ≤6	All >37 weeks	All singleton	Hospital	NR
Abdelaziz 2018	Vaginal PGE ₂ (tablet)	Vaginal PGE ₂ pessary (slow release)				None	Mixed	NR	All ≤6	All >37 weeks	All singleton	Hospital	No industry funding
Abdul 2007	Vaginal misoprostol (≥50mcg)	IV oxytocin				None	Mixed	Some ruptured*	NR	Mixed	All singleton	Hospital	NR
Abedi-Asi 2007	Vaginal misoprostol (≥50mcg)	IV oxytocin				None	Mixed	All intact	All ≤6	NR	All singleton	Hospital	No industry funding
Abotorabi 2019	Placebo	Nitric oxide				None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	outpatient	NR

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Adair 1998	Vaginal misoprostol ($\geq 50\text{mcg}$)	Oral misoprostol tablet ($\geq 50\text{mcg}$)				None	Mixed	All intact	All ≤ 6	Mixed	All singleton	Hospital	NR
Adam 2005	Vaginal misoprostol ($\geq 50\text{mcg}$)	Oral misoprostol tablet ($\geq 50\text{mcg}$)				None	Mixed	NR	All ≤ 6	NR	All singleton	Hospital	NR
Adeniji 2005	Vaginal misoprostol ($\geq 50\text{mcg}$)	Foley catheter				None	Mixed	All intact	All ≤ 6	All >37 weeks	All singleton	Hospital	NR
Adeniyi 2014	Vaginal misoprostol ($< 50\text{mcg}$)	Vaginal misoprostol ($\geq 50\text{mcg}$)				None	NR	All intact	All ≤ 6	All >37 weeks	All singleton	Hospital	NR
Aduloju 2016	Vaginal misoprostol ($< 50\text{mcg}$)	Foley catheter				None	Mixed	All intact	All ≤ 6	All >37 weeks	All singleton	Hospital	No industry funding
Aduloju 2019	Oral misoprostol tablet ($< 50\text{mcg}$)	Titration (low dose) oral misoprostol solution				None	Mixed	All intact	All ≤ 6	All >37 weeks	All singleton	Hospital	No industry funding
Agarwal 2003	Intracervical PGE ₂	Vaginal misoprostol ($\geq 50\text{mcg}$)				None	Mixed	All intact	All > 6	Mixed	All singleton	Hospital	NR
Agarwal 2012	Placebo	Nitric oxide				None	Mixed	All intact	All ≤ 6	All ≥ 40 weeks	All singleton	Outpatient	No industry funding

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Agarwal 2014	Intracervical PGE ₂	Nitric oxide				None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	NR
Ajori 2013	Placebo	Acupuncture				None	Mixed	All intact	All ≤6	All ≥ 40 weeks	All singleton	Outpatient	NR
Akay 2012	Vaginal PGE ₂ pessary (slow release)	IV oxytocin				NR	Mixed	All intact	All ≤6	All ≥ 40 weeks	All singleton	Hospital	NR
Alcoseba-Lim 1992	No treatment	Membrane sweeping				NR	Mixed	All intact	Mixed	All >37 weeks	NR	Outpatient	Some industry
Allott 1993	No treatment	Membrane sweeping				NR	Mixed	All intact	Mixed	All ≥ 40 weeks	NR	Outpatient	NR
Al-Malt 1995	Placebo	Vaginal PGE ₂ (gel)				NR	NR	NR	All ≤6	All >37 weeks	All singleton	NR	NR
Al-Sebai 1993	Vaginal PGE ₂ (tablet)	Vaginal PGE ₂ (gel)				None	All nulliparous	NR	All ≤6	All >37 weeks	All singleton	NR	NR
Alsharnoubi 2015	Placebo	Acupuncture				None	All nulliparous	NR	NR	All ≥ 40 weeks	All singleton	Hospital	No industry funding
Al-Taani 2004	Vaginal PGE ₂ (tablet)	Foley catheter				None	All multiparous	All intact	All ≤6	All >37 weeks	All singleton	Hospital	NR
Anand 2012	Intracervical PGE ₂	Vaginal misoprost				None	Mixed	NR	All ≤6	All >37 weeks	All singleton	Hospital	NR

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
		ol (<50mcg)											
Andersen 2013	No treatment	Membrane sweeping	Acupuncture			NR	Mixed	All intact	NR	All ≥ 40 weeks	All singleton	Hospital	No industry funding
Asher 2009	No treatment	Placebo	Acupuncture			None	All nulliparous	All intact	NR	All >37 weeks	NR	Outpatient	No industry funding
Ashrafunnessa 1997	Intracervical PGE ₂	IV oxytocin				None	All nulliparous	All intact	All ≤6	All >37 weeks	All singleton	Hospital	No industry funding
Atad 1996	Vaginal PGE ₂ (tablet)	IV oxytocin	Double balloon/Cook's catheter			None	Mixed	All intact	All ≤6	Mixed	All singleton	Hospital	No industry funding
Ayaz 2010	Vaginal PGE ₂ (tablet)	Vaginal misoprostol (≥50mcg)				None	All nulliparous	All intact	All ≤6	All >37 weeks	All singleton	Hospital	NR
Azubuike 2015	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)				None	All nulliparous	All intact	All ≤6	All ≥ 40 weeks	All singleton	Hospital	NR
Bagratee 1990	Vaginal PGE ₂ (tablet)	Laminaria				None	Mixed	All intact	All ≤6	All >37 weeks	NR	Hospital	NR

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Bakos 1987	IV oxytocin	Amniotomy				NR	Mixed	All intact	Mixed	NR	NR	Hospital	NR
Balci 2010	Vaginal misoprostol (≥50mcg)	IV oxytocin				None	All multiparous	All intact	All ≤6	All >37 weeks	All singleton	Hospital	No industry funding
Balci 2011	Vaginal misoprostol (≥50mcg)	IV oxytocin				None	All nulliparous	All intact	All ≤6	All >37 weeks	All singleton	Hospital	No industry funding
Barda 2018	Vaginal PGE ₂ (tablet)	Foley catheter				None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	NR
Barkai 1994	No treatment	Placebo	Intracervical PGE ₂			None	Mixed	All intact	All ≤6	All ≥ 40 weeks	NR	Hospital	No industry funding
Bartha 2000	Intracervical PGE ₂	Oral misoprostol tablet (≥50mcg)				Some previous*	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	NR
Bartusevicius 2006	Vaginal misoprostol (<50mcg)	Buccal/sublingual misoprostol				None	Mixed	Some ruptured*	All ≤6	All >37 weeks	All singleton	Hospital	NR
Beigi 2003	Placebo	Oral misoprostol tablet (≥50mcg)				None	Mixed	Some ruptured*	All ≤6	All >37 weeks	All singleton	Hospital	NR

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Bell 1993	Placebo	Relaxin				None	Mixed	All intact	All >6	All ≥ 40 weeks	All singleton	Hospital	Some industry
Bennett 1998	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)				None	Mixed	All intact	Mixed	All >37 weeks	All singleton	Hospital	No industry funding
Berghella 1996	No treatment	Membrane sweeping				NR	Mixed	All intact	Mixed	All >37 weeks	All singleton	Outpatient	NR
Berkane 2005	Placebo	Mifepristone				Some previous*	Mixed	Some ruptured*	All ≤6	All >37 weeks	Mixed	NR	NR
Bernstein 1991	Placebo	Intracervical PGE ₂				None	Mixed	All intact	All ≤6	Mixed	NR	Hospital	Some industry
Biron-Shental 2004	Vaginal PGE ₂ (gel)	Double balloon/Cook's catheter				NR	NR	NR	All ≤6	All >37 weeks	All singleton	Hospital	NR
Bollapragada 2009	Placebo	Nitric oxide				None	All nulliparous	All intact	All ≤6	All >37 weeks	All singleton	Outpatient	No industry funding
Boulvain 1998	No treatment	Membrane sweeping				NR	Mixed	All intact	Mixed	All >37 weeks	All singleton	Outpatient	Some industry
Bounyasing 2000	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)				None	Mixed	All intact	NR	All >37 weeks	All singleton	Hospital	NR

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Bremme 1980	IV oxytocin plus amniotomy	Oral prostaglandins				NR	Mixed	NR	NR	All >37 weeks	NR	Hospital	No industry funding
Brennand 1997	Placebo	Relaxin				None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	Some industry
Buchanan 1984	Placebo	Vaginal PGE ₂ pessary (normal release)				None	Mixed	NR	All ≤6	Mixed	All singleton	Hospital	NR
Bullarbo 2007	Placebo	Nitric oxide				NR	Mixed	All intact	All ≤6	All ≥ 40 weeks	All singleton	Outpatient	NR
Buser 1997	Intracervical PGE ₂	Vaginal misoprostol (≥50mcg)				None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	NR
Buttino 1990	Placebo	Intracervical PGE ₂				NR	NR	NR	NR	All ≥ 40 weeks	NR	Outpatient	NR
Cahill 1988	Vaginal PGE ₂ (tablet)	Laminaria				None	All nulliparous	NR	All ≤6	All >37 weeks	NR	Hospital	NR
Caliskan 2005	Vaginal misoprostol (≥50mcg)	Buccal/sublingual misoprostol				None	Mixed	Some ruptured*	All ≤6	All >37 weeks	All singleton	Hospital	NR
Cammu 1998	No treatment	Membrane sweeping				None	All nulliparous	All intact	Mixed	All >37 weeks	All singleton	Outpatient	NR

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Campbell 1984	Placebo	Vaginal PGE ₂ pessary (normal release)				NR	Mixed	Some ruptured*	Mixed	Mixed	NR	Hospital	NR
Campos Perez 1991	Vaginal misoprostol (≥50mcg)	IV oxytocin				NR	Mixed	All intact	Mixed	All >37 weeks	All singleton	Hospital	NR
Cardozo 1986	No treatment	Vaginal PGE ₂ pessary (normal release)				NR	NR	All intact	Mixed	All ≥ 40 weeks	NR	Hospital	NR
Carlan 2001	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)				Some previous*	Mixed	NR	All ≤6	Mixed	All singleton	Hospital	NR
Carlan 2002	Vaginal misoprostol (≥50mcg)	Buccal/sublingual misoprostol				Some previous*	Mixed	NR	All ≤6	Mixed	All singleton	Hospital	NR
Castro 2014	No treatment	Sexual intercourse				None	Mixed	All intact	NR	All >37 weeks	All singleton	Outpatient	No industry funding
Cecatti 2000	Vaginal misoprostol (<50mcg)	IV oxytocin				NR	NR	All intact	All >6	All >37 weeks	NR	Hospital	NR
Chai 2018	Vaginal PGE ₂ pessary	Foley catheter				NR	NR	All intact	All ≤6	All >37 weeks	NR	Hospital	No industry funding

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
	(normal release)												
Chang 1997	Vaginal PGE ₂ (tablet)	Vaginal misoprostol (≥50mcg)				None	All nulliparous	All intact	All ≤6	All >37 weeks	All singleton	Hospital	No industry funding
Chanrachakul 2000a	Vaginal PGE ₂ (tablet)	Nitric oxide				None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	No industry funding
Chanrachakul 2000b	Vaginal PGE ₂ (tablet)	Nitric oxide				None	All nulliparous	NR	All ≤6	All >37 weeks	All singleton	Hospital	NR
Chanrachakul 2002	Vaginal misoprostol (≥50mcg)	Nitric oxide				NR	Mixed	NR	All ≤6	All >37 weeks	All singleton	Hospital	No industry funding
Chanrachakul 2003	No treatment	IV oxytocin plus amniotomy				None	Mixed	All intact	All >6	All ≥ 40 weeks	All singleton	Hospital	No industry funding
Chanrachakul 2010	Vaginal misoprostol (≥50mcg)	Buccal/sublingual misoprostol				NR	NR	NR	All ≤6	All >37 weeks	NR	Hospital	NR
Charoenkul 2000	Vaginal PGE ₂ (tablet)	Vaginal misoprostol (≥50mcg)				None	Mixed	NR	All ≤6	All >37 weeks	All singleton	Hospital	NR

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Chatterjee 1991	Placebo	Vaginal PGE ₂ (gel)				NR	Mixed	NR	All ≤6	Mixed	NR	Hospital	NR
Chavakula 2015	Vaginal misoprostol (<50mcg)	Foley catheter				None	Mixed	All intact	All ≤6	Mixed	All singleton	Hospital	No industry funding
Chayen 1986	IV oxytocin	Breast stimulation				NR	Mixed	NR	Mixed	NR	NR	Hospital	NR
Chen 2014	Vaginal PGE ₂ pessary (slow release)	IV oxytocin				NR	All nulliparous	All intact	All ≤6	All >37 weeks	All singleton	Hospital	No industry funding
Cheng 2008	Vaginal misoprostol (<50mcg)	Titrated (low dose) oral misoprostol solution				None	Mixed	Some ruptured*	All ≤6	Mixed	All singleton	Hospital	No industry funding
Chitrakar 2012	Intracervical PGE ₂	Vaginal misoprostol (<50mcg)				None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	NR
Chua 1988	Vaginal PGE ₂ (tablet)	IV oxytocin plus amniotomy				NR	Mixed	NR	Mixed	All >37 weeks	All singleton	Hospital	NR
Chua 1997	Intracervical PGE ₂	Laminaria				NR	Mixed	NR	All ≤6	All >37 weeks	All singleton	Hospital	NR

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Chuck 1995	Intracervical PGE ₂	Vaginal misoprostol (≥50mcg)				Some previous*	Mixed	Some ruptured*	Mixed	Mixed	All singleton	Hospital	NR
Chung 2003	Vaginal misoprostol (<50mcg)	Foley catheter				None	Mixed	All intact	All ≤6	Mixed	All singleton	Hospital	No industry funding
Chyu 1997	Vaginal PGE ₂ pessary (slow release)	Intracervical PGE ₂				NR	Mixed	Some ruptured*	Mixed	NR	NR	Hospital	NR
Clark 1998	Intracervical PGE ₂	Vaginal misoprostol (<50mcg)				None	Mixed	NR	All ≤6	NR	All singleton	Hospital	NR
Colon 2005	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)				None	Mixed	Some ruptured*	All ≤6	Mixed	NR	Hospital	NR
Conde 2017	Vaginal misoprostol (≥50mcg)	Buccal/sublingual misoprostol				NR	NR	NR	NR	Mixed	NR	Hospital	No industry funding
Corrado 2001	Vaginal PGE ₂ (gel)	Intracervical PGE ₂				None	Mixed	All intact	All ≤6	Mixed	NR	Hospital	NR
Craft 1971	IV oxytocin	IV prostaglandin				NR	Mixed	All intact	NR	All >37 weeks	All singleton	Hospital	No industry funding

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Crane 1997	No treatment	Membrane sweeping				NR	Mixed	All intact	Mixed	All >37 weeks	All singleton	Outpatient	NR
Cromi 2011	Vaginal PGE ₂ pessary (slow release)	Foley catheter				None	Mixed	All intact	All ≤6	Mixed	All singleton	Hospital	No industry funding
Cromi 2012	Vaginal PGE ₂ pessary (slow release)	Double balloon/Cook's catheter				None	Mixed	All intact	All ≤6	Mixed	All singleton	Hospital	No industry funding
Curet 1989	Placebo	Vaginal PGE ₂ (gel)				NR	Mixed	All intact	All ≤6	Mixed	All singleton	Hospital	No industry funding
Dällenbach 2003	Vaginal PGE ₂ (gel)	Oral misoprostol tablet (<50mcg)				None	Mixed	Some ruptured*	All ≤6	All >37 weeks	All singleton	Hospital	NR
Dalui 2005	Intracervical PGE ₂	Foley catheter				None	Mixed	All intact	All ≤6	Mixed	All singleton	Hospital	NR
Damania 1992	No treatment	IV oxytocin	Breast stimulation			None	All nulliparous	NR	All ≤6	All >37 weeks	NR	Hospital	NR
Danielian 1999	Vaginal PGE ₂ (gel)	Vaginal misoprostol (≥50mcg)				Some previous*	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	NR

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Dare 2002	No treatment	Membrane sweeping				None	Mixed	All intact	Mixed	All >37 weeks	All singleton	Outpatient	NR
Darroca 1996	Placebo	Intracervical PGE ₂				None	Mixed	NR	All ≤6	Mixed	NR	Outpatient	NR
Davey 1979	Vaginal PGE ₂ (gel)	Oral prostaglandins				NR	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	Some industry
De Aquino 2003	Vaginal misoprostol (<50mcg)	IV oxytocin				None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	NR
De Bonrosto Torralba 2019	Vaginal PGE ₂ pessary (slow release)	Vaginal misoprostol (<50mcg)				NR	All nulliparous	NR	All ≤6	All >37 weeks	All singleton	Hospital	No industry funding
De la Torre 2001	Vaginal misoprostol (≥50mcg)	IV oxytocin				None	Mixed	NR	Mixed	Mixed	All singleton	Hospital	No industry funding
De Miranda 2006	No treatment	Membrane sweeping				NR	Mixed	All intact	NR	All ≥ 40 weeks	All singleton	Outpatient	No industry funding
DeBarm a 2015	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (<50mcg)				NR	NR	NR	All ≤6	All >37 weeks	All singleton	Hospital	NR
Demirel 2015	No treatment	Breast stimulation				NR	Mixed	NR	All >6	NR	All singleton	Hospital	No industry funding

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Denguezli 2007	Intracervical PGE ₂	Vaginal misoprostol (≥50mcg)				None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	No industry funding
Deo 2012	Vaginal PGE ₂ (gel)	Vaginal misoprostol (<50mcg)	Foley catheter			NR	Mixed	All intact	All ≤6	Mixed	All singleton	Hospital	NR
Deshmukh 2011	Intracervical PGE ₂	Foley catheter				None	All nulliparous	All intact	All ≤6	All >37 weeks	All singleton	Hospital	NR
Deshmukh 2013	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)				None	All nulliparous	Some ruptured*	All ≤6	Mixed	All singleton	Hospital	NR
Diro 1999	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)				None	Mixed	NR	All ≤6	Mixed	All singleton	Hospital	NR
Doany 1997	Placebo	Vaginal PGE ₂ (gel)	Membrane sweeping			None	Mixed	All intact	Mixed	All ≥ 40 weeks	All singleton	Hospital	NR
Dodd 2006	Vaginal PGE ₂ (gel)	Titrated (low dose) oral misoprostol solution				None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	No industry funding

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Dogra 2019	No treatment	IV oxytocin				None	Mixed	NR	All >6	All >37 weeks	All singleton	Hospital	No industry funding
Domisse 1980	Placebo	Vaginal PGE ₂ (tablet)				NR	Mixed	All intact	All >6	Mixed	NR	Hospital	NR
Domisse 1987	Vaginal PGE ₂ (gel)	IV oxytocin plus amniotomy				None	Mixed	All intact	All >6	All >37 weeks	NR	Hospital	Some industry
Dulger 2018	Placebo	Nitric oxide				None	Mixed	All intact	All ≤6	All ≥ 40 weeks	All singleton	Hospital	No industry funding
Dyar 2000	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)				None	NR	NR	All ≤6	All >37 weeks	All singleton	Hospital	NR
Edwards 2014	Vaginal PGE ₂ pessary (slow release)	Foley catheter				NR	NR	All intact	All ≤6	All >37 weeks	All singleton	Hospital	NR
Egarter 1989	Vaginal PGE ₂ (gel)	IV oxytocin				None	Mixed	All intact	Mixed	All >37 weeks	NR	Hospital	NR
Ekman 1983	Vaginal PGE ₂ (gel)	Intracervical PGE ₂				NR	Mixed	All intact	All ≤6	All >37 weeks	NR	Hospital	NR

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Ekman 1986	Vaginal PGE ₂ pessary (normal release)	IV oxytocin				NR	Mixed	NR	All ≤6	All >37 weeks	NR	Hospital	No industry funding
El-Azeem 1997	Vaginal PGE ₂ (gel)	Vaginal misoprostol (≥50mcg)				NR	Mixed	NR	NR	NR	NR	Hospital	NR
El-Din 2000	Vaginal PGE ₂ (tablet)	Intracervical PGE ₂	Vaginal misoprostol (≥50 mcg)			NR	NR	NR	All ≤6	NR	NR	Hospital	NR
Elhassan 2004	Vaginal PGE ₂ (tablet)	Vaginal misoprostol (≥50mcg)				None	Mixed	NR	NR	NR	All singleton	Hospital	NR
Elhassan 2005a	Vaginal misoprostol (≥50mcg)	IV oxytocin				None	Mixed	All intact	All >6	NR	All singleton	Hospital	NR
Elhassan 2005b	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)				None	Mixed	All intact	All ≤6	NR	All singleton	Hospital	NR
El-Mardi 1991	Vaginal PGE ₂ (tablet)	Vaginal PGE ₂ pessary				NR	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	NR

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
		(normal release)											
El-Shawarby 2006	Vaginal PGE ₂ (gel)	Vaginal PGE ₂ pessary (slow release)				NR	Mixed	Some ruptured*	Mixed	All >37 weeks	All singleton	Hospital	NR
El-Sherbiny 2001	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)				None	Mixed	All intact	Mixed	All >37 weeks	All singleton	Hospital	NR
El-Torkey 1992	No treatment	Membrane sweeping				NR	Mixed	All intact	Mixed	All ≥ 40 weeks	NR	Outpatient	NR
Eroglu 2007	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)				None	Mixed	Some ruptured*	All ≤6	All >37 weeks	All singleton	Hospital	NR
Escudero 1997	Vaginal misoprostol (≥50mcg)	IV oxytocin				None	Mixed	Some ruptured*	NR	NR	All singleton	Hospital	NR
Ezechukwu 2015	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)				None	Mixed	All intact	Mixed	All >37 weeks	All singleton	Hospital	No industry funding
Facchinetti 2005	Vaginal PGE ₂ pessary (slow release)	Intracervical PGE ₂				None	All nulliparous	All intact	All ≤6	All >37 weeks	All singleton	Hospital	NR

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Facchinetti 2007	Vaginal PGE ₂ pessary (slow release)	Intracervical PGE ₂				None	All nulliparous	All intact	All ≤6	All ≥ 40 weeks	All singleton	Hospital	NR
Farah 1997	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)				None	Mixed	Some ruptured*	All ≤6	Mixed	All singleton	Hospital	NR
Feitosa 2006	Vaginal misoprostol (<50mcg)	Buccal/sublingual misoprostol				None	NR	All intact	All ≤6	All >37 weeks	All singleton	Hospital	Some industry
Fenton 1985	Placebo	Extra-amniotic prostaglandin				None	All nulliparous	All intact	All ≤6	All >37 weeks	NR	Hospital	NR
Ferguson 2002	Vaginal misoprostol (≥50mcg)	IV oxytocin				Some previous*	Mixed	All intact	All ≤6	Mixed	Mixed	Hospital	NR
Ferraiolo 2010	Vaginal PGE ₂ (gel)	Vaginal PGE ₂ pessary (slow release)				None	All nulliparous	All intact	All ≤6	All >37 weeks	NR	Hospital	No industry funding
Fisher 2001	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)				None	Mixed	All intact	Mixed	Mixed	All singleton	Hospital	No industry funding

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Fletcher 1993	Placebo	Vaginal misoprostol (≥50mcg)				NR	Mixed	NR	NR	Mixed	NR	Hospital	NR
Fletcher 1994	Vaginal PGE ₂ (tablet)	Vaginal misoprostol (≥50mcg)				None	Mixed	All intact	Mixed	NR	All singleton	Hospital	NR
Fonseca 2008	Vaginal misoprostol (<50mcg)	IV oxytocin				None	Mixed	All intact	All ≤6	Mixed	All singleton	Hospital	NR
Frass 2011	No treatment	Vaginal misoprostol (≥50mcg)				None	Mixed	All intact	All ≤6	Mixed	All singleton	Hospital	No industry funding
Frydman 1991	Placebo	Mifepristone				Some previous*	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	NR
Gagnon-Gervais 2012	IV oxytocin	IV oxytocin plus amniotomy				None	Mixed	All intact	All >6	All >37 weeks	All singleton	Hospital	No industry funding
Gaikwad 2014	Intracervical PGE ₂	Mifepristone				None	Mixed	All intact	NR	Mixed	NR	Hospital	NR
Garry 2000	No treatment	Castor oil				NR	Mixed	All intact	All ≤6	All ≥ 40 weeks	All singleton	Hospital	NR
Garry 2003	Vaginal PGE ₂ pessary	Vaginal misoprostol				Some previous*	Mixed	Some ruptured*	All ≤6	Mixed	All singleton	Hospital	NR

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
	(slow release)	ol (≥50mcg)											
Gattas 2020	Vaginal misoprostol (<50 mcg)	Buccal/sublingual misoprostol				None	Mixed	Mixed	All ≤6	All >37 weeks	All singleton	Hospital	No industry funding
Gaudet 2008	Placebo	Acupuncture				None	All nulliparous	All intact	All ≤6	All ≥ 40 weeks	All singleton	Outpatient	No industry funding
Gelisen 2005	No treatment	Vaginal misoprostol (≥50mcg)	IV oxytocin	Foley catheter		None	Mixed	All intact	All ≤6	All ≥ 40 weeks	All singleton	Hospital	NR
Getgan 2003	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)				NR	NR	All intact	All ≤6	NR	All singleton	Hospital	NR
Ghanaie 2013	Intracervical PGE ₂	Foley catheter				NR	All nulliparous	All intact	All ≤6	All >37 weeks	All singleton	Hospital	No industry funding
Gherman 2001	Vaginal PGE ₂ (gel)	Oral misoprostol tablet (≥50mcg)				None	Mixed	All intact	All ≤6	Mixed	All singleton	Hospital	No industry funding
Giacalone 1998	Placebo	Mifepristone				None	Mixed	All intact	All ≤6	All ≥ 40 weeks	All singleton	Outpatient	NR
Gihwala 1987	Vaginal PGE ₂ (gel)	IV oxytocin				None	Mixed	NR	Mixed	All >37 weeks	NR	Hospital	Some industry

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Gilad 2018	Placebo	Castor oil				None	Mixed	All intact	Mixed	All ≥ 40 weeks	All singleton	Outpatient	No industry funding
Gilson 1993	Placebo	Intracervical PGE ₂				Some previous*	Mixed	All intact	All ≤6	Mixed	All singleton	Outpatient	No industry funding
Gilson 1996	No treatment	Laminaria				Some previous*	Mixed	All intact	All ≤6	Mixed	All singleton	Hospital	No industry funding
Girija 2009	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)				None	Mixed	Some ruptured*	All ≤6	All >37 weeks	All singleton	Hospital	NR
Girija 2011	Intracervical PGE ₂	Vaginal misoprostol (<50mcg)				None	Mixed	Some ruptured*	All ≤6	All >37 weeks	All singleton	Hospital	NR
Glagoleva 1999	Intracervical PGE ₂	Laminaria				None	Mixed	NR	All ≤6	NR	NR	Hospital	NR
Goel 1986	Vaginal misoprostol (<50mcg)	Buccal/sublingual misoprostol				NR	NR	NR	NR	All >37 weeks	NR	Hospital	NR
Golbus 1977	Placebo	Oral prostaglandins				NR	Mixed	All intact	Mixed	Mixed	NR	Hospital	Some industry
Goldenberg 1996	No treatment	Membrane sweeping				NR	Mixed	NR	Mixed	All >37 weeks	NR	Outpatient	NR

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Gottschall 1997	Vaginal PGE ₂ (gel)	Vaginal misoprostol (≥50mcg)				None	Mixed	All intact	NR	Mixed	All singleton	Hospital	NR
Gower 1982	Placebo	Laminaria				NR	Mixed	NR	All ≤6	NR	NR	Hospital	NR
Graves 1985	Placebo	Vaginal PGE ₂ (gel)				None	Mixed	All intact	All ≤6	NR	All singleton	Hospital	Some industry
Green 1998	Vaginal PGE ₂ (gel)	Vaginal PGE ₂ pessary (slow release)				NR	Mixed	NR	All ≤6	All >37 weeks	All singleton	Hospital	NR
Greer 1989	Vaginal PGE ₂ (tablet)	Extra-amniotic prostaglandin				None	All nulliparous	All intact	All ≤6	All >37 weeks	All singleton	Hospital	NR
Greer 1990	Vaginal PGE ₂ (tablet)	Vaginal PGE ₂ (gel)				NR	All multiparous	NR	Mixed	All >37 weeks	NR	Hospital	NR
Gregson 2005	Vaginal PGE ₂ (gel)	Vaginal misoprostol (<50mcg)				None	Mixed	Some ruptured*	Mixed	All >37 weeks	All singleton	Hospital	NR
Gregson 2015	Placebo	Acupuncture				NR	All nulliparous	All intact	NR	All ≥ 40 weeks	All singleton	Hospital	NR

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Greybush 2001	Vaginal misoprostol (<50mcg)	Foley catheter				Some previous*	Mixed	Some ruptured*	All ≤6	Mixed	All singleton	Hospital	No industry funding
Gribel 2011	Vaginal misoprostol (<50mcg)	Acupuncture				NR	Mixed	Some ruptured*	All ≤6	All ≥ 40 weeks	All singleton	Hospital	No industry funding
Grünberger 1986	Placebo	Intracervical PGE ₂				None	NR	NR	All ≤6	All ≥ 40 weeks	All singleton	Hospital	NR
Guha 2015	Vaginal misoprostol (≥50mcg)	Nitric oxide				NR	All nulliparous	All intact	All ≤6	NR	All singleton	Hospital	NR
Gupta 1998	No treatment	Membrane sweeping				None	All nulliparous	All intact	Mixed	All >37 weeks	All singleton	Outpatient	NR
Gupta 2006	Intracervical PGE ₂	Vaginal misoprostol (<50mcg)				None	Mixed	Some ruptured*	All ≤6	All >37 weeks	All singleton	Hospital	NR
Gupta 2010	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)				None	Mixed	All intact	All ≤6	All >37 weeks	Mixed	Hospital	NR
Haas 2019	Vaginal misoprostol (<50 mcg)	Buccal/sublingual misoprostol				None	Mixed	All intact	Mixed	All >37 weeks	All singleton	Hospital	No industry funding
Habib 2008	Placebo	Nitric oxide				None	Mixed	All intact	All ≤6	NR	All singleton	Outpatient	NR

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Haghighi 2013	Vaginal misoprostol (<50mcg)	Nitric oxide				None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	No industry funding
Haghighi 2015	No treatment	Nitric oxide				None	All nulliparous	NR	All ≤6	All ≥ 40 weeks	All singleton	Hospital	No industry funding
Hales 1994	Vaginal PGE ₂ (gel)	Intracervical PGE ₂				NR	NR	All intact	All ≤6	All >37 weeks	NR	Hospital	No industry funding
Hall 2002	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)				None	Mixed	Some ruptured*	NR	All >37 weeks	All singleton	Hospital	NR
Harper 2006	No treatment	Acupuncture				None	All nulliparous	NR	All ≤6	All ≥ 40 weeks	All singleton	Outpatient	No industry funding
Has 2002	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)				None	Mixed	Some ruptured*	All ≤6	All >37 weeks	All singleton	Hospital	NR
Haugland 2012	Foley catheter	Double balloon/Cook's catheter				NR	NR	NR	All ≤6	All >37 weeks	All singleton	Hospital	NR
Hay 1995	Intracervical PGE ₂	Laminaria				NR	NR	NR	NR	NR	NR	Hospital	NR
Heden 1991	No treatment	IV oxytocin plus				None	Mixed	All intact	Mixed	All ≥ 40 weeks	All singleton	NR	NR

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
		amniotomy											
Hemlin 1998	Intracervical PGE ₂	Foley catheter				NR	Mixed	All intact	All ≤6	Mixed	All singleton	Hospital	NR
Henry 2013	Vaginal PGE ₂ (gel)	Foley catheter				None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	No industry funding
Herabutya 1988	Intracervical PGE ₂	Oral prostaglandins				None	All nulliparous	NR	All ≤6	All >37 weeks	NR	Hospital	NR
Herabutya 1992	No treatment	Intracervical PGE ₂				None	Mixed	All intact	All ≤6	All ≥ 40 weeks	All singleton	Outpatient	NR
Herabutya 1993	Vaginal PGE ₂ (tablet)	Intracervical PGE ₂				NR	All nulliparous	All intact	All ≤6	NR	NR	Outpatient	NR
Herabutya 1997	Intracervical PGE ₂	Vaginal misoprostol (≥50mcg)				NR	Mixed	All intact	All ≤6	Mixed	All singleton	Hospital	NR
Hill 2008	No treatment	Membrane sweeping				NR	Mixed	All intact	Mixed	All >37 weeks	All singleton	Outpatient	No industry funding
Hofmeyr 2001	Vaginal PGE ₂ (gel)	Titrated (low dose) oral misoprostol solution	Foley catheter			None	Mixed	Some ruptured*	Mixed	Mixed	All singleton	Hospital	NR

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Hokkila 2019	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)				None	All nulliparous	All intact	All ≤6	All >37 weeks	All singleton	Hospital	No industry funding
Hoppe 2016	Foley catheter	Double balloon/Cook's catheter				Some previous*	Mixed	NR	All ≤6	NR	All singleton	Hospital	No industry funding
Hosli 2008	Vaginal PGE ₂ (gel)	Vaginal misoprostol (≥50mcg)				None	Mixed	Some ruptured*	All ≤6	All >37 weeks	All singleton	Hospital	No industry funding
Howarth 1996	Vaginal PGE ₂ (gel)	Vaginal misoprostol (≥50mcg)				None	Mixed	All intact	Mixed	Mixed	All singleton	Hospital	NR
Hudon 1999	Intracervical PGE ₂	Foley catheter				None	NR	All intact	All ≤6	All >37 weeks	NR	Hospital	NR
Hutchon 1980	Placebo	Intracervical PGE ₂				None	Mixed	NR	All ≤6	NR	All singleton	Outpatient	No industry funding
Incerpi 2001	Placebo	Vaginal misoprostol (<50mcg)				None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Outpatient	NR
Irion 1998	Vaginal PGE ₂ (gel)	Intracervical PGE ₂				Some previous*	Mixed	All intact	All ≤6	Mixed	All singleton	Hospital	NR

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Iskander 1978	Extra-amniotic prostaglandins	IV prostaglandin				None	Mixed	All intact	All ≤6	Mixed	All singleton	Hospital	Some industry
Jackson 1994	Vaginal PGE ₂ (gel)	IV oxytocin				Some previous*	Mixed	Some ruptured*	All ≤6	Mixed	All singleton	Hospital	NR
Jagani 1982	No treatment	IV oxytocin	Amniotomy	Foley catheter	Laminaria	NR	Mixed	All intact	All >6	All >37 weeks	All singleton	Hospital	NR
Jagani 1984	No treatment	Vaginal PGE ₂ pessary (normal release)	IV oxytocin			NR	Mixed	All intact	All ≤6	Mixed	NR	Hospital	NR
Janakiraman 2011	No treatment	Membrane sweeping				NR	Mixed	All intact	NR	All >37 weeks	NR	Outpatient	NR
Jeeva 1982	Vaginal PGE ₂ (tablet)	Laminaria				NR	Mixed	NR	All ≤6	Mixed	NR	Hospital	NR
Jindal 2019	Vaginal PGE ₂ (gel)	Mifepristone				NR	Mixed	NR	All ≤6	All >37 weeks	All singleton	Hospital	NR
Johnson 1985	Vaginal PGE ₂ (gel)	Laminaria				None	All nulliparous	NR	All ≤6	All >37 weeks	NR	Hospital	NR
Jozwiak 2011	Vaginal PGE ₂ (gel)	Foley catheter				None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	No industry funding

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Jozwiak 2013	Vaginal PGE ₂ pessary (slow release)	Foley catheter				None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	No industry funding
Jozwiak 2014	Vaginal misoprostol (<50mcg)	Foley catheter				None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	No industry funding
Kadanali 1996	Intracervical PGE ₂	Vaginal misoprostol (≥50mcg)				None	Mixed	Some ruptured*	All ≤6	All >37 weeks	All singleton	Hospital	NR
Kadian 2008	Vaginal PGE ₂ (gel)	Nitric oxide				None	All nulliparous	NR	All ≤6	All >37 weeks	All singleton	Hospital	NR
Kalkat 2008	Vaginal PGE ₂ (gel)	Vaginal PGE ₂ pessary (slow release)				None	Mixed	NR	Mixed	Mixed	Mixed	Hospital	NR
Kaminski 1994	PGF ₂ gel	IV oxytocin				None	Mixed	NR	Mixed	All >37 weeks	All singleton	Hospital	NR
Kandil 2012	Vaginal misoprostol (<50mcg)	Foley catheter				None	All nulliparous	All intact	All ≤6	All ≥ 40 weeks	All singleton	Hospital	NR
Karatas 2016	Vaginal PGE ₂ pessary (slow release)	Foley catheter				NR	All nulliparous	All intact	All ≤6	All >37 weeks	All singleton	Hospital	NR

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Kashanian 2006a	Vaginal misoprostol (<50mcg)	Foley catheter				NR	NR	All intact	All ≤6	Mixed	All singleton	Hospital	NR
Kashanian 2006b	No treatment	Membrane sweeping				NR	Mixed	All intact	Mixed	All >37 weeks	All singleton	Outpatient	NR
Kashanian 2008	Placebo	Corticosteroids				None	All nulliparous	All intact	All >6	All >37 weeks	All singleton	Hospital	NR
Kashanian 2020	Titrated (low dose) oral misoprostol solution	IV oxytocin				None	Mixed	NR	Mixed	All ≥ 40 weeks	All singleton	Hospital	NR
Katz 1983	No treatment	IV oxytocin plus amniotomy				None	Mixed	NR	NR	All ≥ 40 weeks	NR	Hospital	NR
Kaul 2004	Intracervical PGE ₂	Membrane sweeping				NR	Mixed	All intact	All ≤6	Mixed	All singleton	Hospital	NR
Keirse 1995	Vaginal PGE ₂ (gel)	Intracervical PGE ₂				None	Mixed	All intact	Mixed	All >37 weeks	All singleton	Hospital	No industry funding
Kennedy 1978	Intracervical PGE ₂	IV oxytocin plus amniotomy				NR	Mixed	All intact	All >6	All >37 weeks	NR	Hospital	NR

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Kennedy 1982	Vaginal PGE ₂ (tablet)	IV oxytocin plus amniotomy				NR	Mixed	All intact	Mixed	All >37 weeks	All singleton	Hospital	Some industry
Kennel 2018	Vaginal misoprostol (<50mcg)	Titrated (low dose) oral misoprostol solution				NR	NR	NR	NR	NR	NR	Hospital	No industry funding
Khatib 2019	Vaginal PGE ₂ pessary (slow release)	Double balloon/Cook's catheter				None	Mixed	NR	All ≤6	All >37 weeks	All singleton	Hospital	NR
Khazardoost 2011	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)				None	Mixed	All intact	All ≤6	All ≥ 40 weeks	All singleton	Hospital	NR
Khoury 2001	Vaginal PGE ₂ pessary (slow release)	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)			None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	Some industry
Kidanto 2007	Vaginal misoprostol (<50mcg)	IV oxytocin				None	Mixed	NR	NR	Mixed	Mixed	Hospital	NR

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Kim 2000	Vaginal PGE ₂ (tablet)	Vaginal misoprostol (≥50mcg)				None	All nulliparous	All intact	All ≤6	All >37 weeks	All singleton	Hospital	NR
Kipikasa 2005	Oral misoprostol tablet (<50mcg)	Oral misoprostol tablet (≥50mcg)				None	Mixed	All intact	All ≤6	All ≥ 40 weeks	All singleton	Outpatient	No industry funding
Koc 2013	Vaginal PGE ₂ pessary (slow release)	IV oxytocin				None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	No industry funding
Kolderup 1999	Intracervical PGE ₂	Vaginal misoprostol (≥50mcg)				None	Mixed	All intact	All ≤6	Mixed	All singleton	Hospital	NR
Komala 2013	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)				None	Mixed	Some ruptured*	All ≤6	NR	All singleton	Hospital	No industry funding
Kovavisarach 1997	Vaginal PGE ₂ (tablet)	Vaginal misoprostol (≥50mcg)				NR	Mixed	NR	All ≤6	All >37 weeks	NR	Hospital	NR
Kovavisarach 1998	Vaginal PGE ₂ (tablet)	Vaginal misoprostol (≥50mcg)				NR	Mixed	NR	All ≤6	All >37 weeks	NR	Hospital	NR

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Krammer 1995	Intracervical PGE ₂	Laminaria				Some previous*	Mixed	NR	Mixed	All >37 weeks	NR	Hospital	NR
Krishnamurthy 2015	Placebo	Nitric oxide				None	All nulliparous	All intact	All ≤6	All >37 weeks	All singleton	Hospital	No industry funding
Krithika 2008	Intracervical PGE ₂	Vaginal misoprostol (<50mcg)				None	Mixed	NR	All ≤6	Mixed	All singleton	Hospital	No industry funding
Kulshreshta 2007	Intracervical PGE ₂	Vaginal misoprostol (≥50mcg)				None	Mixed	Some ruptured*	Mixed	All >37 weeks	All singleton	Hospital	NR
Kumar 2001	Intracervical PGE ₂	Vaginal misoprostol (<50mcg)				None	Mixed	NR	Mixed	Mixed	All singleton	Hospital	NR
Kwon 2001	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)				None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	NR
Lackritz 1979	Placebo	Laminaria				NR	NR	All intact	All ≤6	NR	NR	Hospital	NR
Laloha 2015	Placebo	Corticosteroids				NR	All nulliparous	All intact	All ≤6	All ≥ 40 weeks	All singleton	Hospital	NR
Lange 1984	Vaginal PGE ₂ pessary	IV oxytocin				None	Mixed	NR	All ≤6	NR	All singleton	Hospital	NR

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
	(normal release)												
Langenegger 2005	Intracervical PGE ₂	Oral misoprostol tablet (≥50mcg)				None	Mixed	All intact	All ≤6	Mixed	All singleton	Hospital	NR
Larmon 2002	Placebo	Intracervical PGE ₂	Oestrogens			NR	Mixed	All intact	All ≤6	All >37 weeks	NR	Outpatient	NR
Laube 1986	Placebo	Intracervical PGE ₂				None	Mixed	All intact	All ≤6	NR	All singleton	Hospital	Some industry
Le Roux 2002	Vaginal PGE ₂ (gel)	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)			None	Mixed	All intact	All ≤6	Mixed	All singleton	Hospital	NR
Lee 1997	Vaginal PGE ₂ (tablet)	Vaginal misoprostol (≥50mcg)				None	Mixed	NR	All ≤6	All ≥ 40 weeks	All singleton	Hospital	NR
Legarth 1987	Vaginal PGE ₂ pessary (normal release)	IV oxytocin				None	Mixed	NR	All >6	Mixed	All singleton	Hospital	NR
Legarth 1988	Intracervical PGE ₂	Vaginal PGE ₂ pessary				NR	Mixed	NR	All ≤6	NR	All singleton	Hospital	NR

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
		(normal release)											
Lemancewicz 1999	Intracervical PGE ₂	Vaginal misoprostol (≥50mcg)	IV oxytocin			None	Mixed	NR	All ≤6	All ≥ 40 weeks	All singleton	Hospital	NR
Lemyre 2006	Vaginal misoprostol (<50mcg)	Foley catheter				NR	NR	NR	NR	All >37 weeks	NR	Hospital	NR
Levine 2016	Vaginal misoprostol (<50mcg)	Foley catheter				NR	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	No industry funding
Lewis 1983	No treatment	Vaginal PGE ₂ pessary (normal release)	Foley catheter			NR	Mixed	All intact	All ≤6	NR	NR	Hospital	NR
Lien 1998	Placebo	Intracervical PGE ₂				None	Mixed	Some ruptured*	All ≤6	All ≥ 40 weeks	All singleton	Hospital	Some industry
Liggins 1979	Placebo	Vaginal PGE ₂ pessary (normal release)				NR	Mixed	NR	Mixed	All >37 weeks	NR	Hospital	Some industry
Lim 2018	Vaginal PGE ₂ (tablet)	Double balloon/Cook's catheter				None	Mixed	All intact	NR	All >37 weeks	All singleton	Hospital	No industry funding

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Lo 1994	Vaginal PGE ₂ (tablet)	IV oxytocin plus amniotomy				None	Mixed	NR	Mixed	All >37 weeks	All singleton	Hospital	Some industry
Lo 2006	IV oxytocin plus amniotomy	Buccal/sublingual misoprostol				None	All nulliparous	All intact	All >6	All >37 weeks	All singleton	Hospital	NR
Lokkegaard 2015	Vaginal PGE ₂ (tablet)	Double balloon/Cook's catheter				Some previous*	Mixed	All intact	All ≤6	All ≥ 40 weeks	Mixed	Hospital	No industry funding
Lokugamaige 2003	Vaginal PGE ₂ (gel)	Vaginal misoprostol (≥50mcg)				None	All nulliparous	Some ruptured*	All ≤6	All >37 weeks	Mixed	Hospital	NR
Lopes 1991	Vaginal PGE ₂ (gel)	Intracervical PGE ₂				NR	Mixed	Some ruptured*	All ≤6	NR	NR	Hospital	NR
Lughmani 2009	Vaginal misoprostol (<50mcg)	IV oxytocin				NR	All multiparous	NR	All ≤6	NR	All singleton	Hospital	NR
Luther 1980	Placebo	Oestrogens				NR	Mixed	NR	All ≤6	Mixed	All singleton	Hospital	NR
Lykkesfeldt 1979	IV oxytocin plus amniotomy	Oral prostaglandins				NR	NR	NR	All >6	Mixed	NR	Hospital	Some industry
Lyndrup 1989	Vaginal PGE ₂	IV oxytocin				None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	NR

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
	pessary (normal release)												
Lyndrup 1991	Intracervical PGE ₂	Vaginal PGE ₂ pessary (normal release)				None	Mixed	NR	All ≤6	Mixed	All singleton	Hospital	NR
Lyndrup 1994	Vaginal PGE ₂ pessary (normal release)	Foley catheter				None	Mixed	All intact	All ≤6	Mixed	All singleton	Hospital	NR
Macer 1984	Vaginal PGE ₂ pessary (normal release)	IV oxytocin				None	Mixed	NR	All >6	All >37 weeks	All singleton	Hospital	NR
MacKenzie 1979	Placebo	Vaginal PGE ₂ (gel)	PGF ₂ gel			None	All nulliparous	NR	All ≤6	All >37 weeks	All singleton	Hospital	NR
MacLennan 1979	Placebo	PGF ₂ gel				None	Mixed	NR	Mixed	Mixed	All singleton	Hospital	NR
MacLennan 1980a	Placebo	Relaxin				None	Mixed	All intact	Mixed	All >37 weeks	All singleton	Hospital	No industry funding
MacLennan 1980b	Placebo	PGF ₂ gel				None	Mixed	NR	NR	NR	All singleton	Hospital	NR

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
MacLennan 1986	Placebo	Relaxin				None	Mixed	NR	All ≤6	NR	All singleton	Hospital	No industry funding
MacLennan 1989	Vaginal PGE ₂ (gel)	IV oxytocin plus amniotomy				Some previous*	Mixed	All intact	Mixed	All >37 weeks	Mixed	Hospital	NR
Madaan 2014	Intracervical PGE ₂	Vaginal misoprostol (<50mcg)				None	Mixed	NR	All ≤6	All >37 weeks	All singleton	Hospital	No industry funding
Magann 1995	Intracervical PGE ₂	IV oxytocin	Oestrogens			None	Mixed	All intact	All ≤6	Mixed	All singleton	Hospital	No industry funding
Magann 1998a	No treatment	Membrane sweeping				NR	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Outpatient	No industry funding
Magann 1998b	No treatment	Intracervical PGE ₂	Membrane sweeping			NR	Mixed	All intact	All ≤6	All ≥ 40 weeks	NR	Outpatient	No industry funding
Magann 1999	Vaginal PGE ₂ pessary (slow release)	Membrane sweeping				NR	Mixed	All intact	All ≤6	All ≥ 40 weeks	All singleton	Outpatient	No industry funding
Magtibay 1998	Intracervical PGE ₂	Vaginal misoprost				None	Mixed	NR	All ≤6	All >37 weeks	All singleton	Hospital	NR

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
		ol (≥50mcg)											
Mahacakri 2018	Vaginal misoprostol (<50mcg)	Titrated (low dose) oral misoprostol solution				None	Mixed	NR	All ≤6	Mixed	All singleton	Hospital	NR
Mahmood 1989	Vaginal PGE ₂ (tablet)	Vaginal PGE ₂ (gel)				None	All nulliparous	NR	All ≤6	All >37 weeks	All singleton	Hospital	NR
Mahmood 1995	Vaginal PGE ₂ (gel)	Amniotomy				None	Mixed	All intact	All >6	Mixed	All singleton	Hospital	No industry funding
Majoko 2002a	Vaginal misoprostol (≥50mcg)	Extra-amniotic prostaglandin				None	Mixed	Some ruptured*	Mixed	All >37 weeks	All singleton	Hospital	NR
Majoko 2002b	Vaginal PGE ₂ pessary (normal release)	Vaginal misoprostol (≥50mcg)	Titrated (low dose) oral misoprostol solution	Extra-amniotic prostaglandins		None	Mixed	NR	NR	All >37 weeks	All singleton	Hospital	NR
Manandhar 2017	IV oxytocin	Mifepristone				None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	NR

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Martin 1989	No treatment	Laminaria				NR	Mixed	NR	All ≤6	All ≥ 40 weeks	NR	Hospital	No industry funding
Mawire 1999	Foley catheter	Extra-amniotic prostaglandin				None	Mixed	All intact	All ≤6	Mixed	All singleton	Hospital	NR
McColgin 1990a	No treatment	Membrane sweeping				None	Mixed	All intact	Mixed	All >37 weeks	NR	Outpatient	NR
McColgin 1990b	No treatment	Membrane sweeping				Some previous*	Mixed	All intact	Mixed	All >37 weeks	NR	Outpatient	NR
McKenna 1999	Placebo	Intracervical PGE ₂				Some previous*	Mixed	All intact	Mixed	All >37 weeks	All singleton	Outpatient	NR
McKenna 2004	Placebo	Vaginal misoprostol (<50mcg)				None	Mixed	All intact	Mixed	All ≥ 40 weeks	All singleton	Outpatient	NR
McLaren 1987	Vaginal PGE ₂ (tablet)	Vaginal PGE ₂ pessary (slow release)				NR	All multiparous	NR	Mixed	All >37 weeks	NR	Hospital	NR
Megalo 2004	Intracervical PGE ₂	Vaginal misoprostol (≥50mcg)				None	Mixed	Some ruptured*	Mixed	Mixed	All singleton	Hospital	NR

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Mehrotra 2010	Vaginal misoprostol ($\geq 50\text{mcg}$)	Oral misoprostol tablet ($\geq 50\text{mcg}$)				None	Mixed	All intact	All ≤ 6	All >37 weeks	All singleton	Hospital	No industry funding
Mei-Dan 2012	Foley catheter	Double balloon/Cook's catheter				None	Mixed	All intact	All ≤ 6	All >37 weeks	All singleton	Hospital	No industry funding
Mei-Dan 2014	Foley catheter	Double balloon/Cook's catheter				None	Mixed	All intact	All ≤ 6	All >37 weeks	All singleton	Hospital	No industry funding
Mercer 1995	IV oxytocin	IV oxytocin plus amniotomy				NR	Mixed	All intact	Mixed	All >37 weeks	NR	Hospital	NR
Meydanli 2003	Vaginal misoprostol ($<50\text{mcg}$)	Vaginal misoprostol ($\geq 50\text{mcg}$)				None	Mixed	All intact	All ≤ 6	All ≥ 40 weeks	All singleton	Hospital	NR
Meyer 2002	Intracervical PGE ₂	Vaginal misoprostol ($<50\text{mcg}$)				None	Mixed	All intact	All ≤ 6	All >37 weeks	All singleton	Outpatient	NR
Miller 1991	Vaginal PGE ₂ (gel)	Vaginal PGE ₂ pessary (slow release)				NR	Mixed	NR	All ≤ 6	All >37 weeks	All singleton	Hospital	Some industry

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Misra 1994	Intracervical PGE ₂	IV oxytocin				NR	Mixed	All intact	All ≤6	Mixed	NR	Hospital	NR
Modarres 2000	No treatment	Breast stimulation				NR	Mixed	NR	All ≤6	All ≥ 40 weeks	NR	Outpatient	NR
Modlock 2010	Placebo	Acupuncture				None	Mixed	All intact	NR	All ≥ 40 weeks	All singleton	Hospital	No industry funding
Moini 2003	Intracervical PGE ₂	Foley catheter				None	All nulliparous	All intact	All ≤6	All >37 weeks	All singleton	Hospital	NR
Moldin 1996	Amniotomy	IV oxytocin plus amniotomy				NR	Mixed	All intact	All >6	All >37 weeks	All singleton	Hospital	NR
Mollart 2016	No treatment	Acupuncture				NR	All nulliparous	NR	NR	All ≥ 40 weeks	All singleton	Outpatient	No industry funding
Moodley 2003	Vaginal PGE ₂ (gel)	Vaginal misoprostol (<50mcg)	Titrated (low dose) oral misoprostol solution			None	Mixed	Some ruptured*	All ≤6	Mixed	All singleton	Hospital	NR

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Moraes Filho 2010	Vaginal misoprostol (<50mcg)	Foley catheter				None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	No industry funding
Movahed 2016	Nitric oxide	Foley catheter	Laminaria			NR	All nulliparous	All intact	All ≤6	All >37 weeks	All singleton	Hospital	NR
Mukhopadhyay 2002	Vaginal PGE ₂ (gel)	Vaginal PGE ₂ pessary (slow release)				NR	All nulliparous	NR	All ≤6	NR	All singleton	Hospital	NR
Mundle 2018	Oral misoprostol tablet (<50mcg)	Foley catheter				None	Mixed	All intact	All ≤6	Mixed	All singleton	Hospital	No industry funding
Murphy 1980	Placebo	PGF ₂ gel				NR	Mixed	NR	Mixed	All >37 weeks	NR	Hospital	Some industry
Murray 1995	Vaginal PGE ₂ (tablet)	Vaginal PGE ₂ (gel)				None	All nulliparous	All intact	All ≤6	All >37 weeks	All singleton	Hospital	NR
Murthy 2006	Intracervical PGE ₂	Vaginal misoprostol (<50mcg)				None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	NR
Nager 1987	No treatment	Intracervical PGE ₂				None	Mixed	All intact	All ≤6	All >37 weeks	NR	Hospital	NR
Naismith 1973	IV oxytocin	IV prostaglandin				None	All nulliparous	All intact	Mixed	All ≥ 40 weeks	All singleton	Hospital	Some industry

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Nanda 2007	Intracervical PGE ₂	Vaginal misoprostol (<50mcg)				None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	No industry funding
Nassar 2006	Vaginal misoprostol (≥50mcg)	Buccal/sublingual misoprostol				None	Mixed	Some ruptured*	Mixed	All >37 weeks	All singleton	Hospital	No industry funding
Nayak 2015	Vaginal PGE ₂ (tablet)	Intracervical PGE ₂				None	Mixed	NR	All ≤6	Mixed	All singleton	Hospital	No industry funding
Neiger 2001	Intracervical PGE ₂	Vaginal misoprostol (≥50mcg)				None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	NR
Neilson 1983	Vaginal PGE ₂ (gel)	PGF ₂ gel				NR	Mixed	All intact	All ≤6	Mixed	NR	Hospital	NR
Netta 2002	No treatment	Membrane sweeping				NR	Mixed	All intact	NR	All >37 weeks	NR	Outpatient	NR
Newman 1997	No treatment	Vaginal PGE ₂ (gel)				NR	Mixed	NR	All ≤6	All >37 weeks	NR	Outpatient	NR
Nicoll 2001	No treatment	Nitric oxide				None	All nulliparous	NR	All ≤6	All ≥ 40 weeks	All singleton	Hospital	NR
Nigam 2004	Oral misoprostol	IV oxytocin				None	NR	NR	All ≤6	All >37 weeks	All singleton	Hospital	NR

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
	tablet (≥50mcg)												
Nigam 2010	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)				None	Mixed	NR	All ≤6	All >37 weeks	All singleton	Hospital	NR
Nimrod 1984	Placebo	Intracervical PGE ₂				NR	NR	All intact	All ≤6	NR	NR	Hospital	NR
Niromanesh 2003	Vaginal PGE ₂ (tablet)	Foley catheter				None	Mixed	All intact	All ≤6	All ≥ 40 weeks	All singleton	Hospital	NR
Noah 1987	No treatment	Intracervical PGE ₂				None	Mixed	All intact	All ≤6	Mixed	NR	Hospital	Some industry
Nongkhlaw 2015	Intracervical PGE ₂	Vaginal misoprostol (<50mcg)				NR	Mixed	Some ruptured*	All ≤6	All >37 weeks	All singleton	Hospital	No industry funding
Noor 2015	Vaginal misoprostol (<50mcg)	Foley catheter				None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	No industry funding
Nopdonratagoon 2003	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)				None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	NR
Norzilawati 2010	Vaginal PGE ₂ (tablet)	Vaginal misoprostol (≥50mcg)				None	All nulliparous	NR	NR	NR	All singleton	Hospital	NR

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Ntsaluba 1997	Intracervical PGE ₂	Foley catheter				None	NR	All intact	All ≤6	All >37 weeks	All singleton	Hospital	NR
Nunes 1999	Vaginal PGE ₂ (gel)	Vaginal misoprostol (≥50mcg)				None	Mixed	Some ruptured*	All ≤6	All >37 weeks	All singleton	Hospital	NR
Nuutila 1995	Placebo	Intracervical PGE ₂				NR	Mixed	NR	All ≤6	All >37 weeks	All singleton	Hospital	NR
Nuutila 1996	Vaginal PGE ₂ (gel)	Intracervical PGE ₂				NR	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	NR
Oboro 2005	No treatment	Vaginal misoprostol (<50mcg)				None	Mixed	All intact	Mixed	All ≥ 40 weeks	All singleton	Outpatient	NR
O'Brien 1995	Placebo	Vaginal PGE ₂ (gel)				Some previous*	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Outpatient	No industry funding
Ohel 1996	No treatment	Vaginal PGE ₂ (tablet)				NR	Mixed	NR	Mixed	All ≥ 40 weeks	All singleton	Outpatient	NR
Olmo 2001	Vaginal PGE ₂ pessary (slow release)	IV oxytocin				None	NR	NR	All ≤6	All >37 weeks	All singleton	Hospital	NR
Omar 2013	No treatment	Sexual intercourse				None	Mixed	All intact	NR	Mixed	All singleton	Outpatient	No industry funding

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Ophir 1992	Vaginal PGE ₂ (tablet)	Foley catheter				NR	Mixed	All intact	All ≤6	Mixed	All singleton	Hospital	NR
Orhue 1995	Vaginal PGE ₂ pessary (normal release)	IV oxytocin plus amniotomy	Foley catheter			None	All nulliparous	All intact	All ≤6	All >37 weeks	All singleton	Hospital	Some industry
Osman 2006	Vaginal PGE ₂ (gel)	Nitric oxide				None	All nulliparous	All intact	All ≤6	All >37 weeks	All singleton	Hospital	No industry funding
Ottinger 1998	Vaginal PGE ₂ pessary (slow release)	Intracervical PGE ₂				Some previous*	Mixed	All intact	Mixed	Mixed	All singleton	Hospital	NR
Owen 1991	Placebo	Intracervical PGE ₂				NR	Mixed	All intact	All ≤6	NR	NR	Hospital	NR
Owolabi 2005	Vaginal misoprostol (≥50mcg)	Foley catheter				None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	NR
Ozkan 2009	Vaginal PGE ₂ pessary (slow release)	Vaginal misoprostol (≥50mcg)				None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	No industry funding
Paisarntiwiwong 2005	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)				None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	NR

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Pandis 2001	Vaginal PGE ₂ (gel)	Vaginal misoprostol (≥50mcg)				None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	No industry funding
Papageorgiou 1992	Intracervical PGE ₂	IV oxytocin				NR	Mixed	NR	All ≤6	All ≥ 40 weeks	All singleton	Hospital	NR
Papanikolaou 2004	Vaginal PGE ₂ (tablet)	Vaginal misoprostol (≥50mcg)				None	All nulliparous	All intact	All ≤6	All ≥ 40 weeks	All singleton	Hospital	NR
Parazzini 1998	Vaginal PGE ₂ (gel)	IV oxytocin plus amniotomy				None	Mixed	All intact	Mixed	All ≥ 40 weeks	All singleton	Hospital	NR
Parewijck 1986	Intracervical PGE ₂	Extra-amniotic prostaglandin				NR	Mixed	NR	All ≤6	All >37 weeks	NR	Hospital	No industry funding
Parikh 2001	Intracervical PGE ₂	IV oxytocin				None	Mixed	All intact	All ≤6	Mixed	All singleton	Hospital	NR
Parimkayala 2019	Oral misoprostol tablet (≥50mcg)	Buccal/sublingual misoprostol				None	Mixed	Mixed	All ≤6	All >37 weeks	All singleton	Hospital	No industry funding
Parlakgumus 2014	No treatment	Membrane sweeping				None	Mixed	All intact	Mixed	All >37 weeks	All singleton	Hospital	No industry funding

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Patel 2016	Vaginal misoprostol (<50mcg)	Buccal/sublingual misoprostol				None	Mixed	NR	All ≤6	All >37 weeks	All singleton	Hospital	NR
Patil 2005	Intracervical PGE ₂	Oral misoprostol tablet (≥50mcg)				Some previous*	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	NR
Paungmora 2004	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)				None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	NR
Peccerillo 1995	Vaginal PGE ₂ (gel)	Intracervical PGE ₂				NR	NR	NR	All ≤6	All >37 weeks	NR	Hospital	NR
Peedicayil 1998	Intracervical PGE ₂	Foley catheter				None	All nulliparous	All intact	All ≤6	NR	NR	Hospital	NR
Pennell 2009	Vaginal PGE ₂ (gel)	Foley catheter	Double balloon/Cook's catheter			None	All nulliparous	All intact	All ≤6	All >37 weeks	All singleton	Hospital	Some industry
Pereira Alves Filho 2019	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)				Some previous*	Mixed	Some ruptured*	Mixed	All ≥ 40 weeks	All singleton	Hospital	No industry funding
Perry 2004	Vaginal PGE ₂	Intracervical PGE ₂				None	Mixed	All intact	All ≤6	Mixed	All singleton	Hospital	NR

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
	pessary (slow release)												
Perryman 1992	Vaginal PGE ₂ (gel)	Vaginal PGE ₂ pessary (normal release)				NR	Mixed	All intact	All ≤6	Mixed	NR	Hospital	NR
Pinto 1967	Placebo	Oestrogens				NR	Mixed	NR	Mixed	All >37 weeks	NR	Hospital	NR
Pollnow 1996	Intracervical PGE ₂	IV oxytocin				NR	Mixed	NR	Mixed	NR	NR	Hospital	NR
Pongsatha 2005	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)				None	NR	All intact	All ≤6	Mixed	All singleton	Hospital	NR
PonMalar 2017	Placebo	Vaginal misoprostol (<50mcg)				None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Outpatient	No industry funding
Poulsen 1991	Intracervical PGE ₂	Vaginal PGE ₂ pessary (normal release)				None	Mixed	NR	All ≤6	All >37 weeks	All singleton	Hospital	NR
Prager 2008	Vaginal PGE ₂ (gel)	Vaginal misoprostol (<50mcg)	Foley catheter			None	Mixed	Some ruptured*	All ≤6	All >37 weeks	NR	Hospital	NR

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Prasad 1989	Placebo	Vaginal PGE ₂ pessary (slow release)				None	All nulliparous	NR	All ≤6	All >37 weeks	All singleton	Hospital	Some industry
Prins 1983	Placebo	Vaginal PGE ₂ (gel)				NR	NR	NR	All ≤6	NR	All singleton	Hospital	NR
Pulle 1986	Intracervical PGE ₂	IV oxytocin				None	Mixed	NR	NR	Mixed	NR	Hospital	NR
Putnam 2011	No treatment	Membrane sweeping				NR	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Outpatient	No industry funding
Qazi 2019	Vaginal PGE ₂ (gel)	Vaginal misoprostol (≥50mcg)				None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	NR
Quinn 1981	Foley catheter	Extra-amniotic prostaglandin				None	All nulliparous	NR	All ≤6	NR	NR	Hospital	Some industry
Rabl 2001	No treatment	Acupuncture				None	Mixed	All intact	All ≤6	All ≥ 40 weeks	All singleton	Outpatient	NR
Rabl 2002	Vaginal PGE ₂ (tablet)	Vaginal PGE ₂ pessary (slow release)				Some previous*	Mixed	Some ruptured*	Mixed	All >37 weeks	All singleton	Hospital	No industry funding

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Rahman 2013	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)				None	Mixed	Some ruptured*	All ≤6	All >37 weeks	All singleton	Hospital	NR
Rameez 2007	Placebo	Nitric oxide				NR	Mixed	NR	All ≤6	All ≥ 40 weeks	All singleton	Hospital	NR
Ramsey 2003	Vaginal PGE ₂ pessary (slow release)	Intracervical PGE ₂	Vaginal misoprostol (≥50 mcg)			None	Mixed	All intact	All ≤6	NR	All singleton	Hospital	NR
Ratnam 1974	IV oxytocin	IV oxytocin plus amniotomy	Oral prostaglandins			NR	NR	All intact	NR	NR	NR	Hospital	Some industry
Rayburn 1988	Placebo	Vaginal PGE ₂ (gel)				None	Mixed	All intact	All ≤6	All ≥ 40 weeks	All singleton	Outpatient	NR
Rayburn 1992	Placebo	Vaginal PGE ₂ pessary (slow release)				None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	Some industry
Razaq 2011	Vaginal misoprostol (≥50mcg)	Nitric oxide				NR	All nulliparous	NR	All ≤6	All ≥ 40 weeks	All singleton	Hospital	NR

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Reinhard 2014	Vaginal PGE ₂ (tablet)	Intracervical PGE ₂				None	Mixed	Some ruptured*	All ≤6	Mixed	All singleton	Hospital	No industry funding
Rezaie 2016	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)				None	Mixed	NR	All ≤6	All ≥ 40 weeks	Mixed	Hospital	No industry funding
Richardson 1991	Placebo	Intracervical PGE ₂				NR	NR	All intact	All ≤6	All >37 weeks	All singleton	Hospital	NR
Rix 1996	Vaginal PGE ₂ (tablet)	Intracervical PGE ₂				NR	Mixed	NR	All ≤6	Mixed	All singleton	Hospital	NR
Roach 1997	No treatment	Vaginal PGE ₂ pessary (normal release)				NR	Mixed	NR	NR	All ≥ 40 weeks	All singleton	Outpatient	NR
Roberts 1986	No treatment	Vaginal PGE ₂ (gel)	IV oxytocin	Laminaria		None	Mixed	All intact	All ≤6	Mixed	All singleton	Hospital	No industry funding
Rouben 1993	Vaginal PGE ₂ (gel)	Foley catheter				NR	Mixed	All intact	All ≤6	All >37 weeks	NR	Hospital	NR
Rouzi 2014	Vaginal PGE ₂ pessary (slow release)	Titrated (low dose) oral misoprostol solution				None	Mixed	Some ruptured*	All ≤6	Mixed	All singleton	Hospital	No industry funding

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Rouzi 2017	Oral misoprostol tablet (<50mcg)	Titrated (low dose) oral misoprostol solution				None	Mixed	Some ruptured*	All ≤6	Mixed	All singleton	Hospital	No industry funding
Rowlands 2001	Vaginal PGE ₂ pessary (normal release)	Vaginal misoprostol (≥50mcg)				None	All nulliparous	All intact	All ≤6	All >37 weeks	All singleton	Outpatient	NR
Roy 2015	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)	Buccal/sublingual misoprostol			NR	NR	NR	NR	All >37 weeks	NR	Hospital	NR
Rozenberg 2001	Vaginal PGE ₂ (gel)	Vaginal misoprostol (≥50mcg)				None	Mixed	Some ruptured*	All ≤6	All >37 weeks	All singleton	Hospital	No industry funding
Rozenberg 2004	Vaginal PGE ₂ pessary (slow release)	Vaginal misoprostol (≥50mcg)				None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	NR
Roztocil 1998	Vaginal PGE ₂ (gel)	Oestrogens	Laminaria			NR	NR	NR	All ≤6	Mixed	All singleton	Hospital	NR

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Russell 2007	Vaginal misoprostol (<50mcg)	Buccal/sublingual misoprostol				NR	NR	NR	All ≤6	Mixed	All singleton	Hospital	NR
Saad 2019	Foley catheter	Laminaria				NR	NR	NR	All ≤6	All >37 weeks	NR	Hospital	NR
Sadi 2016	Placebo	Herbal supplements				None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Outpatient	No industry funding
Saeed 2011	Vaginal PGE ₂ (tablet)	Vaginal misoprostol (≥50mcg)				None	Mixed	NR	All ≤6	All >37 weeks	All singleton	Hospital	NR
Saggaf 2001	Vaginal PGE ₂ (gel)	Vaginal misoprostol (≥50mcg)				None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	NR
Sahu 2004	Intracervical PGE ₂	Vaginal misoprostol (≥50mcg)				None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	NR
Salamalekis 2000	No treatment	IV oxytocin	Membrane sweeping			None	All nulliparous	All intact	All ≤6	All ≥ 40 weeks	All singleton	Outpatient	NR
Saleem 2006	Vaginal PGE ₂ pessary	Vaginal misoprostol (≥50mcg)	Foley catheter			None	Mixed	NR	All ≤6	All >37 weeks	All singleton	Hospital	NR

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
	(normal release)												
Saleh 1975	Amniotomy	IV oxytocin plus amniotomy				None	All nulliparous	All intact	All >6	All >37 weeks	All singleton	Hospital	NR
Salim 2011	Foley catheter	Double balloon/Cook's catheter				None	Mixed	All intact	All ≤6	Mixed	All singleton	Hospital	No industry funding
Salmon 1986	No treatment	Breast stimulation				None	All nulliparous	NR	NR	All >37 weeks	NR	Outpatient	NR
Sanchez-Ramos 1992	Vaginal PGE ₂ (gel)	Laminaria				None	Mixed	All intact	All ≤6	NR	All singleton	Hospital	NR
Sanchez-Ramos 1998	Vaginal PGE ₂ pessary (slow release)	Vaginal misoprostol (≥50mcg)				None	Mixed	Some ruptured*	Mixed	Mixed	All singleton	Hospital	NR
Savithri 2018	Intracervical PGE ₂	Oral misoprostol tablet (<50mcg)				None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	No industry funding
Sawai 1991	Placebo	Vaginal PGE ₂ (gel)				None	Mixed	All intact	Mixed	All ≥ 40 weeks	All singleton	Outpatient	NR

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Sawai 1994	Placebo	Vaginal PGE ₂ pessary (normal release)				None	Mixed	All intact	Mixed	All ≥ 40 weeks	NR	Outpatient	NR
Saxena 2011	Intracervical PGE ₂	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)			None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	NR
Sayed 2016	Foley catheter	Double balloon/Cook's catheter				None	All nulliparous	All intact	All ≤6	All ≥ 40 weeks	All singleton	Hospital	NR
Schmitz 2014	Placebo	Nitric oxide				NR	All nulliparous	All intact	All ≤6	All ≥ 40 weeks	All singleton	Outpatient	No industry funding
Schneider 2004	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)				NR	NR	NR	NR	NR	NR	Hospital	NR
Sciscione 1999	Intracervical PGE ₂	Foley catheter				Some previous*	Mixed	All intact	All ≤6	Mixed	All singleton	Hospital	NR
Sciscione 2001	Vaginal misoprostol (≥50mcg)	Foley catheter				Some previous*	Mixed	All intact	All ≤6	Mixed	All singleton	Hospital	NR

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Secher 1981	IV oxytocin	Oral prostaglandins				NR	Mixed	All intact	NR	NR	NR	Hospital	Some industry
Seeras 1995	Vaginal PGE ₂ (gel)	Intracervical PGE ₂				None	Mixed	All intact	NR	All >37 weeks	NR	Hospital	NR
Selo-Ojeme 2009	Amniotomy	IV oxytocin plus amniotomy				None	All nulliparous	All intact	All >6	All >37 weeks	All singleton	Hospital	No industry funding
Shaheen 2013	Vaginal PGE ₂ (gel)	Buccal/sublingual misoprostol				None	Mixed	NR	NR	All >37 weeks	All singleton	Hospital	No industry funding
Shakya 2010	Intracervical PGE ₂	Vaginal misoprostol (≥50mcg)				None	Mixed	All intact	All ≤6	All >37 weeks	NR	Hospital	NR
Sharami 2014	Vaginal misoprostol (≥50mcg)	Buccal/sublingual misoprostol				None	All nulliparous	All intact	All ≤6	Mixed	All singleton	Hospital	No industry funding
Sharma 2005	Intracervical PGE ₂	Vaginal misoprostol (≥50mcg)	Nitric oxide			None	All nulliparous	All intact	All ≤6	All >37 weeks	All singleton	Hospital	NR
Shechter-Maor 2015	Vaginal PGE ₂ pessary	Double balloon/Cook's catheter				None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	No industry funding

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
	(slow release)												
Sheela 2007	Intracervical PGE ₂	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)			None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	NR
Sheela 2015	Vaginal misoprostol (<50mcg)	Buccal/sublingual misoprostol				None	Mixed	Some ruptured*	All ≤6	All >37 weeks	All singleton	Hospital	No industry funding
Sheikher 2009	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)	Foley catheter			None	Mixed	Some ruptured*	All ≤6	All >37 weeks	All singleton	Hospital	NR
Shepherd 1976	Placebo	Extra-amniotic prostaglandin				NR	Mixed	NR	All ≤6	All >37 weeks	NR	Hospital	Some industry
Sherman 2001	Foley catheter	Extra-amniotic prostaglandin				None	Mixed	All intact	All ≤6	NR	All singleton	Hospital	NR
Shetty 2001	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)				None	Mixed	NR	Mixed	All >37 weeks	All singleton	Hospital	NR

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Shetty 2002a	Oral misoprostol tablet (≥ 50 mcg)	Buccal/sublingual misoprostol				None	Mixed	NR	All ≤ 6	All > 37 weeks	All singleton	Hospital	NR
Shetty 2002b	Oral misoprostol tablet (≥ 50 mcg)	Buccal/sublingual misoprostol				None	Mixed	NR	All ≤ 6	All > 37 weeks	All singleton	Hospital	NR
Shetty 2003	Vaginal misoprostol (< 50 mcg)	Oral misoprostol tablet (≥ 50 mcg)				None	Mixed	All intact	Mixed	All > 37 weeks	All singleton	Hospital	NR
Shetty 2004	Vaginal PGE ₂ (tablet)	Oral misoprostol tablet (≥ 50 mcg)				None	Mixed	All intact	Mixed	All > 37 weeks	All singleton	Hospital	NR
Sifakis 2007	Vaginal PGE ₂ (tablet)	Vaginal misoprostol (≥ 50 mcg)				None	Mixed	All intact	All ≤ 6	All > 37 weeks	All singleton	Hospital	NR
Silva-Cruz 1988	Vaginal PGE ₂ (gel)	IV oxytocin				NR	Mixed	All intact	Mixed	All > 37 weeks	All singleton	Hospital	NR
Singh 2014	No treatment	Breast stimulation				NR	All nulliparous	NR	NR	All > 37 weeks	NR	Outpatient	No industry funding
Sitthiwattanawong 1999	Vaginal misoprostol (≥ 50 mcg)	Oral misoprostol tablet (≥ 50 mcg)				None	Mixed	NR	All ≤ 6	Mixed	All singleton	Hospital	NR

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Smith 1990	Vaginal PGE ₂ (gel)	Vaginal PGE ₂ pessary (normal release)				NR	Mixed	All intact	All ≤6	Mixed	NR	Hospital	NR
Smith 1994	Vaginal PGE ₂ (gel)	Vaginal PGE ₂ pessary (slow release)				NR	NR	All intact	All ≤6	All >37 weeks	NR	Hospital	NR
Smith 2008	Placebo	Acupuncture				NR	Mixed	All intact	Mixed	All ≥ 40 weeks	All singleton	Outpatient	No industry funding
Soliman 2013	Vaginal misoprostol (≥50mcg)	Nitric oxide				None	All nulliparous	All intact	All ≤6	All >37 weeks	All singleton	Hospital	No industry funding
Solis Ruiz 2015	Vaginal PGE ₂ pessary (slow release)	Vaginal misoprostol (<50mcg)				NR	All nulliparous	NR	All ≤6	All ≥ 40 weeks	NR	Hospital	NR
Solt 2019	Foley catheter	Double balloon or Cook's catheter				None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	No industry funding
Somirathne 2017	Oral misoprostol tablet (≥50mcg)	Foley catheter				None	Mixed	NR	All ≤6	All ≥ 40 weeks	All singleton	Hospital	No industry funding

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Souzi 2018	Vaginal misoprostol (<50mcg)	Nitric oxide	Laminaria			NR	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	No industry funding
Souza 2013	Vaginal misoprostol (<50mcg)	Titrated (low dose) oral misoprostol solution				None	Mixed	Some ruptured*	All ≤6	All >37 weeks	All singleton	Hospital	No industry funding
Spallicci 2007	Placebo	Hyaluronidase				Some previous*	Mixed	All intact	All ≤6	All >37 weeks	NR	Hospital	Some industry
Spellacy 1973	IV oxytocin	IV prostaglandin				None	Mixed	All intact	Mixed	All >37 weeks	All singleton	Hospital	Some industry
Srisomboon 1996	Placebo	Vaginal misoprostol (≥50mcg)				None	Mixed	All intact	All ≤6	Mixed	All singleton	Hospital	NR
Srisomboon 1998	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)				None	Mixed	All intact	All ≤6	Mixed	All singleton	Hospital	NR
St Onge 1995	Intracervical PGE ₂	Foley catheter				None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	NR
Stampe Sorensen 1992	Vaginal PGE ₂ (tablet)	Vaginal PGE ₂ pessary (normal release)				NR	Mixed	NR	Mixed	Mixed	NR	Hospital	NR

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Steer 1976	IV oxytocin	IV oxytocin plus amniotomy				NR	NR	All intact	NR	NR	NR	Hospital	NR
Stempel 1997	Vaginal PGE ₂ (gel)	Intracervical PGE ₂				NR	Mixed	NR	All ≤6	NR	All singleton	Hospital	No industry funding
Stenlund 1999	Placebo	Mifepristone				None	Mixed	All intact	All ≤6	All ≥ 40 weeks	All singleton	Outpatient	Some industry
Stewart 1983	Vaginal PGE ₂ (tablet)	Extra-amniotic prostaglandin				None	All nulliparous	NR	All ≤6	All >37 weeks	All singleton	Hospital	NR
Stitely 2000	Placebo	Vaginal misoprostol (<50mcg)				None	Mixed	All intact	All ≤6	All ≥ 40 weeks	All singleton	Outpatient	No industry funding
Strobel 2006	Vaginal PGE ₂ pessary (slow release)	Intracervical PGE ₂				None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	NR
Suffecool 2014	Vaginal PGE ₂ pessary (slow release)	Double balloon/Cook's catheter				None	All nulliparous	All intact	All ≤6	All >37 weeks	All singleton	Hospital	No industry funding

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Sultana 2006	Vaginal misoprostol ($\geq 50\text{mcg}$)	Oral misoprostol tablet ($\geq 50\text{mcg}$)				None	Mixed	NR	All ≤ 6	All > 37 weeks	All singleton	Hospital	NR
Surita 2005	Hyaluronidase	Foley catheter				Some previous*	Mixed	All intact	All ≤ 6	All > 37 weeks	All singleton	Hospital	NR
Suvobrata 2011	IV oxytocin	Buccal/sublingual misoprostol				NR	All nulliparous	NR	All > 6	All > 37 weeks	NR	Hospital	NR
Suzuki 2000	No treatment	Oral prostaglandins				None	Mixed	All intact	NR	All > 37 weeks	All multi-fetal	NR	NR
Tabasi 2007	Vaginal misoprostol ($\geq 50\text{mcg}$)	IV oxytocin				None	Mixed	All intact	All ≤ 6	All > 37 weeks	All singleton	Hospital	NR
Tabor 1995	Intracervical PGE ₂	Vaginal misoprostol ($\geq 50\text{mcg}$)				NR	NR	NR	All ≤ 6	NR	NR	Hospital	NR
Tabowei 2003	Vaginal misoprostol ($< 50\text{mcg}$)	Foley catheter				Some previous*	Mixed	All intact	All ≤ 6	All > 37 weeks	All singleton	Hospital	NR
Taechakraichana 1996	Intracervical PGE ₂	Vaginal PGE ₂ pessary (normal release)				None	Mixed	All intact	All ≤ 6	NR	All singleton	Hospital	No industry funding

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Taher 2011	Vaginal PGE ₂ (tablet)	Vaginal PGE ₂ (gel)				None	Mixed	Some ruptured*	All ≤6	All >37 weeks	Mixed	Hospital	No industry funding
Tan 2007	No treatment	Sexual intercourse				None	Mixed	All intact	NR	All >37 weeks	All singleton	Outpatient	NR
Tan 2010	Vaginal PGE ₂ pessary (normal release)	Vaginal misoprostol (<50mcg)				None	Mixed	NR	All ≤6	All >37 weeks	All singleton	Hospital	NR
Tan 2013	Amniotomy	IV oxytocin plus amniotomy				None	All multiparous	All intact	All >6	All >37 weeks	All singleton	Hospital	No industry funding
Tandon 2014	Intracervical PGE ₂	Vaginal misoprostol (≥50mcg)				NR	Mixed	NR	NR	Mixed	All singleton	Hospital	NR
Tannirandorn 1999	No treatment	Membrane sweeping				None	Mixed	All intact	Mixed	All >37 weeks	NR	Outpatient	NR
Ten Eikelder 2016	Oral misoprostol tablet (≥50mcg)	Foley catheter				None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	No industry funding
Tessier 1997	Vaginal PGE ₂ (gel)	Oral misoprost				Some previous*	Mixed	Some ruptured*	Mixed	Mixed	Mixed	Outpatient	NR

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
		ol tablet (≥50mcg)											
Tey 1995	No treatment	Intracervical PGE ₂				NR	NR	NR	Mixed	All >37 weeks	NR	Hospital	NR
Thaisomboon 2012	Oral misoprostol tablet (≥50mcg)	Titrated (low dose) oral misoprostol solution				None	Mixed	All intact	All ≤6	All ≥ 40 weeks	All singleton	Hospital	No industry funding
Thakur 2005	Placebo	Mifepristone				None	All nulliparous	NR	All ≤6	All ≥ 40 weeks	All singleton	NR	NR
Thavarasah 1990	Vaginal PGE ₂ (tablet)	Intracervical PGE ₂				None	Mixed	NR	All ≤6	All >37 weeks	All singleton	Hospital	NR
Thiery 1984	Placebo	Vaginal PGE ₂ (tablet)	Intracervical PGE ₂			None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	NR
Thomas 1986	PGF ₂ gel	Foley catheter				NR	Mixed	NR	All ≤6	NR	All singleton	Hospital	NR
Tomlinson 2001	Vaginal PGE ₂ (gel)	Vaginal PGE ₂ pessary (slow release)				None	Mixed	All intact	Mixed	Mixed	NR	Hospital	NR

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Topozada 1997	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)				NR	Mixed	NR	All ≤6	All >37 weeks	All singleton	Hospital	NR
Torkzahani 2017	No treatment	Placebo	Acupuncture			NR	All nulliparous	NR	All ≤6	All >37 weeks	All singleton	Outpatient	No industry funding
Triglia 2010	Vaginal PGE ₂ (gel)	Vaginal PGE ₂ pessary (slow release)				None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	No industry funding
Trofatter 1985	Placebo	Intracervical PGE ₂				None	Mixed	All intact	All ≤6	Mixed	NR	Hospital	Some industry
Trofatter 1993	No treatment	Intracervical PGE ₂				None	Mixed	NR	All ≤6	All >37 weeks	Mixed	Hospital	Some industry
Tromans 1981	Vaginal PGE ₂ (gel)	Oestrogens				NR	Mixed	NR	All >6	All >37 weeks	All singleton	Hospital	No industry funding
Troostwijk 1992	Placebo	Intracervical PGE ₂				None	Mixed	All intact	All ≤6	Mixed	All singleton	Hospital	Some industry
Tulek 2018	IV oxytocin	Double balloon or Cook's catheter				None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	No industry funding
Tylleskar 1979	No treatment	IV oxytocin plus				NR	Mixed	NR	Mixed	All ≥ 40 weeks	All singleton	NR	NR

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
		amniotomy											
Ugwu 2013	Vaginal misoprostol (<50mcg)	Foley catheter				None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	No industry funding
Ugwu 2014	No treatment	Membrane sweeping				NR	Mixed	All intact	Mixed	All ≥ 40 weeks	All singleton	Outpatient	NR
Ulmsten 1979	Intracervical PGE ₂	IV oxytocin				NR	All nulliparous	All intact	Mixed	All >37 weeks	All singleton	Hospital	NR
Ulmsten 1982	Placebo	Intracervical PGE ₂				None	All nulliparous	NR	NR	All >37 weeks	NR	Hospital	NR
Ulmsten 1985	Placebo	Intracervical PGE ₂	Vaginal PGE ₂ pessary (normal release)			NR	All nulliparous	NR	All ≤6	All >37 weeks	NR	Hospital	NR
Uludag 2005	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)				None	Mixed	Some ruptured*	All ≤6	Mixed	All singleton	Hospital	NR
Vahid Roudsari 2011	Vaginal misoprostol (<50mcg)	Foley catheter				None	NR	All intact	All ≤6	All >37 weeks	All singleton	Hospital	NR

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Vakhariya 1972	IV oxytocin	IV prostaglandin				None	All multiparous	All intact	Mixed	Mixed	NR	Hospital	Some industry
Valadan 2005	Vaginal PGE ₂ (tablet)	IV oxytocin				None	NR	All intact	All ≤6	All ≥ 40 weeks	All singleton	Hospital	No industry funding
Valentine 1977	No treatment	IV oxytocin	Oral prostaglandins			None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	Some industry
van Gemund 2004	Vaginal PGE ₂ (gel)	Vaginal misoprostol (<50mcg)				Some previous*	Mixed	Some ruptured*	All ≤6	Mixed	Mixed	Hospital	NR
Varaklis 1995	Intracervical PGE ₂	Vaginal misoprostol (<50mcg)				None	Mixed	NR	All ≤6	All >37 weeks	All singleton	Hospital	Some industry
Vayssiere 2018	Vaginal PGE ₂ pessary (slow release)	Vaginal misoprostol (<50mcg)				None	NR	NR	All ≤6	Mixed	All singleton	Hospital	NR
Veena 2016	Intracervical PGE ₂	Buccal/sublingual misoprostol				None	Mixed	Some ruptured*	All ≤6	All >37 weeks	All singleton	Hospital	No industry funding
Wallstrom 2019	Titrated (low dose) oral	Sustained release				None	All nulliparous	Mixed	All ≤6	All >37 weeks	All singleton	Hospital	No industry funding

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
	misoprostol solution	misoprostol insert											
Wang 2016	Vaginal PGE ₂ pessary (normal release)	Titrated (low dose) oral misoprostol solution				None	All nulliparous	Some ruptured*	All ≤6	Mixed	All singleton	Hospital	No industry funding
Weiss 2016	Placebo	Relaxin				None	All nulliparous	All intact	All ≤6	All ≥ 40 weeks	All singleton	Hospital	Some industry
Wieland 1999	Vaginal PGE ₂ pessary (slow release)	Intracervical PGE ₂				None	Mixed	All intact	All ≤6	All >37 weeks	NR	Hospital	NR
Wielgos 2007	Vaginal PGE ₂ pessary (slow release)	Intracervical PGE ₂				NR	Mixed	NR	All ≤6	Mixed	All singleton	Hospital	NR
Wilson 1978	Vaginal PGE ₂ (tablet)	IV oxytocin	Extra-amniotic prostaglandins	Oral prostaglandins		NR	All nulliparous	NR	All ≤6	NR	NR	Hospital	NR
Wing 1995a	Intracervical PGE ₂	Vaginal misoprostol				None	Mixed	All intact	All ≤6	Mixed	All singleton	Hospital	NR

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
		ol (≥50mcg)											
Wing 1995b	Intracervical PGE ₂	Vaginal misoprostol (<50mcg)				None	Mixed	All intact	All ≤6	Mixed	All singleton	Hospital	NR
Wing 1997	Vaginal PGE ₂ pessary (slow release)	Vaginal misoprostol (<50mcg)				None	NR	All intact	All ≤6	Mixed	All singleton	Hospital	NR
Wing 1999	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)				None	Mixed	All intact	All ≤6	Mixed	All singleton	Hospital	NR
Wing 2000a	Placebo	Mifepristone				None	Mixed	All intact	All ≤6	All ≥ 40 weeks	All singleton	Hospital	Some industry
Wing 2000b	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)				None	Mixed	Some ruptured*	Mixed	Mixed	All singleton	Hospital	NR
Wing 2004	Oral misoprostol tablet (≥50mcg)	IV oxytocin				None	Mixed	NR	All >6	All >37 weeks	All singleton	Hospital	NR
Wing 2008	Vaginal PGE ₂ pessary (slow release)	Sustained release misoprostol insert				None	Mixed	Some ruptured*	All ≤6	Mixed	All singleton	Hospital	No industry funding

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Wing 2013	Vaginal PGE ₂ pessary (slow release)	Sustained release misoprostol insert				None	Mixed	NR	All ≤6	Mixed	All singleton	Hospital	Some industry
Wingerup 1978	Placebo	Intracervical PGE ₂				NR	All nulliparous	All intact	All ≤6	All >37 weeks	NR	Hospital	NR
Wiriyasirivaj 1996	No treatment	Membrane sweeping				None	Mixed	All intact	NR	All >37 weeks	NR	Outpatient	NR
Witter 1987	No treatment	IV oxytocin				None	Mixed	NR	NR	All ≥ 40 weeks	NR	NR	NR
Witter 1992	Placebo	Vaginal PGE ₂ pessary (slow release)				None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	Some industry
Witter 1996	Placebo	Vaginal PGE ₂ pessary (slow release)				None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	Some industry
Wong 2002	No treatment	Membrane sweeping				None	Mixed	All intact	Mixed	All ≥ 40 weeks	NR	Outpatient	No industry funding
Yazdizadeh 2013	Placebo	Nitric oxide				None	All nulliparous	NR	All ≤6	All ≥ 40 weeks	All singleton	Outpatient	NR

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Yelikar 2015	Placebo	Mifepristone				None	Mixed	All intact	All ≤6	All ≥ 40 weeks	All singleton	Hospital	No industry funding
Yenuberi 2016	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)				None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Hospital	No industry funding
Yildirim 2010	No treatment	Membrane sweeping				None	Mixed	All intact	All ≤6	All >37 weeks	All singleton	Outpatient	No industry funding
Young 2019	Vaginal PGE2 (gel)	Vaginal misoprostol (< 50mcg)	Oral misoprostol tablet (≥50mcg)			None	Mixed	Some ruptured*	Mixed	All >37 weeks	All singleton	Hospital	No industry funding
Yuen 1996	Intracervical PGE ₂	Vaginal PGE ₂ pessary (normal release)	Double balloon/Cook's catheter			Some previous*	Mixed	All intact	All ≤6	Mixed	All singleton	Hospital	NR
Zahran 2009	Vaginal misoprostol (≥50mcg)	Buccal/sublingual misoprostol				None	Mixed	All intact	All ≤6	Mixed	All singleton	Hospital	NR

Trial Name	Arm 1 intervention	Arm 2	Arm 3	Arm 4	Arm 5	Previous CS	Parity	Membranes	Bishop score	Gestational age	Fetus	Setting	Funding
Zanconato 2011	Vaginal PGE ₂ (gel)	Vaginal PGE ₂ pessary (slow release)				None	All nulliparous	All intact	All ≤6	All >37 weeks	All singleton	Hospital	No industry funding
Zanini 1990	Vaginal PGE ₂ (gel)	Intracervical PGE ₂				None	Mixed	All intact	All ≤6	Mixed	All singleton	Hospital	NR
Zeteroglu 2004	Vaginal misoprostol (≥50mcg)	IV oxytocin				None	All multiparous	NR	All ≤6	Mixed	All singleton	Hospital	NR
Zeteroglu 2006a	Vaginal misoprostol (≥50mcg)	IV oxytocin				None	All multiparous	Some ruptured*	All ≤6	Mixed	All singleton	Hospital	NR
Zeteroglu 2006b	Vaginal misoprostol (≥50mcg)	IV oxytocin				None	All multiparous	Some ruptured*	All ≤6	All >37 weeks	All singleton	Hospital	NR
Zhang 2015	Placebo	Vaginal misoprostol (<50mcg)				None	All nulliparous	All intact	All ≤6	All >37 weeks	All singleton	Hospital	No industry funding
Ziaei 2003	No treatment	Corticosteroids				None	Mixed	All intact	All >6	All ≥ 40 weeks	All singleton	Outpatient	NR
Zvandasara 2008	Vaginal misoprostol (≥50mcg)	Titrated (low dose) oral misoprostol solution				None	Mixed	Some ruptured*	NR	Mixed	All singleton	Hospital	NR

1 NR: not reported; Bishop score: cervical status;

2 *these women comprised <1/3 of the total participants recruited in the study

- 1 *Gestational age, mixed: may include some preterm;*
 2 *Membranes, some ruptured: Some participants with ruptured membranes*
 3 *Previous CS, None: No participants with previous CS;*
 4 *Funding, Some industry: Some/all funding from pharmaceutical industry*

5
6
7
8

9 D2 – Risk of bias assessment for included studies

10 **Table 2: Risk of bias assessment**

Trial Name	Selection bias (Random sequence generation)	Selection Bias (allocation concealment)	Performance bias (Blinding of participants and personnel)	Detection bias (Blinding of outcomes)	Attrition bias (incomplete outcome data)	Reporting bias (selective reporting)	Other biases	Cochrane review assessment used for RoB (if available)
Aalami-Harandi 2013	1	3	2	2	3	3	3	Oral misoprostol
Abdelaziz 2018	1	1	1	1	1	1	1	
Abdul 2007	1	1	3	3	2	1	1	Vaginal misoprostol
Abedi-Asl 2007	3	3	2	1	1	3	1	
Abotorabi 2019	1	1	1	1	1	3	1	
Adair 1998	3	1	1	1	3	3	3	Oral misoprostol
Adam 2005	3	3	3	3	3	3	3	Oral misoprostol
Adeniji 2005	1	1	2	3	1	3	1	
Adeniyi 2014	1	1	3	1	1	3	1	

Trial Name	Selection bias (Random sequence generation)	Selection Bias (allocation concealment)	Performance bias (Blinding of participants and personnel)	Detection bias (Blinding of outcomes)	Attrition bias (incomplete outcome data)	Reporting bias (selective reporting)	Other biases	Cochrane review assessment used for RoB (if available)
Aduloju 2016	1	1	2	1	1	1	1	
Aduloju 2019	1	1	3	1	1	3	1	
Agarwal 2003	1	3	3	1	1	3	1	
Agarwal 2012	1	3	2	3	1	1	1	outpatient
Agarwal 2014	1	3	2	1	1	3	1	
Ajori 2013	1	1	1	1	1	1	3	acupuncture
Akay 2012	1	1	2	1	1	3	1	
Alcoseba-Lim 1992	3	2	3	3	3	3	3	could not locate review or study to assess RoB
Allott 1993	1	1	3	1	1	3	1	
Al-Malt 1995	3	3	1	3	1	3	3	PG vaginal
Al-Sebai 1993	3	3	3	3	1	3	3	PG vaginal
Alsharnoubi 2015	3	1	1	1	1	2	3	
Al-Taani 2004	1	3	2	1	1	3	1	
Anand 2012	1	3	3	1	1	3	1	
Andersen 2013	1	1	2	1	1	3	1	
Asher 2009	1	1	1	1	1	3	1	acupuncture
Ashrafunnessa 1997	2	2	2	2	1	1	3	oxytocin
Atad 1996	1	3	2	1	1	3	1	Mechanical
Ayaz 2010	3	1	3	1	1	3	1	
Azubuikwe 2015	1	3	2	1	1	3	1	
Bagratee 1990	1	3	3	1	1	3	3	

Trial Name	Selection bias (Random sequence generation)	Selection Bias (allocation concealment)	Performance bias (Blinding of participants and personnel)	Detection bias (Blinding of outcomes)	Attrition bias (incomplete outcome data)	Reporting bias (selective reporting)	Other biases	Cochrane review assessment used for RoB (if available)
Bakos 1987	2	2	2	1	1	3	1	
Balci 2010	1	3	2	1	1	3	1	
Balci 2011	1	3	2	1	1	3	1	
Barda 2018	3	3	2	1	1	1	2	
Barkai 1994	1	1	2	3	1	3	1	IOL
Bartha 2000	3	1	3	3	3	3	3	Oral misoprostol
Bartusevicius 2006	1	1	1	1	1	3	3	
Beigi 2003	1	3	1	1	3	3	3	Oral misoprostol
Bell 1993	3	3	1	1	1	3	1	
Bennett 1998	1	1	1	1	1	3	3	Oral misoprostol
Berghella 1996	1	1	3	1	1	3	1	
Berkane 2005	3	3	1	1	1	1	1	mifepristone
Bernstein 1991	3	1	1	1	1	3	1	
Biron-Shental 2004	1	3	2	2	3	3	3	Mechanical
Bollapragada 2009	1	1	1	3	2	1	1	outpatient
Boulvain 1998	1	1	3	1	1	3	2	
Bounyasong 2000	3	3	3	3	2	3	3	Vaginal misoprostol
Bremme 1980	3	3	2	1	2	3	2	
Brennand 1997	3	1	1	1	1	3	1	
Buchanan 1984	3	3	1	1	1	3	3	PG vaginal
Bullarbo 2007	1	1	1	3	1	1	1	outpatient
Buser 1997	1	1	2	1	1	3	1	

Trial Name	Selection bias (Random sequence generation)	Selection Bias (allocation concealment)	Performance bias (Blinding of participants and personnel)	Detection bias (Blinding of outcomes)	Attrition bias (incomplete outcome data)	Reporting bias (selective reporting/)	Other biases	Cochrane review assessment used for RoB (if available)
Buttino 1990	1	1	1	3	1	1	1	outpatient
Cahill 1988	2	3	2	1	1	3	3	
Caliskan 2005	1	1	2	1	1	3	1	
Cammu 1998	1	1	3	1	1	3	1	
Campbell 1984	2	2	1	1	1	3	3	PG vaginal
Campos Perez 1991	3	3	3	1	3	3	3	
Cardozo 1986	2	2	3	3	2	3	2	PG vaginal
Carlan 2001	1	1	2	2	3	3	3	Oral misoprostol
Carlan 2002	1	1	2	1	1	3	1	
Castro 2014	1	3	2	1	1	3	1	
Cecatti 2000	3	3	2	1	3	3	3	
Chai 2018	1	3	2	1	1	3	1	
Chang 1997	3	3	3	1	1	1	3	Vaginal misoprostol
Chanrachakul 2000a	1	3	3	1	1	3	1	
Chanrachakul 2000b	1	3	3	1	1	3	3	nitric oxide
Chanrachakul 2002	1	3	3	1	1	1	1	nitric oxide
Chanrachakul 2003	1	3	2	3	1	3	1	IOL
Chanrachakul 2010	3	3	3	1	3	3	3	
Charoenkul 2000	3	3	1	1	1	3	1	
Chatterjee 1991	3	3	1	1	3	3	3	PG vaginal
Chavakula 2015	1	1	2	1	1	3	2	
Chayen 1986	2	2	2	1	1	3	1	

Trial Name	Selection bias (Random sequence generation)	Selection Bias (allocation concealment)	Performance bias (Blinding of participants and personnel)	Detection bias (Blinding of outcomes)	Attrition bias (incomplete outcome data)	Reporting bias (selective reporting)	Other biases	Cochrane review assessment used for RoB (if available)
Chen 2014	3	3	2	1	1	3	1	
Cheng 2008	1	1	2	2	2	3	3	Oral misoprostol
Chitrakar 2012	3	3	2	1	1	3	1	
Chua 1988	3	3	2	1	1	3	1	
Chua 1997	1	3	2	1	1	3	1	
Chuck 1995	1	1	2	1	1	3	1	
Chung 2003	1	1	2	1	1	3	1	
Chyu 1997	1	3	2	1	1	3	1	
Clark 1998	3	3	2	1	3	3	3	
Colon 2005	1	1	2	2	1	3	3	Oral misoprostol
Conde 2017	1	1	2	1	1	1	2	
Corrado 2001	1	3	3	1	1	3	1	
Craft 1971	2	3	2	1	2	3	2	
Crane 1997	1	1	2	1	1	3	1	
Cromi 2011	1	3	2	1	1	3	1	
Cromi 2012	1	1	2	1	1	3	1	
Curet 1989	1	1	1	1	1	1	3	PG vaginal
Dällenbach 2003	1	1	2	2	1	3	3	Oral misoprostol
Dalui 2005	3	3	2	1	1	3	1	
Damania 1992	2	3	2	2	1	3	2	oxytocin
Danielian 1999	3	3	2	1	1	3	1	Vaginal misoprostol
Dare 2002	1	1	2	1	1	3	1	

Trial Name	Selection bias (Random sequence generation)	Selection Bias (allocation concealment)	Performance bias (Blinding of participants and personnel)	Detection bias (Blinding of outcomes)	Attrition bias (incomplete outcome data)	Reporting bias (selective reporting)	Other biases	Cochrane review assessment used for RoB (if available)
Darroca 1996	1	1	1	1	1	3	1	
Davey 1979	3	3	2	1	1	3	3	
De Aquino 2003	1	1	3	3	2	1	1	Vaginal misoprostol
De Bonrosto Torralba 2019	3	1	2	1	1	3	1	
De la Torre 2001	1	3	2	1	1	3	1	
De Miranda 2006	1	1	2	1	1	3	3	
DebBarma 2015	1	3	1	1	1	3	3	
Demirel 2015	1	1	2	1	1	3	2	
Denguezli 2007	1	1	3	3	2	1	1	Vaginal misoprostol
Deo 2012	1	1	2	1	1	3	1	
Deshmukh 2011	3	3	2	1	1	3	1	
Deshmukh 2013	3	3	3	3	1	3	3	Oral misoprostol
Diro 1999	1	3	1	1	1	3	1	
Doany 1997	1	3	1	3	1	3	3	PG vaginal
Dodd 2006	3	1	1	3	3	3	3	Oral misoprostol
Dogra 2019	1	1	2	1	1	3	1	
Domisse 1980	2	3	3	3	1	3	3	PG vaginal
Domisse 1987	1	3	2	1	1	3	1	
Dulger 2018	1	3	3	1	1	3	1	
Dyar 2000	3	3	3	3	3	3	3	Oral misoprostol
Edwards 2014	3	3	2	1	3	3	3	
Egarter 1989	3	3	3	3	3	3	1	PG vaginal

Trial Name	Selection bias (Random sequence generation)	Selection Bias (allocation concealment)	Performance bias (Blinding of participants and personnel)	Detection bias (Blinding of outcomes)	Attrition bias (incomplete outcome data)	Reporting bias (selective reporting)	Other biases	Cochrane review assessment used for RoB (if available)
Ekman 1983	3	3	3	1	1	3	1	
Ekman 1986	3	3	2	2	3	1	1	oxytocin
El-Azeem 1997	3	1	1	1	3	3	3	Vaginal misoprostol
El-Din 2000	3	3	2	1	3	3	3	
Elhassan 2004	3	3	3	3	2	1	1	Vaginal misoprostol
Elhassan 2005a	3	3	2	2	2	1	1	Vaginal misoprostol
Elhassan 2005b	3	3	2	1	1	3	1	
El-Mardi 1991	3	3	3	3	1	3	1	PG vaginal
El-Shawarby 2006	3	1	2	3	2	3	3	PG vaginal
El-Sherbiny 2001	1	3	3	1	1	3	1	
El-Torkey 1992	3	1	2	1	1	3	1	
Eroglu 2007	3	2	2	2	2	1	1	Vaginal misoprostol
Escudero 1997	1	3	2	1	1	3	2	Vaginal misoprostol
Ezechukwu 2015	1	1	2	1	1	3	1	
Facchinetti 2005	1	3	2	1	1	3	1	
Facchinetti 2007	1	3	2	1	1	3	1	
Farah 1997	1	3	1	1	1	3	1	
Feitosa 2006	1	1	1	1	1	3	1	
Fenton 1985	3	3	1	1	1	3	1	
Ferguson 2002	1	3	1	1	1	3	1	
Ferraiolo 2010	2	2	2	2	2	3	3	PG vaginal
Fisher 2001	1	1	1	1	1	3	1	Oral misoprostol

Trial Name	Selection bias (Random sequence generation)	Selection Bias (allocation concealment)	Performance bias (Blinding of participants and personnel)	Detection bias (Blinding of outcomes)	Attrition bias (incomplete outcome data)	Reporting bias (selective reporting)	Other biases	Cochrane review assessment used for RoB (if available)
Fletcher 1993	3	3	1	1	1	3	2	
Fletcher 1994	3	1	2	1	1	3	1	
Fonseca 2008	1	1	2	1	1	3	1	
Frass 2011	3	3	2	1	1	3	1	
Frydman 1991	3	1	1	3	3	3	3	outpatient
Gagnon-Gervais 2012	3	1	2	1	1	3	1	
Gaikwad 2014	3	3	3	1	1	3	3	
Garry 2000	3	2	3	3	3	3	3	castor oil
Garry 2003	1	1	2	2	1	1	1	Vaginal misoprostol
Gattas 2020	1	1	1	1	1	1	2	
Gaudet 2008	1	1	1	1	1	3	1	acupuncture
Gelisen 2005	3	3	2	3	1	3	1	IOL
Getgan 2003	3	3	1	1	3	3	3	
Ghanaie 2013	3	1	2	1	1	3	1	
Gherman 2001	1	1	1	3	3	3	3	Oral misoprostol
Giacalone 1998	1	1	1	1	1	1	1	outpatient
Gihwala 1987	3	3	2	1	1	3	1	
Gilad 2018	1	1	1	1	1	1	1	
Gilson 1993	3	3	1	1	1	3	1	
Gilson 1996	1	3	2	1	1	3	1	
Girija 2009	1	1	2	1	1	3	2	
Girija 2011	3	1	2	1	1	3	2	

Trial Name	Selection bias (Random sequence generation)	Selection Bias (allocation concealment)	Performance bias (Blinding of participants and personnel)	Detection bias (Blinding of outcomes)	Attrition bias (incomplete outcome data)	Reporting bias (selective reporting)	Other biases	Cochrane review assessment used for RoB (if available)
Glagoleva 1999	3	3	3	1	3	3	3	
Goel 1986	3	2	3	3	3	3	3	could not locate review or study to assess RoB
Golbus 1977	3	3	1	1	1	3	1	
Goldenberg 1996	1	3	2	1	1	3	1	
Gottschall 1997	1	1	2	1	1	3	1	
Gower 1982	3	3	1	1	1	3	1	
Graves 1985	3	3	3	3	3	3	3	PG vaginal
Green 1998	3	3	1	3	3	3	3	PG vaginal
Greer 1989	3	3	2	1	1	3	1	
Greer 1990	3	3	3	3	3	3	3	PG vaginal
Gregson 2005	1	1	3	3	2	1	1	Vaginal misoprostol
Gregson 2015	1	1	2	1	1	3	2	
Greybush 2001	1	1	2	1	1	3	1	
Gribel 2011	1	1	2	1	1	3	1	acupuncture
Grünnberger 1986	3	3	2	1	1	3	3	
Guha 2015	3	3	2	1	1	3	3	
Gupta 1998	1	1	2	1	1	3	1	
Gupta 2006	2	3	2	1	1	3	3	
Gupta 2010	3	3	3	1	1	3	1	
Haas 2019	1	1	1	1	1	1	1	
Habib 2008	1	1	1	3	1	1	1	outpatient

Trial Name	Selection bias (Random sequence generation)	Selection Bias (allocation concealment)	Performance bias (Blinding of participants and personnel)	Detection bias (Blinding of outcomes)	Attrition bias (incomplete outcome data)	Reporting bias (selective reporting)	Other biases	Cochrane review assessment used for RoB (if available)
Haghighi 2013	3	1	1	1	1	1	1	nitric oxide
Haghighi 2015	1	3	2	1	1	3	2	
Hales 1994	3	3	1	1	1	3	3	
Hall 2002	1	1	3	3	3	3	1	Oral misoprostol
Harper 2006	1	1	2	3	1	3	1	acupuncture
Has 2002	1	3	1	1	1	3	1	
Haugland 2012	3	3	3	1	1	3	3	
Hay 1995	3	3	3	1	3	3	3	
Heden 1991	2	2	2	1	1	3	3	
Hemlin 1998	3	1	2	1	1	3	1	
Henry 2013	1	1	2	1	1	1	1	
Herabutya 1988	3	3	2	1	1	3	2	
Herabutya 1992	3	3	2	3	1	3	1	IOL
Herabutya 1993	3	3	2	1	1	3	1	
Herabutya 1997	3	3	2	1	1	3	2	Vaginal misoprostol
Hill 2008	1	1	2	1	1	3	1	
Hofmeyr 2001	1	1	1	1	3	3	3	Oral misoprostol
Hokkila 2019	1	1	2	1	1	3	2	
Hoppe 2016	1	1	2	1	1	3	2	
Hosli 2008	1	3	2	1	1	3	1	
Howarth 1996	1	1	3	1	1	3	1	
Hudon 1999	3	3	2	1	3	3	3	

Trial Name	Selection bias (Random sequence generation)	Selection Bias (allocation concealment)	Performance bias (Blinding of participants and personnel)	Detection bias (Blinding of outcomes)	Attrition bias (incomplete outcome data)	Reporting bias (selective reporting)	Other biases	Cochrane review assessment used for RoB (if available)
Hutchon 1980	3	3	1	1	1	3	2	
Incerpi 2001	1	1	1	3	3	3	1	outpatient
Irion 1998	1	3	2	1	1	3	1	
Iskander 1978	3	3	2	1	1	3	1	
Jackson 1994	3	1	1	1	1	1	1	oxytocin
Jagani 1982	2	2	2	1	1	3	1	
Jagani 1984	2	2	2	1	1	3	1	
Janakiraman 2011	1	3	2	1	1	3	2	
Jeeva 1982	3	3	2	1	1	2	3	Mechanical
Jindal 2019	3	1	1	1	1	3	1	
Johnson 1985	1	3	2	1	1	3	1	
Jozwiak 2011	1	1	2	1	1	1	1	
Jozwiak 2013	1	1	2	1	1	1	3	
Jozwiak 2014	1	1	2	1	1	1	3	
Kadanali 1996	3	1	2	1	1	3	1	
Kadian 2008	3	3	3	3	3	3	3	nitric oxide
Kalkat 2008	3	1	3	3	1	3	3	PG vaginal
Kaminski 1994	1	1	2	1	1	3	1	
Kandil 2012	2	2	2	1	1	3	1	
Karatas 2016	3	3	3	1	3	3	1	
Kashanian 2006a	3	3	2	1	3	3	1	
Kashanian 2006b	3	1	3	1	3	3	1	

Trial Name	Selection bias (Random sequence generation)	Selection Bias (allocation concealment)	Performance bias (Blinding of participants and personnel)	Detection bias (Blinding of outcomes)	Attrition bias (incomplete outcome data)	Reporting bias (selective reporting)	Other biases	Cochrane review assessment used for RoB (if available)
Kashanian 2008	3	3	1	1	1	3	1	
Kashanian 2020	1	3	1	1	1	2	1	
Katz 1983	2	2	2	1	1	3	3	
Kaul 2004	3	3	2	1	1	3	3	
Keirse 1995	3	1	3	1	1	3	1	
Kennedy 1978	3	3	2	1	1	3	3	
Kennedy 1982	3	3	2	1	1	3	1	
Kennel 2018	3	3	1	1	2	3	3	
Khatib 2019	3	3	2	1	3	3	1	
Khazardoost 2011	3	3	3	3	3	3	3	Oral misoprostol
Khoury 2001	1	1	2	1	1	3	1	
Kidanto 2007	3	3	2	1	1	3	3	
Kim 2000	3	2	3	3	3	3	3	could not locate review or study to assess RoB
Kipikasa 2005	1	3	1	1	3	3	3	Oral misoprostol
Koc 2013	1	3	2	1	1	3	1	
Kolderup 1999	1	1	2	1	1	3	1	
Komala 2013	3	3	2	1	1	3	3	
Kovavisarach 1997	3	3	3	3	3	3	3	Vaginal misoprostol
Kovavisarach 1998	3	3	3	3	1	3	3	Vaginal misoprostol
Krammer 1995	1	3	2	1	1	3	1	
Krishnamurthy 2015	1	1	3	1	1	3	1	

Trial Name	Selection bias (Random sequence generation)	Selection Bias (allocation concealment)	Performance bias (Blinding of participants and personnel)	Detection bias (Blinding of outcomes)	Attrition bias (incomplete outcome data)	Reporting bias (selective reporting)	Other biases	Cochrane review assessment used for RoB (if available)
Krithika 2008	1	3	3	3	2	3	3	Vaginal misoprostol
Kulshreshtha 2007	3	3	3	3	2	1	1	Vaginal misoprostol
Kumar 2001	3	3	3	3	2	1	1	Vaginal misoprostol
Kwon 2001	3	1	1	1	1	1	1	Oral misoprostol
Lackritz 1979	3	3	2	1	1	3	1	
Laloha 2015	3	3	1	1	1	1	1	
Lange 1984	1	2	2	2	3	1	1	oxytocin
Langenegger 2005	1	1	2	1	1	3	2	
Larmon 2002	1	1	3	3	1	3	3	outpatient
Laube 1986	3	3	1	1	1	3	2	
Le Roux 2002	1	1	2	1	3	3	1	
Lee 1997	3	1	1	1	1	3	1	
Legarth 1987	3	2	2	1	1	3	1	
Legarth 1988	3	1	2	1	1	3	1	
Lemancewicz 1999	1	3	2	1	1	3	1	
Lemyre 2006	3	3	2	1	3	3	3	
Levine 2016	1	1	2	1	1	1	2	
Lewis 1983	3	3	2	1	3	3	1	
Lien 1998	1	1	1	1	1	3	3	outpatient
Liggins 1979	1	3	3	3	3	3	3	PG vaginal
Lim 2018	1	1	2	1	1	3	1	
Lo 1994	2	2	2	1	1	3	1	

Trial Name	Selection bias (Random sequence generation)	Selection Bias (allocation concealment)	Performance bias (Blinding of participants and personnel)	Detection bias (Blinding of outcomes)	Attrition bias (incomplete outcome data)	Reporting bias (selective reporting)	Other biases	Cochrane review assessment used for RoB (if available)
Lo 2006	1	1	2	1	1	3	1	
Lokkegaard 2015	1	1	2	1	1	1	2	
Lokugamage 2003	1	1	2	2	2	1	1	Vaginal misoprostol
Lopes 1991	3	2	3	3	3	3	3	could not locate review or study to assess RoB
Lughmani 2009	3	3	2	1	3	3	3	
Luther 1980	3	3	1	1	3	3	2	
Lykkesfeldt 1979	2	2	2	1	1	3	1	
Lyndrup 1989	3	3	2	2	3	1	1	oxytocin
Lyndrup 1991	3	1	2	1	1	3	2	
Lyndrup 1994	3	1	2	1	1	3	1	
Macer 1984	3	3	2	1	1	3	2	
MacKenzie 1979	1	3	1	1	1	3	3	PG vaginal
MacLennan 1979	1	3	1	1	1	3	3	PG vaginal
MacLennan 1980a	3	3	1	1	1	3	2	
MacLennan 1980b	1	3	3	3	1	3	3	PG vaginal
MacLennan 1986	3	3	1	1	1	3	1	
MacLennan 1989	1	3	2	1	1	3	1	
Madaan 2014	2	3	3	1	1	3	1	
Magann 1995	1	1	2	2	1	1	3	oxytocin
Magann 1998a	1	1	2	1	1	3	1	
Magann 1998b	1	1	2	3	1	3	1	outpatient

Trial Name	Selection bias (Random sequence generation)	Selection Bias (allocation concealment)	Performance bias (Blinding of participants and personnel)	Detection bias (Blinding of outcomes)	Attrition bias (incomplete outcome data)	Reporting bias (selective reporting)	Other biases	Cochrane review assessment used for RoB (if available)
Magann 1999	1	1	2	1	1	3	1	
Magtibay 1998	3	3	2	1	1	3	1	
Mahacakri 2018	1	1	1	1	1	3	1	
Mahmood 1989	3	3	3	3	3	3	3	PG vaginal
Mahmood 1995	3	1	2	1	1	3	1	
Majoko 2002a	1	1	2	1	1	3	1	
Majoko 2002b	1	1	2	2	1	3	3	Vaginal misoprostol
Manandhar 2017	1	3	2	1	1	3	1	
Martin 1989	3	1	2	1	3	3	3	
Mawire 1999	1	1	3	1	1	3	1	
McColgin 1990a	1	3	3	1	1	3	2	
McColgin 1990b	3	3	3	1	1	3	3	
McKenna 1999	1	1	3	3	1	3	1	outpatient
McKenna 2004	1	1	1	1	2	1	1	Vaginal misoprostol
McLaren 1987	3	3	3	3	3	3	3	PG vaginal
Megalo 2004	3	1	2	2	2	1	1	Vaginal misoprostol
Mehrotra 2010	3	1	1	1	3	3	3	Oral misoprostol
Mei-Dan 2012	3	3	2	1	1	3	1	
Mei-Dan 2014	3	2	2	1	1	1	2	
Mercer 1995	1	1	2	1	1	3	1	
Meydanli 2003	1	1	1	1	1	3	1	
Meyer 2002	1	1	1	1	3	1	1	Vaginal misoprostol

Trial Name	Selection bias (Random sequence generation)	Selection Bias (allocation concealment)	Performance bias (Blinding of participants and personnel)	Detection bias (Blinding of outcomes)	Attrition bias (incomplete outcome data)	Reporting bias (selective reporting)	Other biases	Cochrane review assessment used for RoB (if available)
Miller 1991	3	3	2	3	1	3	3	PG vaginal
Misra 1994	3	3	2	1	1	3	1	
Modarres 2000	1	3	2	1	1	3	1	
Modlock 2010	1	1	3	1	1	1	1	acupuncture
Moini 2003	3	3	2	1	1	3	1	
Moldin 1996	3	1	2	1	1	3	1	
Mollart 2016	1	1	2	1	1	1	1	
Moodley 2003	1	1	2	1	1	3	1	
Moraes Filho 2010	1	1	2	1	1	3	1	
Movahed 2016	1	3	2	1	3	1	1	
Mukhopadhyay 2002	1	1	1	1	3	3	3	
Mundle 2018	1	1	2	1	1	1	2	
Murphy 1980	3	3	3	3	1	3	3	PG vaginal
Murray 1995	3	3	3	3	3	3	3	PG vaginal
Murthy 2006	3	1	3	3	2	1	1	Vaginal misoprostol
Nager 1987	1	3	2	1	1	3	1	
Naismith 1973	3	3	3	1	1	3	1	
Nanda 2007	2	2	3	3	2	1	1	Vaginal misoprostol
Nassar 2006	1	1	2	1	1	3	1	
Nayak 2015	1	1	2	1	1	1	1	
Neiger 2001	3	3	2	1	1	3	1	
Neilson 1983	3	1	3	3	1	3	3	PG vaginal

Trial Name	Selection bias (Random sequence generation)	Selection Bias (allocation concealment)	Performance bias (Blinding of participants and personnel)	Detection bias (Blinding of outcomes)	Attrition bias (incomplete outcome data)	Reporting bias (selective reporting)	Other biases	Cochrane review assessment used for RoB (if available)
Netta 2002	3	3	2	1	3	3	3	
Newman 1997	3	3	3	3	1	3	3	PG vaginal
Nicoll 2001	1	1	1	3	1	1	1	nitric oxide
Nigam 2004	3	3	2	1	1	3	3	
Nigam 2010	3	3	2	1	1	3	1	
Nimrod 1984	3	1	1	1	1	3	3	
Niromanesh 2003	1	1	2	1	3	3	1	
Noah 1987	3	3	2	1	1	3	1	
Nongkhlaw 2015	3	3	3	1	1	3	1	
Noor 2015	3	3	3	1	1	3	1	
Nopdonrattakoon 2003	3	1	2	1	1	3	1	
Norzilawati 2010	3	3	2	1	3	3	3	
Ntsaluba 1997		1						Mechanical
Nunes 1999	1	1	2	1	1	3	1	
Nuutila 1995	3	3	3	1	1	3	1	
Nuutila 1996	3	3	3	3	1	3	3	PG vaginal
Oboro 2005	1	1	2	2	3	3	3	Vaginal misoprostol
O'Brien 1995	1	1	3	3	1	3	3	PG vaginal
Ohel 1996	2	3	2	1	2	3	3	
Olmo 2001	3	3	2	1	3	3	3	
Omar 2013	1	1	2	1	1	1	2	
Ophir 1992	3	3	2	1	3	3	1	

Trial Name	Selection bias (Random sequence generation)	Selection Bias (allocation concealment)	Performance bias (Blinding of participants and personnel)	Detection bias (Blinding of outcomes)	Attrition bias (incomplete outcome data)	Reporting bias (selective reporting)	Other biases	Cochrane review assessment used for RoB (if available)
Orhue 1995	1	1	2	1	1	3	1	
Osman 2006	1	1	1	1	1	1	1	nitric oxide
Ottinger 1998	1	1	3	1	1	3	1	
Owen 1991	3	1	3	1	1	3	1	
Owolabi 2005	1	1	2	1	1	3	1	
Ozkan 2009	1	1	2	1	1	3	3	
Paisarntantiwong 2005	3	1	1	1	1	3	2	
Pandis 2001	1	1	2	1	3	3	2	
Papageorgiou 1992	2	2	2	1	1	3	1	
Papanikolaou 2004	1	3	2	2	1	1	1	Vaginal misoprostol
Parazzini 1998	3	1	2	1	1	3	2	
Parewijck 1986	3	1	3	3	3	3	3	could not locate review or study to assess RoB
Parikh 2001	3	3	2	1	1	3	3	
Parimkayala 2019	3	3	2	1	1	3	1	
Parlakgumus 2014	3	1	2	1	1	1	1	
Patel 2016	3	3	2	1	1	3	3	
Patil 2005	3	1	2	1	1	3	1	
Paungmora 2004	1	3	2	1	1	3	1	
Peccerillo 1995	3	3	3	1	3	3	3	
Peedicayil 1998	3	1	2	1	3	3	2	Mechanical
Pennell 2009	3	1	3	1	3	1	1	Mechanical

Trial Name	Selection bias (Random sequence generation)	Selection Bias (allocation concealment)	Performance bias (Blinding of participants and personnel)	Detection bias (Blinding of outcomes)	Attrition bias (incomplete outcome data)	Reporting bias (selective reporting)	Other biases	Cochrane review assessment used for RoB (if available)
Pereira Alves Filho 2019	1	1	1	1	1	3	1	
Perry 2004	1	1	1	1	2	3	1	
Perryman 1992	1	1	3	3	1	3	3	PG vaginal
Pinto 1967	3	3	1	1	1	3	3	
Pollnow 1996	1	1	1	1	3	1	1	oxytocin
Pongsatha 2005	3	3	2	1	1	3	3	
PonMalar 2017	1	1	1	1	1	1	1	
Poulsen 1991	1	1	2	1	1	3	1	
Prager 2008	1	1	2	1	1	3	1	
Prasad 1989	3	3	3	3	1	3	3	PG vaginal
Prins 1983	3	1	3	3	1	3	3	PG vaginal
Pulle 1986	3	3	2	1	1	3	1	
Putnam 2011	1	1	3	1	1	3	2	
Qazi 2019	3	3	3	1	1	3	1	
Quinn 1981	3	3	1	1	1	3	1	
Rabl 2001	1	1	2	2	2	3	3	acupuncture
Rabl 2002	3	3	3	3	3	3	3	PG vaginal
Rahman 2013	1	1	2	2	3	3	3	Oral misoprostol
Rameez 2007	3	1	1	1	1	1	1	nitric oxide
Ramsey 2003	3	3	3	1	1	3	1	
Ratnam 1974	1	3	2	1	1	3	3	
Rayburn 1988	3	1	3	3	1	3	3	PG vaginal

Trial Name	Selection bias (Random sequence generation)	Selection Bias (allocation concealment)	Performance bias (Blinding of participants and personnel)	Detection bias (Blinding of outcomes)	Attrition bias (incomplete outcome data)	Reporting bias (selective reporting)	Other biases	Cochrane review assessment used for RoB (if available)
Rayburn 1992	1	1	1	3	3	3	3	PG vaginal
Razaq 2011	3	3	3	1	1	3	1	
Reinhard 2014	1	3	2	1	1	3	1	
Rezaie 2016	3	3	2	1	1	2	2	
Richardson 1991	3	3	1	1	3	3	3	
Rix 1996	3	1	3	1	1	3	1	
Roach 1997	3	3	3	3	3	3	3	PG vaginal
Roberts 1986	3	3	2	2		1	3	oxytocin
Rouben 1993	1	1	2	1	1	3	2	
Rouzi 2014	1	1	2	1	1	3	1	Oral misoprostol
Rouzi 2017	1	1	2	1	1	2	2	
Rowlands 2001	3	1	2	1	1	3	1	
Roy 2015	3	3	2	1	3	3	3	
Rozenberg 2001	1	1	3	1	1	3	1	
Rozenberg 2004	1	1	3	3	2	2	1	Vaginal misoprostol
Roztocil 1998	3	3	3	1	3	3	3	
Russell 2007	3	3	3	1	3	3	3	
Saad 2019	3	3	3	1	1	3	3	
Sadi 2016	1	1	1	1	1	1	1	
Saeed 2011	1	1	1	1	3	3	3	
Saggaf 2001		1						Vaginal misoprostol
Sahu 2004	3	3	3	3	2	1	3	Vaginal misoprostol

Trial Name	Selection bias (Random sequence generation)	Selection Bias (allocation concealment)	Performance bias (Blinding of participants and personnel)	Detection bias (Blinding of outcomes)	Attrition bias (incomplete outcome data)	Reporting bias (selective reporting)	Other biases	Cochrane review assessment used for RoB (if available)
Salamalekis 2000	3	3	2	1	1	3	1	
Saleem 2006	3	3			2	3	3	Mechanical
Saleh 1975	3	3	2	1	1	3	3	
Salim 2011	1	1	2	1	1	3	2	
Salmon 1986	1	3	2	1	1	3	1	
Sanchez-Ramos 1992	1	3	2	1	1	3	1	
Sanchez-Ramos 1998	1	3	2	1	1	3	1	
Savithri 2018	3	3	2	1	1	3	1	
Sawai 1991	3	3	3	3	3	3	3	PG vaginal
Sawai 1994	1	3	1	3	3	3	3	PG vaginal
Saxena 2011	1	3	2	1	1	3	1	
Sayed 2016	1	1	3	1	1	3	1	
Schmitz 2014	1	1	1	1	1	1	2	outpatient
Schneider 2004	3	3	3	1	3	3	3	
Sciscione 1999	1	1	2	1	1	3	1	
Sciscione 2001	1	1	2	1	1	3	1	
Secher 1981	3	3	2	1	1	3	1	
Seeras 1995	3	1	3	1	1	3	1	
Selo-Ojeme 2009	1	1	2	1	1	1	1	
Shaheen 2013	1	3	2	1	1	3	1	
Shakya 2010	3	3	2	1	1	3	1	
Sharami 2014	1	1	1	1	1	3	1	

Trial Name	Selection bias (Random sequence generation)	Selection Bias (allocation concealment)	Performance bias (Blinding of participants and personnel)	Detection bias (Blinding of outcomes)	Attrition bias (incomplete outcome data)	Reporting bias (selective reporting)	Other biases	Cochrane review assessment used for RoB (if available)
Sharma 2005	3	3	3	3	3	1	3	nitric oxide
Shechter-Maor 2015	1	3	2	1	1	1	1	
Sheela 2007	3	3	3	3	2	1	3	Oral misoprostol/vaginal misoprostol
Sheela 2015	3	3	2	1	1	3	1	
Sheikher 2009	3	3	3	3	3	3	3	Oral misoprostol
Shepherd 1976	2	2	2	1	1	3	1	
Sherman 2001	1	1	1	1	1	3	1	
Shetty 2001	1	1	2	1	1	3	1	
Shetty 2002a	1	1	2	1	1	3	1	
Shetty 2002b	1	1	2	1	1	3	1	
Shetty 2003	1	1	2	1	1	3	1	
Shetty 2004	1	1	2	1	1	3	1	
Sifakis 2007	1	3	3	3	2	1	2	Vaginal misoprostol
Silva-Cruz 1988	3	3	2	1	1	3	1	
Singh 2014	1	3	2	1	1	3	1	
Sitthiwattanawong 1999	1	3	2	2	3	3	3	Oral misoprostol
Smith 1990	1	1	3	3	3	3	3	PG vaginal
Smith 1994	1	3	3	3	1	3	2	PG vaginal
Smith 2008	1	1	1	1	1	1	1	acupuncture
Soliman 2013	1	1	1	1	1	3	1	
Solis Ruiz 2015	3	3	3	1	3	3	3	

Trial Name	Selection bias (Random sequence generation)	Selection Bias (allocation concealment)	Performance bias (Blinding of participants and personnel)	Detection bias (Blinding of outcomes)	Attrition bias (incomplete outcome data)	Reporting bias (selective reporting)	Other biases	Cochrane review assessment used for RoB (if available)
Solt 2019	3	1	1	1	1	1	1	
Somirathne 2017	1	1	2	1	2	1	1	
Souzi 2018	1	3	1	1	1	2	1	
Souza 2013	1	3	1	1	3	3	3	Oral misoprostol
Spallicci 2007	1	3	1	1	1	3	1	
Spellacy 1973	1	3	1	1	1	3	2	
Srisomboon 1996	3	3	1	1	1	3	1	
Srisomboon 1998	3	3	3	1	1	3	1	
St Onge 1995	1	1	2	1	1	3	1	
Stampe Sorensen 1992	3	3	3	3	3	3	1	PG vaginal
Steer 1976	2	2	2	1	1	3	3	
Stempel 1997	1	3	3	1	1	3	1	
Stenlund 1999	1	1	1	1	1	3	3	outpatient
Stewart 1983	3	3	2	1	1	3	1	
Stitely 2000	1	1	1	1	1	3	1	outpatient
Strobelt 2006	3	3	2	1	1	3	1	
Suffecool 2014	1	1	2	1	1	3	1	
Sultana 2006	3	3	3	3	3	3	3	Oral misoprostol
Surita 2005	1	1	2	1	1	3	1	
Suvobrata 2011	3	2	3	3	3	3	3	could not locate review or study to assess RoB
Suzuki 2000	3	3	3	3	1	1	1	Twins

Trial Name	Selection bias (Random sequence generation)	Selection Bias (allocation concealment)	Performance bias (Blinding of participants and personnel)	Detection bias (Blinding of outcomes)	Attrition bias (incomplete outcome data)	Reporting bias (selective reporting)	Other biases	Cochrane review assessment used for RoB (if available)
Tabasi 2007	1	3	2	1	1	3	1	
Tabor 1995	3	3	3	1	3	3	3	
Tabowei 2003	1	1	2	1	1	3	1	
Taechakraichana 1996	3	3	2	1	1	3	1	
Taher 2011	1	1	1	1	1	1	1	PG vaginal
Tan 2007	1	1	2	1	1	3	1	
Tan 2010	1	1	2	1	1	3	1	
Tan 2013	1	1	1	1	1	1	1	
Tandon 2014	3	3	2	1	3	3	3	
Tannirandorn 1999	1	3	3	1	1	3	1	
Ten Eikelder 2016	1	1	2	1	1	1	2	
Tessier 1997	1	1	1	1	3	3	3	Oral misoprostol
Tey 1995	1	1	2	2	3	3	3	Macrosomia
Thaisomboon 2012	1	1	1	1	3	3	3	Oral misoprostol
Thakur 2005	3	3	3	3	3	3	3	mifepristone
Thavarasah 1990	3	1	3	1	1	3	1	
Thiery 1984	3	3	3	3	3	3	3	PG vaginal
Thomas 1986	2	2	2	1	3	3	1	
Tomlinson 2001	3	1	2	3	3	2	3	PG vaginal
Topozada 1997	1	3	2	1	1	3	1	
Torkzahrani 2017	1	3	1	1	1	1	1	
Triglia 2010	3	3	3	3	3	3	3	PG vaginal

Trial Name	Selection bias (Random sequence generation)	Selection Bias (allocation concealment)	Performance bias (Blinding of participants and personnel)	Detection bias (Blinding of outcomes)	Attrition bias (incomplete outcome data)	Reporting bias (selective reporting)	Other biases	Cochrane review assessment used for RoB (if available)
Trofatter 1985	3	3	2	1	1	3	1	
Trofatter 1993	3	3	2	1	1	3	1	
Tromans 1981	2	2	3	1	1	3	1	
Troostwijk 1992	3	1	1	1	1	3	1	
Tulek 2018	3	1	2	1	1	3	1	
Tylleskar 1979	3	3	2	3	2	2	3	IOL
Ugwu 2013	1	1	2	1	1	3	1	
Ugwu 2014	1	1	3	1	2	3	1	
Ulmsten 1979	3	3	2	1	1	3	1	
Ulmsten 1982	3	3	1	1	1	3	1	
Ulmsten 1985	3	3	3	3	3	3	3	PG vaginal
Uludag 2005	3	1	3	3	1	3	1	Oral misoprostol
Vahid Roudsari 2011	3	3	2	1	1	3	1	
Vakhariya 1972	3	3	1	1	1	3	3	
Valadan 2005	3	3	2	1	1	3	1	
Valentine 1977	3	3	2	2	1	1	3	oxytocin
van Gemund 2004	1	1	2	2	2	1	1	Vaginal misoprostol
Varaklis 1995	1	1	2	1	1	3	1	
Vayssiere 2018	3	3	2	1	1	1	3	
Veena 2016	1	1	2	1	1	3	2	
Wallstrom 2019	1	1	2	1	1	1	2	
Wang 2016	1	1	2	1	1	3	1	

Trial Name	Selection bias (Random sequence generation)	Selection Bias (allocation concealment)	Performance bias (Blinding of participants and personnel)	Detection bias (Blinding of outcomes)	Attrition bias (incomplete outcome data)	Reporting bias (selective reporting)	Other biases	Cochrane review assessment used for RoB (if available)
Weiss 2016	1	1	1	1	1	1	1	
Wieland 1999	1	1	2	1	1	3	1	
Wielgos 2007	3	3	2	1	3	3	1	
Wilson 1978	3	3	2	1	1	3	1	
Wing 1995a	1	1	2	1	1	3	2	
Wing 1995b	1	1	2	1	1	3	2	
Wing 1997	1	1	2	1	1	3	1	
Wing 1999	1	1	3	3	1	3	3	Oral misoprostol
Wing 2000a	1	1	1	1	1	1	1	mifepristone
Wing 2000b	3	1	2	3	1	3	1	Oral misoprostol
Wing 2004	1	1	2	2	1	3	3	Oral misoprostol
Wing 2008	1	1	1	1	1	3	1	
Wing 2013	3	3	1	1	1	3	1	
Wingerup 1978	3	3	1	1	1	3	1	
Wiriyasirivaj 1996	1	1	3	1	1	3	1	
Witter 1987	1	3	2	3	1	3	1	IOL
Witter 1992	3	3	3	3	2	3	3	PG vaginal
Witter 1996	1	1	3	3	2	3	3	PG vaginal
Wong 2002	1	1	2	1	1	3	1	
Yazdizadeh 2013	1	1	1	1	3	3	3	nitric oxide
Yelikar 2015	1	1	1	1	1	3	1	
Yenuberi 2016	1	1	1	1	1	3	1	

Trial Name	Selection bias (Random sequence generation)	Selection Bias (allocation concealment)	Performance bias (Blinding of participants and personnel)	Detection bias (Blinding of outcomes)	Attrition bias (incomplete outcome data)	Reporting bias (selective reporting)	Other biases	Cochrane review assessment used for RoB (if available)
Yildirim 2010	1	1	2	1	1	3	1	
Young 2019	1	1	2	1	1	1	2	
Yuen 1996	1	1	2	1	1	3	1	
Zahran 2009	1	1	1	1	1	3	1	
Zanconato 2011	3	3	3	3	1	2	3	PG vaginal
Zanini 1990	3	3	3	1	1	3	1	
Zeteroglu 2004	1	3	2	1	1	3	2	
Zeteroglu 2006a	1	1	2	1	1	3	2	
Zeteroglu 2006b	3	3	2	1	1	3	2	
Zhang 2015	1	1	1	1	1	1	1	
Ziaei 2003	1	3	3	1	1	3	1	
Zvandasara 2008	1	1	2	1	1	3	1	

1 1: low risk of bias (RoB); 2: high risk of bias; 3: unclear risk of bias

2 Where original study or Cochrane review including the study could not be located, RoB was assessed as unclear across remaining domains (allocation
 3 concealment was previously assessed)

4

5

1 D3 - No vaginal delivery in 24 hours

2 Table 3: Evidence table for no vaginal delivery in 24 hours

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 1 events	Arm 1 total	Arm 2 events	Arm 2 total	Arm 3 events	Arm 3 total
Aalami-Harandi 2013	Titrated (low dose) oral misoprostol solution	IV oxytocin		26	128	49	128	NA	NA
Adair 1998	Vaginal misoprostol (≥ 50 mcg)	Oral misoprostol tablet (≥ 50 mcg)		23	85	26	93	NA	NA
Adeniji 2005	Vaginal misoprostol (≥ 50 mcg)	Foley catheter		3	50	1	46	NA	NA
Adeniyi 2014	Vaginal misoprostol (< 50 mcg)	Vaginal misoprostol (≥ 50 mcg)		11	65	8	63	NA	NA
Aduloju 2019	Oral misoprostol tablet (< 50 mcg)	Titrated (low dose) oral misoprostol solution		33	75	35	75	NA	NA
Al-Sebai 1993	Vaginal PGE2 (tablet)	Vaginal PGE2 (gel)		24	36	20	37	NA	NA
Anand 2012	Intracervical PGE2	Vaginal misoprostol (< 50 mcg)		31	100	16	100	NA	NA
Azubuike 2015	Vaginal misoprostol (< 50 mcg)	Vaginal misoprostol (≥ 50 mcg)		17	40	17	43	NA	NA
Bartha 2000	Intracervical PGE2	Oral misoprostol tablet (≥ 50 mcg)		50	100	36	100	NA	NA
Bartusevicius 2006	Vaginal misoprostol (< 50 mcg)	Buccal/sublingual misoprostol		17	70	12	70	NA	NA
Bollapragada 2009	Placebo	Nitric oxide		86	121	81	117	NA	NA
Buttino 1990	Placebo	Intracervical PGE2		20	20	19	23	NA	NA
Carlan 2002	Vaginal misoprostol (≥ 50 mcg)	Buccal/sublingual misoprostol		45	79	38	73	NA	NA
Chanrachakul 2002	Vaginal misoprostol (≥ 50 mcg)	Nitric oxide		22	52	31	55	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 1 events	Arm 1 total	Arm 2 events	Arm 2 total	Arm 3 events	Arm 3 total
Chanrachakul 2010	Vaginal misoprostol (≥ 50 mcg)	Buccal/sublingual misoprostol		68	107	68	111	NA	NA
Charoenkul 2000	Vaginal PGE2 (tablet)	Vaginal misoprostol (≥ 50 mcg)		51	71	47	72	NA	NA
Chavakula 2015	Vaginal misoprostol (< 50 mcg)	Foley catheter		17	46	21	54	NA	NA
Cheng 2008	Vaginal misoprostol (< 50 mcg)	Titrated (low dose) oral misoprostol solution		49	106	6	101	NA	NA
Chitrakar 2012	Intracervical PGE2	Vaginal misoprostol (< 50 mcg)		50	100	40	100	NA	NA
Chuck 1995	Intracervical PGE2	Vaginal misoprostol (≥ 50 mcg)		23	50	10	49	NA	NA
Colon 2005	Vaginal misoprostol (< 50 mcg)	Oral misoprostol tablet (≥ 50 mcg)		48	111	37	93	NA	NA
Corrado 2001	Vaginal PGE2 (gel)	Intracervical PGE2		42	111	43	122	NA	NA
Cromi 2012	Vaginal PGE2 pessary (slow release)	Double balloon/Cook's catheter		52	103	33	105	NA	NA
Dällenbach 2003	Vaginal PGE2 (gel)	Oral misoprostol tablet (< 50 mcg)		38	100	44	100	NA	NA
Danielian 1999	Vaginal PGE2 (gel)	Vaginal misoprostol (≥ 50 mcg)		52	106	21	105	NA	NA
De Aquino 2003	Vaginal misoprostol (< 50 mcg)	IV oxytocin		20	105	38	105	NA	NA
De Bonrostro Torralba 2019	Vaginal PGE2 pessary (slow release)	Vaginal misoprostol (< 50 mcg)		57	99	50	99	NA	NA
Denguezli 2007	Intracervical PGE2	Vaginal misoprostol (≥ 50 mcg)		30	65	16	65	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 1 events	Arm 1 total	Arm 2 events	Arm 2 total	Arm 3 events	Arm 3 total
Dodd 2006	Vaginal PGE2 (gel)	Titrated (low dose) oral misoprostol solution		155	376	168	365	NA	NA
Edwards 2014	Vaginal PGE2 pessary (slow release)	Foley catheter		115	191	104	195	NA	NA
Ekman 1986	Vaginal PGE2 pessary (normal release)	IV oxytocin		2	19	12	19	NA	NA
Facchinetti 2005	Vaginal PGE2 pessary (slow release)	Intracervical PGE2		31	72	38	72	NA	NA
Facchinetti 2007	Vaginal PGE2 pessary (slow release)	Intracervical PGE2		25	58	39	58	NA	NA
Farah 1997	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)		47	192	56	207	NA	NA
Feitosa 2006	Vaginal misoprostol (<50mcg)	Buccal/sublingual misoprostol		34	75	40	75	NA	NA
Fisher 2001	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)		47	64	32	62	NA	NA
Frass 2011	No treatment	Vaginal misoprostol (≥50mcg)		57	57	17	56	NA	NA
Garry 2003	Vaginal PGE2 pessary (slow release)	Vaginal misoprostol (≥50mcg)		55	89	31	97	NA	NA
Girija 2009	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)		16	50	20	50	NA	NA
Girija 2011	Intracervical PGE2	Vaginal misoprostol (<50mcg)		55	161	61	159	NA	NA
Goel 1986	Vaginal misoprostol (<50mcg)	Buccal/sublingual misoprostol		24	100	30	100	NA	NA
Grünberger 1986	Placebo	Intracervical PGE2		13	15	3	15	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 1 events	Arm 1 total	Arm 2 events	Arm 2 total	Arm 3 events	Arm 3 total
Gupta 2010	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)		38	80	24	68	NA	NA
Haas 2019	Vaginal misoprostol (<50 mcg)	Buccal/sublingual misoprostol		63	152	90	148	NA	NA
Hales 1994	Vaginal PGE2 (gel)	Intracervical PGE2		36	48	42	52	NA	NA
Has 2002	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)		33	58	35	56	NA	NA
Henry 2013	Vaginal PGE2 (gel)	Foley catheter		36	51	44	50	NA	NA
Herabutya 1997	Intracervical PGE2	Vaginal misoprostol (≥50mcg)		33	58	35	56	NA	NA
Hofmeyr 2001	Vaginal PGE2 (gel)	Titrated (low dose) oral misoprostol solution	Foley catheter	123	349	133	346	95	174
Hokkila 2019	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)		90	133	118	135	NA	NA
Hoppe 2016	Foley catheter	Double balloon/Cook's catheter		40	48	35	50	NA	NA
Jackson 1994	Vaginal PGE2 (gel)	IV oxytocin		32	83	41	75	NA	NA
Kadian 2008	Vaginal PGE2 (gel)	Nitric oxide		76	200	48	200	NA	NA
Kalkat 2008	Vaginal PGE2 (gel)	Vaginal PGE2 pessary (slow release)		20	60	22	60	NA	NA
Keirse 1995	Vaginal PGE2 (gel)	Intracervical PGE2		36	140	39	142	NA	NA
Khoury 2001	Vaginal PGE2 pessary (slow release)	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)	22	39	21	39	21	40
Kim 2000	Vaginal PGE2 (tablet)	Vaginal misoprostol (≥50mcg)		32	74	8	39	NA	NA
Kolderup 1999	Intracervical PGE2	Vaginal misoprostol (≥50mcg)		50	78	38	81	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 1 events	Arm 1 total	Arm 2 events	Arm 2 total	Arm 3 events	Arm 3 total
Krithika 2008	Intracervical PGE2	Vaginal misoprostol (<50mcg)		26	50	6	50	NA	NA
Kulshreshtha 2007	Intracervical PGE2	Vaginal misoprostol (≥50mcg)		3	20	1	20	NA	NA
Kumar 2001	Intracervical PGE2	Vaginal misoprostol (<50mcg)		30	100	26	100	NA	NA
Langenegger 2005	Intracervical PGE2	Oral misoprostol tablet (≥50mcg)		50	95	45	96	NA	NA
Le Roux 2002	Vaginal PGE2 (gel)	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)	109	240	51	120	73	120
Legarth 1988	Intracervical PGE2	Vaginal PGE2 pessary (normal release)		32	50	13	48	NA	NA
Lim 2018	Vaginal PGE2 (tablet)	Double balloon/Cook's catheter		27	52	14	31	NA	NA
Lo 1994	Vaginal PGE2 (tablet)	IV oxytocin plus amniotomy		11	101	5	99	NA	NA
Lo 2006	IV oxytocin plus amniotomy	Buccal/sublingual misoprostol		4	25	10	25	NA	NA
Lyndrup 1991	Intracervical PGE2	Vaginal PGE2 pessary (normal release)		53	64	50	61	NA	NA
Lyndrup 1994	Vaginal PGE2 pessary (normal release)	Foley catheter + EASI		21	50	43	59	NA	NA
Mahacakri 2018	Vaginal misoprostol (<50mcg)	Titrated (low dose) oral misoprostol solution		0	15	1	14	NA	NA
Majoko 2002a	Vaginal misoprostol (≥50mcg)	Extra-amniotic prostaglandin		14	76	34	76	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 1 events	Arm 1 total	Arm 2 events	Arm 2 total	Arm 3 events	Arm 3 total
Megalo 2004	Intracervical PGE2	Vaginal misoprostol (≥50mcg)		39	100	20	100	NA	NA
Mehrotra 2010	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)		18	68	25	60	NA	NA
Meydanli 2003	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)		11	60	13	60	NA	NA
Moodley 2003	Vaginal PGE2 (gel)	Vaginal misoprostol (<50mcg)	Titrated (low dose) oral misoprostol solution	89	193	46	100	46	103
Moraes Filho 2010	Vaginal misoprostol (<50mcg)	Foley catheter		51	119	57	121	NA	NA
Mundle 2018	Oral misoprostol tablet (<50mcg)	Foley catheter		130	302	159	300	NA	NA
Murthy 2006	Intracervical PGE2	Vaginal misoprostol (<50mcg)		15	35	8	37	NA	NA
Nassar 2006	Vaginal misoprostol (≥50mcg)	Buccal/sublingual misoprostol		27	85	30	85	NA	NA
Nayak 2015	Vaginal PGE2 (tablet)	Intracervical PGE2		35	64	12	64	NA	NA
Nigam 2004	Oral misoprostol tablet (≥50mcg)	IV oxytocin		3	36	2	34	NA	NA
Nigam 2010	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)		14	60	20	60	NA	NA
Nopdonrattakoon 2003	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)		11	53	18	53	NA	NA
Nunes 1999	Vaginal PGE2 (gel)	Vaginal misoprostol (≥50mcg)		25	94	23	95	NA	NA
Ottinger 1998	Vaginal PGE2 pessary (slow release)	Intracervical PGE2		24	45	27	45	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 1 events	Arm 1 total	Arm 2 events	Arm 2 total	Arm 3 events	Arm 3 total
Ozkan 2009	Vaginal PGE2 pessary (slow release)	Vaginal misoprostol (≥ 50 mcg)		20	56	15	56	NA	NA
Parimkayala 2019	Oral misoprostol tablet (≥ 50 mcg)	Buccal/sublingual misoprostol		24	60	17	60	NA	NA
Pandis 2001	Vaginal PGE2 (gel)	Vaginal misoprostol (≥ 50 mcg)		103	225	72	210	NA	NA
Papanikolaou 2004	Vaginal PGE2 (tablet)	Vaginal misoprostol (≥ 50 mcg)		18	83	7	80	NA	NA
Pennell 2009	Vaginal PGE2 (gel)	Foley catheter	Double balloon/Cook's catheter	64	113	57	110	67	107
Pereira Alves Filho 2019	Vaginal misoprostol (< 50 mcg)	Vaginal misoprostol (≥ 50 mcg)		4	21	4	16	NA	NA
Poulsen 1991	Intracervical PGE2	Vaginal PGE2 pessary (normal release)		49	116	45	110	NA	NA
Prasad 1989	Placebo	Vaginal PGE2 pessary (slow release)		36	36	33	33	NA	NA
Rabl 2002	Vaginal PGE2 (tablet)	Vaginal PGE2 pessary (slow release)		45	100	49	100	NA	NA
Rahman 2013	Vaginal misoprostol (< 50 mcg)	Oral misoprostol tablet (≥ 50 mcg)		52	110	56	110	NA	NA
Razaq 2011	Vaginal misoprostol (≥ 50 mcg)	Nitric oxide		42	75	61	75	NA	NA
Rix 1996	Vaginal PGE2 (tablet)	Intracervical PGE2		42	98	54	110	NA	NA
Rouzi 2014	Vaginal PGE2 pessary (slow release)	Titrated (low dose) oral misoprostol solution		36	80	24	80	NA	NA
Rouzi 2017	Oral misoprostol tablet (< 50 mcg)	Titrated (low dose) oral misoprostol solution		25	73	26	73	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 1 events	Arm 1 total	Arm 2 events	Arm 2 total	Arm 3 events	Arm 3 total
Rozenberg 2001	Vaginal PGE2 (gel)	Vaginal misoprostol (≥50mcg)		80	185	60	184	NA	NA
Sadi 2016	Placebo	Herbal supplements		24	25	23	25	NA	NA
Sahu 2004	Intracervical PGE2	Vaginal misoprostol (≥50mcg)		7	25	2	25	NA	NA
Salim 2011	Foley catheter	Double balloon/Cook's catheter		40	145	45	148	NA	NA
Sanchez-Ramos 1998	Vaginal PGE2 pessary (slow release)	Vaginal misoprostol (≥50mcg)		45	115	31	108	NA	NA
Saxena 2011	Intracervical PGE2	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)	29	70	26	70	24	70
Sharami 2014	Vaginal misoprostol (≥50mcg)	Buccal/sublingual misoprostol		18	63	10	63	NA	NA
Sheela 2007	Intracervical PGE2	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)	28	50	17	50	40	50
Sheikher 2009	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)	Foley catheter	4	30	17	30	20	30
Shetty 2001	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)		47	123	78	122	NA	NA
Shetty 2002a	Oral misoprostol tablet (≥50mcg)	Buccal/sublingual misoprostol		34	50	19	50	NA	NA
Shetty 2002b	Oral misoprostol tablet (≥50mcg)	Buccal/sublingual misoprostol		61	124	58	125	NA	NA
Shetty 2003	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)		24	50	35	51	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 1 events	Arm 1 total	Arm 2 events	Arm 2 total	Arm 3 events	Arm 3 total
Shetty 2004	Vaginal PGE2 (tablet)	Oral misoprostol tablet (≥50mcg)		60	100	62	100	NA	NA
Sifakis 2007	Vaginal PGE2 (tablet)	Vaginal misoprostol (≥50mcg)		82	211	61	204	NA	NA
Soliman 2013	Vaginal misoprostol (≥50mcg)	Nitric oxide		26	65	47	65	NA	NA
Souza 2013	Vaginal misoprostol (<50mcg)	Titrated (low dose) oral misoprostol solution		58	100	63	100	NA	NA
Srisomboon 1998	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)		5	24	3	24	NA	NA
Strobelt 2006	Vaginal PGE2 pessary (slow release)	Intracervical PGE2		18	56	25	51	NA	NA
Suvobrata 2011	IV oxytocin	Buccal/sublingual misoprostol		12	50	12	45	NA	NA
Tabasi 2007	Vaginal misoprostol (≥50mcg)	IV oxytocin		15	55	31	55	NA	NA
Tabowei 2003	Vaginal misoprostol (<50mcg)	Foley catheter		16	60	29	61	NA	NA
Thaisomboon 2012	Oral misoprostol tablet (≥50mcg)	Titrated (low dose) oral misoprostol solution		17	32	23	32	NA	NA
Ulmsten 1982	Placebo	Intracervical PGE2		23	25	14	25	NA	NA
Ulmsten 1985	Placebo	Intracervical PGE2	Vaginal PGE2 pessary (normal release)	18	20	8	19	15	19
van Gemund 2004	Vaginal PGE2 (gel)	Vaginal misoprostol (<50mcg)		141	340	177	341	NA	NA
Wallstrom 2019	Titrated (low dose) oral misoprostol solution	Sustained release misoprostol insert		49	99	43	97	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 1 events	Arm 1 total	Arm 2 events	Arm 2 total	Arm 3 events	Arm 3 total
Wang 2016	Vaginal PGE2 pessary (normal release)	Titrated (low dose) oral misoprostol solution		68	199	94	212	NA	NA
Wing 1995a	Intracervical PGE2	Vaginal misoprostol (≥ 50 mcg)		35	67	20	68	NA	NA
Wing 1995b	Intracervical PGE2	Vaginal misoprostol (< 50 mcg)		96	137	66	138	NA	NA
Wing 1997	Vaginal PGE2 pessary (slow release)	Vaginal misoprostol (< 50 mcg)		53	98	48	99	NA	NA
Wing 1999	Vaginal misoprostol (< 50 mcg)	Oral misoprostol tablet (≥ 50 mcg)		58	110	76	110	NA	NA
Wing 2000a	Placebo	Mifepristone		76	83	85	97	NA	NA
Wing 2000b	Vaginal misoprostol (< 50 mcg)	Oral misoprostol tablet (≥ 50 mcg)		59	113	47	121	NA	NA
Wing 2004	Oral misoprostol tablet (≥ 50 mcg)	IV oxytocin		20	110	10	88	NA	NA
Wing 2008	Vaginal PGE2 pessary (slow release)	Sustained release misoprostol insert		214	426	424	871	NA	NA
Wing 2013	Vaginal PGE2 pessary (slow release)	Sustained release misoprostol insert		449	680	308	678	NA	NA
Wingerup 1978	Placebo	Intracervical PGE2		7	10	2	10	NA	NA
Yelikar 2015	Placebo	Mifepristone		48	50	42	50	NA	NA
Yenuberi 2016	Vaginal misoprostol (< 50 mcg)	Oral misoprostol tablet (≥ 50 mcg)		126	380	126	383	NA	NA
Young 2020	Vaginal PGE2 (gel)	Vaginal misoprostol (< 50 mcg)	Oral misoprostol tablet (≥ 50 mcg)	90	172	80	172	92	167

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 1 events	Arm 1 total	Arm 2 events	Arm 2 total	Arm 3 events	Arm 3 total
Yuen 1996	Intracervical PGE2	Vaginal PGE2 pessary (normal release)	Double balloon/Cook's catheter	20	39	14	39	21	36
Zhang 2015	Placebo	Vaginal misoprostol (<50mcg)		44	49	116	173	NA	NA

1 NA: not available; EASI: extra-amniotic saline infusion

2

3

4

5

6 D4 - Hyperstimulation with fetal heart rate changes

7 Table 4: Evidence table for hyperstimulation with fetal heart rate changes

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Abotorabi 2019	Placebo	Nitric oxide			0	30	0	28	NA	NA	NA	NA
Adeniji 2005	Vaginal misoprostol (≥50mcg)	Foley catheter			0	50	0	46	NA	NA	NA	NA
Aduloju 2016	Vaginal misoprostol (<50mcg)	Foley catheter			0	70	0	70	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Aduloju 2019	Oral misoprostol tablet (<50 mcg)	Titrated (low dose) oral misoprostol solution			1	75	2	75	NA	NA	NA	NA
Agarwal 2003	Intracervical PGE2	Vaginal misoprostol (≥50mcg)			0	60	0	60	NA	NA	NA	NA
Agarwal 2012	Placebo	Nitric oxide			0	100	0	100	NA	NA	NA	NA
Akay 2012	Vaginal PGE2 pessary (slow release)	IV oxytocin			5	72	6	72	NA	NA	NA	NA
Ayaz 2010	Vaginal PGE2 (tablet)	Vaginal misoprostol (≥50mcg)			2	60	6	60	NA	NA	NA	NA
Azubuike 2015	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)			1	40	2	43	NA	NA	NA	NA
Balci 2010	Vaginal misoprostol (≥50mcg)	IV oxytocin			0	50	0	50	NA	NA	NA	NA
Balci 2011	Vaginal misoprostol (≥50mcg)	IV oxytocin			0	50	0	51	NA	NA	NA	NA
Bartha 2000	Intracervical PGE2	Oral misoprostol tablet (≥50mcg)			2	100	6	100	NA	NA	NA	NA
Bartusevicius 2006	Vaginal misoprostol (<50mcg)	Buccal/sublingual misoprostol			5	70	5	70	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Beigi 2003	Placebo	Oral misoprostol tablet ($\geq 50\text{mcg}$)			0	78	0	78	NA	NA	NA	NA
Bell 1993	Placebo	Relaxin			0	22	0	18	NA	NA	NA	NA
Bennett 1998	Vaginal misoprostol ($\geq 50\text{mcg}$)	Oral misoprostol tablet ($\geq 50\text{mcg}$)			6	102	5	104	NA	NA	NA	NA
Bernstein 1991	Placebo	Intracervical PGE2			4	194	2	203	NA	NA	NA	NA
Buser 1997	Intracervical PGE2	Vaginal misoprostol ($\geq 50\text{mcg}$)			2	79	15	76	NA	NA	NA	NA
Buttino 1990	Placebo	Intracervical PGE2			0	20	1	23	NA	NA	NA	NA
Caliskan 2005	Vaginal misoprostol ($\geq 50\text{mcg}$)	Buccal/sublingual misoprostol			1	80	4	80	NA	NA	NA	NA
Campbell 1984	Placebo	Vaginal PGE2 pessary (normal release)			0	104	0	95	NA	NA	NA	NA
Carlan 2001	Vaginal misoprostol ($\geq 50\text{mcg}$)	Oral misoprostol tablet ($\geq 50\text{mcg}$)			66	501	90	503	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Carlan 2002	Vaginal misoprostol (≥ 50 mcg)	Buccal/sublingual misoprostol			14	79	19	73	NA	NA	NA	NA
Cecatti 2000	Vaginal misoprostol (< 50 mcg)	IV oxytocin			2	53	4	53	NA	NA	NA	NA
Chanrachakul 2000a	Vaginal PGE2 (tablet)	Nitric oxide			2	56	0	54	NA	NA	NA	NA
Chanrachakul 2002	Vaginal misoprostol (≥ 50 mcg)	Nitric oxide			8	52	0	55	NA	NA	NA	NA
Charoenkul 2000	Vaginal PGE2 (tablet)	Vaginal misoprostol (≥ 50 mcg)			0	71	5	72	NA	NA	NA	NA
Chatterjee 1991	Placebo	Vaginal PGE2 (gel)			0	18	0	15	NA	NA	NA	NA
Chavakula 2015	Vaginal misoprostol (< 50 mcg)	Foley catheter			1	46	0	54	NA	NA	NA	NA
Cheng 2008	Vaginal misoprostol (< 50 mcg)	Titrated (low dose) oral misoprostol solution			12	106	0	101	NA	NA	NA	NA
Chua 1988	Vaginal PGE2 (tablet)	IV oxytocin plus amniotomy			0	40	0	40	NA	NA	NA	NA
Chua 1997	Intracervical PGE2	Laminaria			3	95	0	90	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Chuck 1995	Intracervical PGE2	Vaginal misoprostol (≥ 50 mcg)			2	50	1	49	NA	NA	NA	NA
Chung 2003	Vaginal misoprostol (< 50 mcg)	Foley catheter			16	49	6	54	NA	NA	NA	NA
Chyu 1997	Vaginal PGE2 pessary (slow release)	Intracervical PGE2			0	37	1	36	NA	NA	NA	NA
Clark 1998	Intracervical PGE2	Vaginal misoprostol (< 50 mcg)			14	66	13	72	NA	NA	NA	NA
Colon 2005	Vaginal misoprostol (< 50 mcg)	Oral misoprostol tablet (≥ 50 mcg)			6	111	2	93	NA	NA	NA	NA
Cromi 2011	Vaginal PGE2 pessary (slow release)	Foley catheter			8	132	0	265	NA	NA	NA	NA
Cromi 2012	Vaginal PGE2 pessary (slow release)	Double balloon/Cook's catheter			6	103	0	105	NA	NA	NA	NA
Curet 1989	Placebo	Vaginal PGE2 (gel)			0	26	1	28	NA	NA	NA	NA
Dällenbach 2003	Vaginal PGE2 (gel)	Oral misoprostol tablet (< 50 mcg)			14	100	9	100	NA	NA	NA	NA
Dalui 2005	Intracervical PGE2	Foley catheter			0	50	0	50	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Danielian 1999	Vaginal PGE2 (gel)	Vaginal misoprostol (≥ 50 mcg)			1	106	0	105	NA	NA	NA	NA
De Aquino 2003	Vaginal misoprostol (< 50 mcg)	IV oxytocin			3	105	4	105	NA	NA	NA	NA
De Bonrostro Torralba 2019	Vaginal PGE2 pessary (slow release)	Vaginal misoprostol (< 50 mcg)			6	100	3	98	NA	NA	NA	NA
De la Torre 2001	Vaginal misoprostol (≥ 50 mcg)	IV oxytocin			27	168	9	192	NA	NA	NA	NA
Denguezli 2007	Intracervical PGE2	Vaginal misoprostol (≥ 50 mcg)			3	65	5	65	NA	NA	NA	NA
Deshmukh 2013	Vaginal misoprostol (≥ 50 mcg)	Oral misoprostol tablet (≥ 50 mcg)			2	100	1	100	NA	NA	NA	NA
Dodd 2006	Vaginal PGE2 (gel)	Titrated (low dose) oral misoprostol solution			6	376	3	365	NA	NA	NA	NA
Domisse 1980	Placebo	Vaginal PGE2 (tablet)			0	28	0	28	NA	NA	NA	NA
Dulger 2018	Placebo	Nitric oxide			0	34	0	36	NA	NA	NA	NA
Dyar 2000	Vaginal misoprostol (≥ 50 mcg)	Oral misoprostol			15	77	5	76	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
		tablet (≥50mcg)										
Egarter 1989	Vaginal PGE2 (gel)	IV oxytocin			0	49	0	50	NA	NA	NA	NA
Ekman 1983	Vaginal PGE2 (gel)	Intracervical PGE2			0	30	0	30	NA	NA	NA	NA
El-Mardi 1991	Vaginal PGE2 (tablet)	Vaginal PGE2 pessary (normal release)			0	100	0	100	NA	NA	NA	NA
El-Shawarby 2006	Vaginal PGE2 (gel)	Vaginal PGE2 pessary (slow release)			0	38	0	34	NA	NA	NA	NA
El-Sherbiny 2001	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)			0	93	6	92	NA	NA	NA	NA
Eroglu 2007	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)			0	73	1	74	NA	NA	NA	NA
Escudero 1997	Vaginal misoprostol (≥50mcg)	IV oxytocin			5	57	0	63	NA	NA	NA	NA
Ezechukwu 2015	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)			0	70	0	70	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Farah 1997	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)			10	192	12	207	NA	NA	NA	NA
Feitosa 2006	Vaginal misoprostol (<50mcg)	Buccal/sublingual misoprostol			1	75	3	75	NA	NA	NA	NA
Ferguson 2002	Vaginal misoprostol (≥50mcg)	IV oxytocin			4	51	1	53	NA	NA	NA	NA
Fisher 2001	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)			5	64	1	62	NA	NA	NA	NA
Fletcher 1994	Vaginal PGE2 (tablet)	Vaginal misoprostol (≥50mcg)			4	31	3	32	NA	NA	NA	NA
Garry 2003	Vaginal PGE2 pessary (slow release)	Vaginal misoprostol (≥50mcg)			1	89	4	97	NA	NA	NA	NA
Gelisen 2005	No treatment	Vaginal misoprostol (≥50mcg)	IV oxytocin	Foley catheter	5	300	3	100	2	100	0	100
Getgan 2003	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)			1	36	0	36	NA	NA	NA	NA
Ghanaie 2013	Intracervical PGE2	Foley catheter			9	118	8	121	NA	NA	NA	NA
Gherman 2001	Vaginal PGE2 (gel)	Oral misoprostol			1	30	1	28	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
		tablet (≥50mcg)										
Gilson 1993	Placebo	Intracervical PGE2			0	38	0	41	NA	NA	NA	NA
Girija 2009	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)			1	50	0	50	NA	NA	NA	NA
Girija 2011	Intracervical PGE2	Vaginal misoprostol (<50mcg)			2	161	0	159	NA	NA	NA	NA
Gottschall 1997	Vaginal PGE2 (gel)	Vaginal misoprostol (≥50mcg)			0	37	1	38	NA	NA	NA	NA
Graves 1985	Placebo	Vaginal PGE2 (gel)			0	20	2	60	NA	NA	NA	NA
Gregson 2005	Vaginal PGE2 (gel)	Vaginal misoprostol (<50mcg)			4	129	1	139	NA	NA	NA	NA
Greybush 2001	Vaginal misoprostol (<50mcg)	Foley catheter			0	65	0	71	NA	NA	NA	NA
Gupta 2010	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)			1	80	3	68	NA	NA	NA	NA
Hales 1994	Vaginal PGE2 (gel)	Intracervical PGE2			0	48	1	52	NA	NA	NA	NA
Hall 2002	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)			4	48	4	59	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Henry 2013	Vaginal PGE2 (gel)	Foley catheter			2	51	0	50	NA	NA	NA	NA
Hofmeyr 2001	Vaginal PGE2 (gel)	Titrated (low dose) oral misoprostol solution	Foley catheter		10	334	13	328	6	163	NA	NA
Hosli 2008	Vaginal PGE2 (gel)	Vaginal misoprostol (≥ 50 mcg)			2	55	0	52	NA	NA	NA	NA
Howarth 1996	Vaginal PGE2 (gel)	Vaginal misoprostol (≥ 50 mcg)			4	36	5	36	NA	NA	NA	NA
Hudon 1999	Intracervical PGE2	Foley catheter			0	55	0	56	NA	NA	NA	NA
Incerpi 2001	Placebo	Vaginal misoprostol (< 50 mcg)			2	63	3	57	NA	NA	NA	NA
Irion 1998	Vaginal PGE2 (gel)	Intracervical PGE2			1	125	0	122	NA	NA	NA	NA
Jeeva 1982	Vaginal PGE2 (tablet)	Laminaria			0	10	0	10	NA	NA	NA	NA
Johnson 1985	Vaginal PGE2 (gel)	Laminaria			1	40	0	40	NA	NA	NA	NA
Jozwiak 2011	Vaginal PGE2 (gel)	Foley catheter			12	408	8	411	NA	NA	NA	NA
Kadanali 1996	Intracervical PGE2	Vaginal misoprostol (≥ 50 mcg)			6	112	4	112	NA	NA	NA	NA
Kaminski 1994	PGF2 gel	IV oxytocin			0	150	0	146	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Kandil 2012	Vaginal misoprostol (<50mcg)	Foley catheter			1	50	0	50	NA	NA	NA	NA
Kennedy 1982	Vaginal PGE2 (tablet)	IV oxytocin plus amniotomy			0	50	0	50	NA	NA	NA	NA
Khazardoost 2011	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)			0	30	0	30	NA	NA	NA	NA
Khoury 2001	Vaginal PGE2 pessary (slow release)	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)		1	39	0	39	3	40	NA	NA
Kipikasa 2005	Oral misoprostol tablet (<50mcg)	Oral misoprostol tablet (≥50mcg)			0	23	0	29	NA	NA	NA	NA
Kolderup 1999	Intracervical PGE2	Vaginal misoprostol (≥50mcg)			1	78	5	81	NA	NA	NA	NA
Komala 2013	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)			1	100	0	100	NA	NA	NA	NA
Kovavisarach 1997	Vaginal PGE2 (tablet)	Vaginal misoprostol (≥50mcg)			2	30	1	30	NA	NA	NA	NA
Krammer 1995	Intracervical PGE2	Laminaria			0	202	0	214	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Kumar 2001	Intracervical PGE2	Vaginal misoprostol (<50mcg)			6	100	7	100	NA	NA	NA	NA
Kwon 2001	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)			0	82	0	78	NA	NA	NA	NA
Langenegger 2005	Intracervical PGE2	Oral misoprostol tablet (≥50mcg)			12	95	12	96	NA	NA	NA	NA
Laube 1986	Placebo	Intracervical PGE2			0	15	1	30	NA	NA	NA	NA
Lee 1997	Vaginal PGE2 (tablet)	Vaginal misoprostol (≥50mcg)			1	25	0	25	NA	NA	NA	NA
Legarth 1988	Intracervical PGE2	Vaginal PGE2 pessary (normal release)			0	57	0	56	NA	NA	NA	NA
Lemancewicz 1999	Intracervical PGE2	Vaginal misoprostol (≥50mcg)	IV oxytocin		0	40	0	44	1	47	NA	NA
Lewis 1983	No treatment	Vaginal PGE2 pessary (normal release)	Foley catheter		0	22	0	22	0	22	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Lien 1998	Placebo	Intracervical PGE2			1	47	2	46	NA	NA	NA	NA
Lokugamage 2003	Vaginal PGE2 (gel)	Vaginal misoprostol (≥ 50 mcg)			12	95	10	96	NA	NA	NA	NA
Lopes 1991	Vaginal PGE2 (gel)	Intracervical PGE2			1	22	1	28	NA	NA	NA	NA
Lykkesfeldt 1979	IV oxytocin plus amniotomy	Oral prostaglandins			0	92	0	69	NA	NA	NA	NA
Lyndrup 1994	Vaginal PGE2 pessary (normal release)	Foley catheter + EASI			1	50	0	59	NA	NA	NA	NA
MacLennan 1980b	Placebo	PGF2 gel			0	33	0	33	NA	NA	NA	NA
MacLennan 1989	Vaginal PGE2 (gel)	IV oxytocin plus amniotomy			0	165	0	155	NA	NA	NA	NA
Magtibay 1998	Intracervical PGE2	Vaginal misoprostol (≥ 50 mcg)			0	19	3	17	NA	NA	NA	NA
Mahacakri 2018	Vaginal misoprostol (<50mcg)	Titrated (low dose) oral misoprostol solution			1	15	1	14	NA	NA	NA	NA
McKenna 1999	Placebo	Intracervical PGE2			0	31	1	30	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
McKenna 2004	Placebo	Vaginal misoprostol (<50mcg)			1	35	1	33	NA	NA	NA	NA
Meydanli 2003	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)			3	60	2	60	NA	NA	NA	NA
Meyer 2002	Intracervical PGE2	Vaginal misoprostol (<50mcg)			0	42	0	42	NA	NA	NA	NA
Moodley 2003	Vaginal PGE2 (gel)	Vaginal misoprostol (<50mcg)	Titrated (low dose) oral misoprostol solution		17	193	21	100	17	103	NA	NA
Moraes Filho 2010	Vaginal misoprostol (<50mcg)	Foley catheter			3	119	2	121	NA	NA	NA	NA
Mundle 2018	Oral misoprostol tablet (<50mcg)	Foley catheter			2	302	1	300	NA	NA	NA	NA
Murray 1995	Vaginal PGE2 (tablet)	Vaginal PGE2 (gel)			1	100	2	100	NA	NA	NA	NA
Murthy 2006	Intracervical PGE2	Vaginal misoprostol (<50mcg)			0	35	1	37	NA	NA	NA	NA
Nager 1987	No treatment	Intracervical PGE2			0	15	0	15	NA	NA	NA	NA
Nanda 2007	Intracervical PGE2	Vaginal misoprostol (<50mcg)			2	50	3	50	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Nassar 2006	Vaginal misoprostol (≥ 50 mcg)	Buccal/sublingual misoprostol			8	85	7	85	NA	NA	NA	NA
Neiger 2001	Intracervical PGE2	Vaginal misoprostol (≥ 50 mcg)			0	29	4	32	NA	NA	NA	NA
Neilson 1983	Vaginal PGE2 (gel)	PGF2 gel			0	38	0	37	NA	NA	NA	NA
Nigam 2010	Vaginal misoprostol (< 50 mcg)	Vaginal misoprostol (≥ 50 mcg)			0	60	1	60	NA	NA	NA	NA
Nimrod 1984	Placebo	Intracervical PGE2			0	15	0	30	NA	NA	NA	NA
Noah 1987	No treatment	Intracervical PGE2			1	403	1	413	NA	NA	NA	NA
Noor 2015	Vaginal misoprostol (< 50 mcg)	Foley catheter			7	60	0	44	NA	NA	NA	NA
Nopdonrattakon 2003	Vaginal misoprostol (≥ 50 mcg)	Oral misoprostol tablet (≥ 50 mcg)			0	53	1	53	NA	NA	NA	NA
Ntsaluba 1997	Intracervical PGE2	Foley catheter			1	59	0	53	NA	NA	NA	NA
Nunes 1999	Vaginal PGE2 (gel)	Vaginal misoprostol (≥ 50 mcg)			4	94	3	95	NA	NA	NA	NA
Nuutila 1996	Vaginal PGE2 (gel)	Intracervical PGE2			1	71	1	39	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Olmo 2001	Vaginal PGE2 pessary (slow release)	IV oxytocin			1	25	0	25	NA	NA	NA	NA
Orhue 1995	Vaginal PGE2 pessary (normal release)	IV oxytocin plus amniotomy	Foley catheter		0	34	2	30	1	30	NA	NA
Owen 1991	Placebo	Intracervical PGE2			0	53	1	47	NA	NA	NA	NA
Owolabi 2005	Vaginal misoprostol (≥ 50 mcg)	Foley catheter			4	60	2	60	NA	NA	NA	NA
Ozkan 2009	Vaginal PGE2 pessary (slow release)	Vaginal misoprostol (≥ 50 mcg)			1	56	2	56	NA	NA	NA	NA
Paisarntantiwong 2005	Vaginal misoprostol (< 50 mcg)	Oral misoprostol tablet (≥ 50 mcg)			2	73	0	73	NA	NA	NA	NA
Pandis 2001	Vaginal PGE2 (gel)	Vaginal misoprostol (≥ 50 mcg)			2	225	5	210	NA	NA	NA	NA
Papageorgiou 1992	Intracervical PGE2	IV oxytocin			2	83	4	82	NA	NA	NA	NA
Papanikolaou 2004	Vaginal PGE2 (tablet)	Vaginal misoprostol (≥ 50 mcg)			1	83	2	80	NA	NA	NA	NA
Parikh 2001	Intracervical PGE2	IV oxytocin			1	15	1	15	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Patil 2005	Intracervical PGE2	Oral misoprostol tablet (≥ 50 mcg)			0	95	5	95	NA	NA	NA	NA
Paungmora 2004	Vaginal misoprostol (≥ 50 mcg)	Oral misoprostol tablet (≥ 50 mcg)			0	76	0	75	NA	NA	NA	NA
Pennell 2009	Vaginal PGE2 (gel)	Foley catheter	Double balloon/Cook's catheter		6	113	0	110	0	107	NA	NA
Perry 2004	Vaginal PGE2 pessary (slow release)	Intracervical PGE2			3	30	3	33	NA	NA	NA	NA
Perryman 1992	Vaginal PGE2 (gel)	Vaginal PGE2 pessary (normal release)			0	45	2	45	NA	NA	NA	NA
Pongsatha 2005	Vaginal misoprostol (≥ 50 mcg)	Oral misoprostol tablet (≥ 50 mcg)			6	84	1	82	NA	NA	NA	NA
Rabl 2002	Vaginal PGE2 (tablet)	Vaginal PGE2 pessary (slow release)			3	100	4	100	NA	NA	NA	NA
Rahman 2013	Vaginal misoprostol (< 50 mcg)	Oral misoprostol			2	110	0	110	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
		tablet (≥50mcg)										
Ramsey 2003	Vaginal PGE2 pessary (slow release)	Intracervical PGE2	Vaginal misoprostol (≥50mcg)		2	38	2	35	5	38	NA	NA
Ratnam 1974	IV oxytocin	IV oxytocin plus amniotomy	Oral prostaglandins		0	50	0	50	0	54	NA	NA
Rayburn 1988	Placebo	Vaginal PGE2 (gel)			0	63	0	55	NA	NA	NA	NA
Rayburn 1992	Placebo	Vaginal PGE2 pessary (slow release)			0	114	4	101	NA	NA	NA	NA
Rix 1996	Vaginal PGE2 (tablet)	Intracervical PGE2			0	98	0	110	NA	NA	NA	NA
Rouzi 2014	Vaginal PGE2 pessary (slow release)	Titrated (low dose) oral misoprostol solution			5	80	7	80	NA	NA	NA	NA
Rouzi 2017	Oral misoprostol tablet (<50mcg)	Titrated (low dose) oral misoprostol solution			0	73	1	73	NA	NA	NA	NA
Rowlands 2001	Vaginal PGE2 pessary (normal release)	Vaginal misoprostol (≥50mcg)			0	63	10	62	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Rozenberg 2001	Vaginal PGE2 (gel)	Vaginal misoprostol (≥ 50 mcg)			2	185	5	184	NA	NA	NA	NA
Rozenberg 2004	Vaginal PGE2 pessary (slow release)	Vaginal misoprostol (≥ 50 mcg)			1	70	5	70	NA	NA	NA	NA
Saeed 2011	Vaginal PGE2 (tablet)	Vaginal misoprostol (≥ 50 mcg)			4	100	10	100	NA	NA	NA	NA
Saggaf 2001	Vaginal PGE2 (gel)	Vaginal misoprostol (≥ 50 mcg)			0	27	0	30	NA	NA	NA	NA
Salmon 1986	No treatment	Breast stimulation			0	50	0	50	NA	NA	NA	NA
Sanchez-Ramos 1998	Vaginal PGE2 pessary (slow release)	Vaginal misoprostol (≥ 50 mcg)			9	115	12	108	NA	NA	NA	NA
Sawai 1991	Placebo	Vaginal PGE2 (gel)			0	26	0	24	NA	NA	NA	NA
Saxena 2011	Intracervical PGE2	Vaginal misoprostol (< 50 mcg)	Vaginal misoprostol (≥ 50 mcg)		1	70	1	70	2	70	NA	NA
Sciscione 1999	Intracervical PGE2	Foley catheter			0	72	0	77	NA	NA	NA	NA
Sciscione 2001	Vaginal misoprostol (≥ 50 mcg)	Foley catheter			2	53	0	58	NA	NA	NA	NA
Shakya 2010	Intracervical PGE2	Vaginal misoprostol (≥ 50 mcg)			0	31	0	35	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Sharami 2014	Vaginal misoprostol (≥ 50 mcg)	Buccal/sublingual misoprostol			2	63	5	63	NA	NA	NA	NA
Sharma 2005	Intracervical PGE2	Vaginal misoprostol (≥ 50 mcg)	Nitric oxide		1	21	2	23	0	21	NA	NA
Sheela 2007	Intracervical PGE2	Vaginal misoprostol (< 50 mcg)	Oral misoprostol tablet (≥ 50 mcg)		1	50	2	50	1	50	NA	NA
Sheela 2015	Vaginal misoprostol (< 50 mcg)	Buccal/sublingual misoprostol			2	100	2	100	NA	NA	NA	NA
Shetty 2001	Vaginal misoprostol (≥ 50 mcg)	Oral misoprostol tablet (≥ 50 mcg)			6	123	1	122	NA	NA	NA	NA
Shetty 2002a	Oral misoprostol tablet (≥ 50 mcg)	Buccal/sublingual misoprostol			0	50	1	50	NA	NA	NA	NA
Shetty 2002b	Oral misoprostol tablet (≥ 50 mcg)	Buccal/sublingual misoprostol			2	124	2	125	NA	NA	NA	NA
Shetty 2003	Vaginal misoprostol (< 50 mcg)	Oral misoprostol tablet (≥ 50 mcg)			2	50	1	51	NA	NA	NA	NA
Shetty 2004	Vaginal PGE2 (tablet)	Oral misoprostol			0	100	2	100	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
		tablet (≥50mcg)										
Sitthiwattanawong 1999	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)			0	66	2	65	NA	NA	NA	NA
Soliman 2013	Vaginal misoprostol (≥50mcg)	Nitric oxide			9	65	0	65	NA	NA	NA	NA
Souza 2013	Vaginal misoprostol (<50mcg)	Titrated (low dose) oral misoprostol solution			2	100	2	100	NA	NA	NA	NA
Spallicci 2007	Placebo	Hyaluronidase			0	85	0	83	NA	NA	NA	NA
Srisomboon 1996	Placebo	Vaginal misoprostol (≥50mcg)			0	30	2	32	NA	NA	NA	NA
Stempel 1997	Vaginal PGE2 (gel)	Intracervical PGE2			0	44	0	39	NA	NA	NA	NA
Tabowei 2003	Vaginal misoprostol (<50mcg)	Foley catheter			3	60	1	61	NA	NA	NA	NA
Taechakraichana 1996	Intracervical PGE2	Vaginal PGE2 pessary (normal release)			0	9	0	10	NA	NA	NA	NA
Taher 2011	Vaginal PGE2 (tablet)	Vaginal PGE2 (gel)			7	83	7	82	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Tan 2010	Vaginal PGE2 pessary (normal release)	Vaginal misoprostol (<50mcg)			2	57	1	112	NA	NA	NA	NA
Tan 2013	Amniotomy	IV oxytocin plus amniotomy			0	101	0	105	NA	NA	NA	NA
Ten Eikelder 2016	Oral misoprostol tablet (≥50mcg)	Foley catheter			26	924	22	921	NA	NA	NA	NA
Tessier 1997	Vaginal PGE2 (gel)	Oral misoprostol tablet (≥50mcg)			1	132	2	135	NA	NA	NA	NA
Thiery 1984	Placebo	Vaginal PGE2 (tablet)	Intracervical PGE2		1	40	0	41	1	40	NA	NA
Triglia 2010	Vaginal PGE2 (gel)	Vaginal PGE2 pessary (slow release)			0	65	0	65	NA	NA	NA	NA
Trofatter 1985	Placebo	Intracervical PGE2			1	29	1	30	NA	NA	NA	NA
Trofatter 1993	No treatment	Intracervical PGE2			11	249	16	265	NA	NA	NA	NA
Ugwu 2013	Vaginal misoprostol (<50mcg)	Foley catheter			0	45	0	45	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Ulmsten 1982	Placebo	Intracervical PGE2			0	25	1	25	NA	NA	NA	NA
Uludag 2005	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)			3	48	4	51	NA	NA	NA	NA
van Gemund 2004	Vaginal PGE2 (gel)	Vaginal misoprostol (<50mcg)			26	340	29	341	NA	NA	NA	NA
Varaklis 1995	Intracervical PGE2	Vaginal misoprostol (<50mcg)			0	33	2	36	NA	NA	NA	NA
Wallstrom 2019	Titrated (low dose) oral misoprostol solution	Sustained release misoprostol insert			3	99	14	97	NA	NA	NA	NA
Wang 2016	Vaginal PGE2 pessary (normal release)	Titrated (low dose) oral misoprostol solution			18	199	5	212	NA	NA	NA	NA
Wieland 1999	Vaginal PGE2 pessary (slow release)	Intracervical PGE2			2	34	0	35	NA	NA	NA	NA
Wielgos 2007	Vaginal PGE2 pessary (slow release)	Intracervical PGE2			0	66	0	62	NA	NA	NA	NA
Wing 1995a	Intracervical PGE2	Vaginal misoprostol (≥50mcg)			2	67	5	68	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Wing 1995b	Intracervical PGE2	Vaginal misoprostol (<50mcg)			3	137	8	138	NA	NA	NA	NA
Wing 1997	Vaginal PGE2 pessary (slow release)	Vaginal misoprostol (<50mcg)			4	98	1	99	NA	NA	NA	NA
Wing 1999	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)			3	110	2	110	NA	NA	NA	NA
Wing 2000a	Placebo	Mifepristone			0	83	4	97	NA	NA	NA	NA
Wing 2000b	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)			0	113	3	121	NA	NA	NA	NA
Wing 2004	Oral misoprostol tablet (≥50mcg)	IV oxytocin			7	110	0	88	NA	NA	NA	NA
Wing 2008	Vaginal PGE2 pessary (slow release)	Sustained release misoprostol insert			28	436	39	871	NA	NA	NA	NA
Wing 2013	Vaginal PGE2 pessary (slow release)	Sustained release misoprostol insert			18	680	70	678	NA	NA	NA	NA
Witter 1992	Placebo	Vaginal PGE2 pessary			0	39	3	42	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
		(slow release)										
Witter 1996	Placebo	Vaginal PGE2 pessary (slow release)			0	104	3	102	NA	NA	NA	NA
Yenuberi 2016	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)			41	380	45	383	NA	NA	NA	NA
Young 2020	Vaginal PGE2 (gel)	Vaginal misoprostol (< 50mcg)	Oral misoprostol tablet (≥50mcg)		12	172	16	172	8	167	NA	NA
Yuen 1996	Intracervical PGE2	Vaginal PGE2 pessary (normal release)	Double balloon/Cook's catheter		0	39	0	39	0	36	NA	NA
Zahran 2009	Vaginal misoprostol (≥50mcg)	Buccal/sublingual misoprostol			25	240	16	240	NA	NA	NA	NA
Zanini 1990	Vaginal PGE2 (gel)	Intracervical PGE2			2	48	0	52	NA	NA	NA	NA
Zeteroglu 2006a	Vaginal misoprostol (≥50mcg)	IV oxytocin			0	32	0	32	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Zeteroglu 2006b	Vaginal misoprostol (≥50mcg)	IV oxytocin			0	50	0	50	NA	NA	NA	NA
Ziaei 2003	No treatment	Corticosteroids			0	33	0	33	NA	NA	NA	NA

1 NA: not available, EASI: extra-amniotic saline infusion

2 D5 - Caesarean birth

3 Table 5: Evidence table for caesarean birth

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
Aalami-Harandi 2013	Titrated (low dose) oral misoprostol solution	IV oxytocin				26	128	49	128	NA	NA	NA	NA	NA	NA
Abotorabi 2019	Placebo	Nitric oxide				14	30	10	28	NA	NA	NA	NA	NA	NA
Abdelaziz 2018	Vaginal PGE2 (tablet)	Vaginal PGE2 pessary (slow release)				11	100	15	100	NA	NA	NA	NA	NA	NA
Abdul 2007	Vaginal misoprostol (≥50mcg)	IV oxytocin				5	34	4	28	NA	NA	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
Abedi-Asi 2007	Vaginal misoprostol (≥ 50 mcg)	IV oxytocin				13	60	14	60	NA	NA	NA	NA	NA	NA
Adair 1998	Vaginal misoprostol (≥ 50 mcg)	Oral misoprostol tablet (≥ 50 mcg)				13	85	17	93	NA	NA	NA	NA	NA	NA
Adam 2005	Vaginal misoprostol (≥ 50 mcg)	Oral misoprostol tablet (≥ 50 mcg)				8	40	12	40	NA	NA	NA	NA	NA	NA
Adeniji 2005	Vaginal misoprostol (≥ 50 mcg)	Foley catheter				3	50	1	46	NA	NA	NA	NA	NA	NA
Adeniyi 2014	Vaginal misoprostol (< 50 mcg)	Vaginal misoprostol (≥ 50 mcg)				5	65	7	63	NA	NA	NA	NA	NA	NA
Aduloju 2016	Vaginal misoprostol (< 50 mcg)	Foley catheter				19	70	22	70	NA	NA	NA	NA	NA	NA
Aduloju 2019	Oral misoprostol tablet (< 50 mcg)	Titrated (low dose) oral misoprostol solution				15	75	16	75	NA	NA	NA	NA	NA	NA
Agarwal 2003	Intracervical PGE2	Vaginal misoprostol (≥ 50 mcg)				9	60	16	60	NA	NA	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
Agarwal 2012	Placebo	Nitric oxide				31	100	22	100	NA	NA	NA	NA	NA	NA
Agarwal 2014	Intracervical PGE2	Nitric oxide				27	100	17	100	NA	NA	NA	NA	NA	NA
Ajori 2013	Placebo	Acupuncture				7	37	3	38	NA	NA	NA	NA	NA	NA
Akay 2012	Vaginal PGE2 pessary (slow release)	IV oxytocin				18	72	14	72	NA	NA	NA	NA	NA	NA
Alcoseba-Lim 1992	No treatment	Membrane sweeping				3	65	4	65	NA	NA	NA	NA	NA	NA
Allott 1993	No treatment	Membrane sweeping				5	96	4	99	NA	NA	NA	NA	NA	NA
Al-Malt 1995	Placebo	Vaginal PGE2 (gel)				12	54	12	49	NA	NA	NA	NA	NA	NA
Alsharnoubi 2015	Placebo	Acupuncture				4	30	10	30	NA	NA	NA	NA	NA	NA
Al-Taani 2004	Vaginal PGE2 (tablet)	Foley catheter				10	75	12	72	NA	NA	NA	NA	NA	NA
Anand 2012	Intracervical PGE2	Vaginal misoprostol (<50mcg)				24	100	15	100	NA	NA	NA	NA	NA	NA
Andersen 2013	No treatment	Membrane sweeping	Acupuncture			17	100	20	103	13	104	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
Asher 2009	No treatment	Placebo	Acupuncture			3	30	2	29	6	30	NA	NA	NA	NA
Ashrafunnessa 1997	Intracervical PGE2	IV oxytocin				8	49	14	49	NA	NA	NA	NA	NA	NA
Atad 1996	Vaginal PGE2 (tablet)	IV oxytocin	Double balloon/Cook's catheter			4	30	14	30	7	35	NA	NA	NA	NA
Ayaz 2010	Vaginal PGE2 (tablet)	Vaginal misoprostol (≥ 50 mcg)				18	60	4	60	NA	NA	NA	NA	NA	NA
Azubuikwe 2015	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥ 50 mcg)				8	40	11	43	NA	NA	NA	NA	NA	NA
Bagratee 1990	Vaginal PGE2 (tablet)	Laminaria				10	40	8	40	NA	NA	NA	NA	NA	NA
Bakos 1987	IV oxytocin	Amniotomy				3	113	5	110	NA	NA	NA	NA	NA	NA
Balci 2010	Vaginal misoprostol (≥ 50 mcg)	IV oxytocin				7	50	9	50	NA	NA	NA	NA	NA	NA
Balci 2011	Vaginal misoprostol (≥ 50 mcg)	IV oxytocin				12	50	9	51	NA	NA	NA	NA	NA	NA
Barda 2018	Vaginal PGE2 (tablet)	Foley catheter				26	150	17	150	NA	NA	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
Barkai 1994	No treatment	Placebo	Intracervical PGE2			32	175	16	91	39	174	NA	NA	NA	NA
Bartha 2000	Intracervical PGE2	Oral misoprostol tablet (≥50mcg)				20	100	14	100	NA	NA	NA	NA	NA	NA
Bartusevicius 2006	Vaginal misoprostol (<50mcg)	Buccal/sublingual misoprostol				14	70	12	70	NA	NA	NA	NA	NA	NA
Beigi 2003	Placebo	Oral misoprostol tablet (≥50mcg)				22	78	10	78	NA	NA	NA	NA	NA	NA
Bell 1993	Placebo	Relaxin				4	22	2	18	NA	NA	NA	NA	NA	NA
Bennett 1998	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)				23	102	16	104	NA	NA	NA	NA	NA	NA
Berghella 1996	No treatment	Membrane sweeping				3	69	0	73	NA	NA	NA	NA	NA	NA
Berkane 2005	Placebo	Mifepristone				22	57	89	289	NA	NA	NA	NA	NA	NA
Bernstein 1991	Placebo	Intracervical PGE2				65	194	56	203	NA	NA	NA	NA	NA	NA
Bollapragada 2009	Placebo	Nitric oxide				56	173	65	177	NA	NA	NA	NA	NA	NA
Boulvain 1998	No treatment	Membrane sweeping				12	99	12	99	NA	NA	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
Bounyasong 2000	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)				2	83	9	83	NA	NA	NA	NA	NA	NA
Bremme 1980	IV oxytocin plus amniotomy	Oral prostaglandins				3	39	4	44	NA	NA	NA	NA	NA	NA
Brennand 1997	Placebo	Relaxin				4	23	15	73	NA	NA	NA	NA	NA	NA
Buchanan 1984	Placebo	Vaginal PGE2 pessary (normal release)				17	39	15	38	NA	NA	NA	NA	NA	NA
Bullarbo 2007	Placebo	Nitric oxide				17	100	14	100	NA	NA	NA	NA	NA	NA
Buser 1997	Intracervical PGE2	Vaginal misoprostol (≥50mcg)				17	79	27	76	NA	NA	NA	NA	NA	NA
Buttino 1990	Placebo	Intracervical PGE2				7	20	5	23	NA	NA	NA	NA	NA	NA
Cahill 1988	Vaginal PGE2 (tablet)	Laminaria				3	22	2	20	NA	NA	NA	NA	NA	NA
Caliskan 2005	Vaginal misoprostol (≥50mcg)	Buccal/sublingual misoprostol				14	80	15	80	NA	NA	NA	NA	NA	NA
Cammu 1998	No treatment	Membrane sweeping				8	138	5	140	NA	NA	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
Campbell 1984	Placebo	Vaginal PGE2 pessary (normal release)				6	104	10	95	NA	NA	NA	NA	NA	NA
Campos Perez 1991	Vaginal misoprostol (≥ 50 mcg)	IV oxytocin				3	78	19	75	NA	NA	NA	NA	NA	NA
Cardozo 1986	No treatment	Vaginal PGE2 pessary (normal release)				20	207	25	195	NA	NA	NA	NA	NA	NA
Carlan 2001	Vaginal misoprostol (≥ 50 mcg)	Oral misoprostol tablet (≥ 50 mcg)				120	501	147	503	NA	NA	NA	NA	NA	NA
Carlan 2002	Vaginal misoprostol (≥ 50 mcg)	Buccal/sublingual misoprostol				28	79	18	73	NA	NA	NA	NA	NA	NA
Castro 2014	No treatment	Sexual intercourse				6	60	9	63	NA	NA	NA	NA	NA	NA
Cecatti 2000	Vaginal misoprostol (< 50 mcg)	IV oxytocin				11	53	21	53	NA	NA	NA	NA	NA	NA
Chai 2018	Vaginal PGE2 pessary (normal release)	Foley catheter				20	80	9	80	NA	NA	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
Chang 1997	Vaginal PGE2 (tablet)	Vaginal misoprostol (≥50mcg)				2	30	3	30	NA	NA	NA	NA	NA	NA
Chanrachakul 2000a	Vaginal PGE2 (tablet)	Nitric oxide				20	56	19	54	NA	NA	NA	NA	NA	NA
Chanrachakul 2000b	Vaginal PGE2 (tablet)	Nitric oxide				6	10	8	20	NA	NA	NA	NA	NA	NA
Chanrachakul 2002	Vaginal misoprostol (≥50mcg)	Nitric oxide				16	52	20	55	NA	NA	NA	NA	NA	NA
Chanrachakul 2003	No treatment	IV oxytocin plus amniotomy				27	125	33	124	NA	NA	NA	NA	NA	NA
Chanrachakul 2010	Vaginal misoprostol (≥50mcg)	Buccal/sublingual misoprostol				40	107	41	111	NA	NA	NA	NA	NA	NA
Charoenkul 2000	Vaginal PGE2 (tablet)	Vaginal misoprostol (≥50mcg)				13	71	18	72	NA	NA	NA	NA	NA	NA
Chatterjee 1991	Placebo	Vaginal PGE2 (gel)				5	18	7	15	NA	NA	NA	NA	NA	NA
Chavakula 2015	Vaginal misoprostol (<50mcg)	Foley catheter				7	46	16	54	NA	NA	NA	NA	NA	NA
Chayen 1986	IV oxytocin	Breast stimulation				14	32	10	29	NA	NA	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
Chen 2014	Vaginal PGE2 pessary (slow release)	IV oxytocin				12	58	38	59	NA	NA	NA	NA	NA	NA
Cheng 2008	Vaginal misoprostol (<50mcg)	Titrated (low dose) oral misoprostol solution				18	106	4	101	NA	NA	NA	NA	NA	NA
Chitrakar 2012	Intracervical PGE2	Vaginal misoprostol (<50mcg)				29	100	22	100	NA	NA	NA	NA	NA	NA
Chua 1988	Vaginal PGE2 (tablet)	IV oxytocin plus amniotomy				3	40	5	40	NA	NA	NA	NA	NA	NA
Chua 1997	Intracervical PGE2	Laminaria				20	95	22	90	NA	NA	NA	NA	NA	NA
Chuck 1995	Intracervical PGE2	Vaginal misoprostol (≥50mcg)				10	50	10	49	NA	NA	NA	NA	NA	NA
Chung 2003	Vaginal misoprostol (<50mcg)	Foley catheter				18	49	23	54	NA	NA	NA	NA	NA	NA
Chyu 1997	Vaginal PGE2 pessary (slow release)	Intracervical PGE2				8	37	15	36	NA	NA	NA	NA	NA	NA

DRAFT FOR CONSULTATION

Evidence tables for pharmacological and mechanical methods for induction of labour

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
Clark 1998	Intracervical PGE2	Vaginal misoprostol (<50mcg)				20	66	11	72	NA	NA	NA	NA	NA	NA
Colon 2005	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)				36	111	18	93	NA	NA	NA	NA	NA	NA
Conde 2017	Vaginal misoprostol (≥50mcg)	Buccal/sublingual misoprostol				7	51	10	51	NA	NA	NA	NA	NA	NA
Corrado 2001	Vaginal PGE2 (gel)	Intracervical PGE2				11	111	9	122	NA	NA	NA	NA	NA	NA
Crane 1997	No treatment	Membrane sweeping				10	74	10	76	NA	NA	NA	NA	NA	NA
Cromi 2011	Vaginal PGE2 pessary (slow release)	Foley catheter				40	132	84	265	NA	NA	NA	NA	NA	NA
Cromi 2012	Vaginal PGE2 pessary (slow release)	Double balloon/Cook's catheter				27	103	25	105	NA	NA	NA	NA	NA	NA
Curet 1989	Placebo	Vaginal PGE2 (gel)				13	26	14	28	NA	NA	NA	NA	NA	NA
Dällenbach 2003	Vaginal PGE2 (gel)	Oral misoprostol				19	100	18	100	NA	NA	NA	NA	NA	NA

DRAFT FOR CONSULTATION

Evidence tables for pharmacological and mechanical methods for induction of labour

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
		tablet (<50mcg)													
Dalui 2005	Intracervical PGE2	Foley catheter				13	50	8	50	NA	NA	NA	NA	NA	NA
Danielian 1999	Vaginal PGE2 (gel)	Vaginal misoprostol (≥50mcg)				14	106	12	105	NA	NA	NA	NA	NA	NA
Dare 2002	No treatment	Membrane sweeping				13	68	6	69	NA	NA	NA	NA	NA	NA
Darroca 1996	Placebo	Intracervical PGE2				18	57	8	61	NA	NA	NA	NA	NA	NA
Davey 1979	Vaginal PGE2 (gel)	Oral prostaglandins				10	17	4	16	NA	NA	NA	NA	NA	NA
De Aquino 2003	Vaginal misoprostol (<50mcg)	IV oxytocin				20	105	38	105	NA	NA	NA	NA	NA	NA
De Bonrosto Torralba 2015	Vaginal PGE2 pessary (slow release)	Vaginal misoprostol (<50mcg)				10	24	2	20	NA	NA	NA	NA	NA	NA
De Bonrosto Torralba 2019	Vaginal PGE2 pessary (slow release)	Vaginal misoprostol (<50mcg)				26	99	22	99	NA	NA	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
De la Torre 2001	Vaginal misoprostol (≥ 50 mcg)	IV oxytocin				36	168	38	192	NA	NA	NA	NA	NA	NA
De Miranda 2006	No treatment	Membrane sweeping				35	367	37	375	NA	NA	NA	NA	NA	NA
DebBarm a 2015	Vaginal misoprostol (< 50 mcg)	Oral misoprostol tablet (< 50 mcg)				14	65	26	65	NA	NA	NA	NA	NA	NA
Demirel 2015	No treatment	Breast stimulation				11	130	0	130	NA	NA	NA	NA	NA	NA
Denguezli 2007	Intracervical PGE2	Vaginal misoprostol (≥ 50 mcg)				21	65	10	65	NA	NA	NA	NA	NA	NA
Deo 2012	Vaginal PGE2 (gel)	Vaginal misoprostol (< 50 mcg)	Foley catheter			12	52	16	54	9	52	NA	NA	NA	NA
Deshmukh 2011	Intracervical PGE2	Foley catheter				37	200	28	200	NA	NA	NA	NA	NA	NA
Deshmukh 2013	Vaginal misoprostol (≥ 50 mcg)	Oral misoprostol tablet (≥ 50 mcg)				17	100	26	100	NA	NA	NA	NA	NA	NA
Diro 1999	Vaginal misoprostol (< 50 mcg)	Vaginal misoprostol (≥ 50 mcg)				44	125	40	126	NA	NA	NA	NA	NA	NA
Doany 1997	Placebo	Vaginal PGE2 (gel)	Membrane sweeping			1	28	3	37	4	50	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
Dodd 2006	Vaginal PGE2 (gel)	Titrated (low dose) oral misoprostol solution				100	376	83	365	NA	NA	NA	NA	NA	NA
Dogra 2019	No treatment	IV oxytocin				2	25	1	25	NA	NA	NA	NA	NA	NA
Domisse 1980	Placebo	Vaginal PGE2 (tablet)				3	28	5	28	NA	NA	NA	NA	NA	NA
Domisse 1987	Vaginal PGE2 (gel)	IV oxytocin plus amniotomy				3	25	5	25	NA	NA	NA	NA	NA	NA
Dulger 2018	Placebo	Nitric oxide				8	34	5	36	NA	NA	NA	NA	NA	NA
Dyar 2000	Vaginal misoprostol (≥ 50 mcg)	Oral misoprostol tablet (≥ 50 mcg)				21	77	11	76	NA	NA	NA	NA	NA	NA
Edwards 2014	Vaginal PGE2 pessary (slow release)	Foley catheter				73	191	56	195	NA	NA	NA	NA	NA	NA
Egarter 1989	Vaginal PGE2 (gel)	IV oxytocin				2	49	6	50	NA	NA	NA	NA	NA	NA
Ekman 1983	Vaginal PGE2 (gel)	Intracervical PGE2				4	30	1	30	NA	NA	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
Ekman 1986	Vaginal PGE2 pessary (normal release)	IV oxytocin				0	19	1	19	NA	NA	NA	NA	NA	NA
El-Din 2000	Vaginal PGE2 (tablet)	Intracervical PGE2	Vaginal misoprostol (≥ 50 mcg)			7	49	5	48	6	52	NA	NA	NA	NA
Elhassan 2004	Vaginal PGE2 (tablet)	Vaginal misoprostol (≥ 50 mcg)				22	60	10	60	NA	NA	NA	NA	NA	NA
Elhassan 2005a	Vaginal misoprostol (≥ 50 mcg)	IV oxytocin				5	70	14	70	NA	NA	NA	NA	NA	NA
Elhassan 2005b	Vaginal misoprostol (< 50 mcg)	Vaginal misoprostol (≥ 50 mcg)				10	31	2	32	NA	NA	NA	NA	NA	NA
El-Mardi 1991	Vaginal PGE2 (tablet)	Vaginal PGE2 pessary (normal release)				4	100	4	100	NA	NA	NA	NA	NA	NA
El-Shawarby 2006	Vaginal PGE2 (gel)	Vaginal PGE2 pessary (slow release)				3	38	5	34	NA	NA	NA	NA	NA	NA
El-Sherbiny 2001	Vaginal misoprostol (< 50 mcg)	Vaginal misoprostol (≥ 50 mcg)				16	93	13	92	NA	NA	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
El-Torkey 1992	No treatment	Membrane sweeping				4	32	5	33	NA	NA	NA	NA	NA	NA
Eroglu 2007	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)				14	73	17	74	NA	NA	NA	NA	NA	NA
Escudero 1997	Vaginal misoprostol (≥50mcg)	IV oxytocin				10	53	4	67	NA	NA	NA	NA	NA	NA
Ezechukwu 2015	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)				21	70	24	70	NA	NA	NA	NA	NA	NA
Facchinetti 2005	Vaginal PGE2 pessary (slow release)	Intracervical PGE2				17	72	26	72	NA	NA	NA	NA	NA	NA
Facchinetti 2007	Vaginal PGE2 pessary (slow release)	Intracervical PGE2				13	58	21	58	NA	NA	NA	NA	NA	NA
Farah 1997	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)				23	192	33	207	NA	NA	NA	NA	NA	NA
Feitosa 2006	Vaginal misoprostol (<50mcg)	Buccal/sublingual misoprostol				23	75	32	75	NA	NA	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
Fenton 1985	Placebo	Extra-amniotic prostaglandin				5	15	2	15	NA	NA	NA	NA	NA	NA
Ferguson 2002	Vaginal misoprostol (≥50mcg)	IV oxytocin				20	51	18	53	NA	NA	NA	NA	NA	NA
Ferraiolo 2010	Vaginal PGE2 (gel)	Vaginal PGE2 pessary (slow release)				21	72	23	79	NA	NA	NA	NA	NA	NA
Fisher 2001	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)				14	64	12	62	NA	NA	NA	NA	NA	NA
Fletcher 1993	Placebo	Vaginal misoprostol (≥50mcg)				3	21	2	24	NA	NA	NA	NA	NA	NA
Fletcher 1994	Vaginal PGE2 (tablet)	Vaginal misoprostol (≥50mcg)				3	31	1	32	NA	NA	NA	NA	NA	NA
Fonseca 2008	Vaginal misoprostol (<50mcg)	IV oxytocin				31	164	22	163	NA	NA	NA	NA	NA	NA
Frass 2011	No treatment	Vaginal misoprostol (≥50mcg)				48	57	17	56	NA	NA	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
Frydman 1991	Placebo	Mifepristone				23	60	21	60	NA	NA	NA	NA	NA	NA
Gagnon-Gervais 2012	IV oxytocin	IV oxytocin plus amniotomy				6	72	7	71	NA	NA	NA	NA	NA	NA
Gaikwad 2014	Intracervical PGE2	Mifepristone				22	50	8	50	NA	NA	NA	NA	NA	NA
Garry 2000	No treatment	Castor oil				4	48	10	52	NA	NA	NA	NA	NA	NA
Garry 2003	Vaginal PGE2 pessary (slow release)	Vaginal misoprostol (≥50mcg)				35	89	28	97	NA	NA	NA	NA	NA	NA
Gattas 2020	Vaginal misoprostol (<50 mcg)	Buccal/sublingual misoprostol				56	100	56	98	NA	NA	NA	NA	NA	NA
Gaudet 2008	Placebo	Acupuncture				2	7	2	9	NA	NA	NA	NA	NA	NA
Gelisen 2005	No treatment	Vaginal misoprostol (≥50mcg)	IV oxytocin	Foley catheter		66	300	17	100	24	100	17	100	NA	NA
Ghanaie 2013	Intracervical PGE2	Foley catheter				41	118	30	121	NA	NA	NA	NA	NA	NA
Gherman 2001	Vaginal PGE2 (gel)	Oral misoprostol tablet (≥50mcg)				6	30	9	28	NA	NA	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
Giacalone 1998	Placebo	Mifepristone				6	42	7	41	NA	NA	NA	NA	NA	NA
Gihwala 1987	Vaginal PGE2 (gel)	IV oxytocin				5	25	5	25	NA	NA	NA	NA	NA	NA
Gilad 2018	Placebo	Castor oil				4	43	6	38	NA	NA	NA	NA	NA	NA
Gilson 1993	Placebo	Intracervical PGE2				6	38	16	41	NA	NA	NA	NA	NA	NA
Gilson 1996	No treatment	Laminaria				49	128	41	112	NA	NA	NA	NA	NA	NA
Girija 2009	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)				12	50	10	50	NA	NA	NA	NA	NA	NA
Girija 2011	Intracervical PGE2	Vaginal misoprostol (<50mcg)				42	161	40	159	NA	NA	NA	NA	NA	NA
Glagoleva 1999	Intracervical PGE2	Laminaria				5	26	7	27	NA	NA	NA	NA	NA	NA
Golbus 1977	Placebo	Oral prostaglandins				2	25	1	25	NA	NA	NA	NA	NA	NA
Goldenberg 1996	No treatment	Membrane sweeping				9	141	10	152	NA	NA	NA	NA	NA	NA
Gottschall 1997	Vaginal PGE2 (gel)	Vaginal misoprostol (≥50mcg)				10	37	7	38	NA	NA	NA	NA	NA	NA
Gower 1982	Placebo	Laminaria				6	22	11	26	NA	NA	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
Graves 1985	Placebo	Vaginal PGE2 (gel)				3	20	16	60	NA	NA	NA	NA	NA	NA
Green 1998	Vaginal PGE2 (gel)	Vaginal PGE2 pessary (slow release)				8	54	7	53	NA	NA	NA	NA	NA	NA
Greer 1989	Vaginal PGE2 (tablet)	Extra-amniotic prostaglandin				4	25	5	25	NA	NA	NA	NA	NA	NA
Greer 1990	Vaginal PGE2 (tablet)	Vaginal PGE2 (gel)				0	12	0	12	NA	NA	NA	NA	NA	NA
Gregson 2005	Vaginal PGE2 (gel)	Vaginal misoprostol (<50mcg)				31	129	36	139	NA	NA	NA	NA	NA	NA
Gregson 2015	Placebo	Acupuncture				19	60	23	70	NA	NA	NA	NA	NA	NA
Greybush 2001	Vaginal misoprostol (<50mcg)	Foley catheter				13	65	15	71	NA	NA	NA	NA	NA	NA
Gribel 2011	Vaginal misoprostol (<50mcg)	Acupuncture				21	32	11	35	NA	NA	NA	NA	NA	NA
Guha 2015	Vaginal misoprostol (≥50mcg)	Nitric oxide				31	100	23	100	NA	NA	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
Gupta 1998	No treatment	Membrane sweeping				8	50	6	50	NA	NA	NA	NA	NA	NA
Gupta 2006	Intracervical PGE2	Vaginal misoprostol (<50mcg)				26	100	12	100	NA	NA	NA	NA	NA	NA
Gupta 2010	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)				15	80	11	68	NA	NA	NA	NA	NA	NA
Haas 2019	Vaginal misoprostol (<50 mcg)	Buccal/sublingual misoprostol				24	152	33	148	NA	NA	NA	NA	NA	NA
Habib 2008	Placebo	Nitric oxide				17	51	15	51	NA	NA	NA	NA	NA	NA
Haghighi 2013	Vaginal misoprostol (<50mcg)	Nitric oxide				16	66	11	66	NA	NA	NA	NA	NA	NA
Haghighi 2015	No treatment	Nitric oxide				30	50	51	99	NA	NA	NA	NA	NA	NA
Hales 1994	Vaginal PGE2 (gel)	Intracervical PGE2				11	48	14	52	NA	NA	NA	NA	NA	NA
Hall 2002	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)				8	48	9	59	NA	NA	NA	NA	NA	NA
Harper 2006	No treatment	Acupuncture				10	26	5	30	NA	NA	NA	NA	NA	NA
Has 2002	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)				12	58	22	56	NA	NA	NA	NA	NA	NA

DRAFT FOR CONSULTATION

Evidence tables for pharmacological and mechanical methods for induction of labour

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
Haugland 2012	Foley catheter	Double balloon/Coak's catheter				18	90	19	88	NA	NA	NA	NA	NA	NA
Hay 1995	Intracervical PGE2	Laminaria				1	13	2	15	NA	NA	NA	NA	NA	NA
Heden 1991	No treatment	IV oxytocin plus amniotomy				9	129	10	109	NA	NA	NA	NA	NA	NA
Hemlin 1998	Intracervical PGE2	Foley catheter + EASI				6	42	11	43	NA	NA	NA	NA	NA	NA
Henry 2013	Vaginal PGE2 (gel)	Foley catheter				15	51	17	50	NA	NA	NA	NA	NA	NA
Herabuta 1988	Intracervical PGE2	Oral prostaglandins				8	25	5	25	NA	NA	NA	NA	NA	NA
Herabuta 1992	No treatment	Intracervical PGE2				24	51	27	57	NA	NA	NA	NA	NA	NA
Herabuta 1993	Vaginal PGE2 (tablet)	Intracervical PGE2				6	26	6	22	NA	NA	NA	NA	NA	NA
Herabuta 1997	Intracervical PGE2	Vaginal misoprostol (≥50mcg)				16	50	19	60	NA	NA	NA	NA	NA	NA
Hill 2008	No treatment	Membrane sweeping				23	138	17	162	NA	NA	NA	NA	NA	NA
Hofmeyr 2001	Vaginal PGE2 (gel)	Titrated (low dose)	Foley catheter			68	347	54	345	36	174	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
		oral misoprostol solution													
Hokkila 2019	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)				45	133	40	135	NA	NA	NA	NA	NA	NA
Hoppe 2016	Foley catheter	Double balloon/Coak's catheter				21	48	14	50	NA	NA	NA	NA	NA	NA
Hosli 2008	Vaginal PGE2 (gel)	Vaginal misoprostol (≥50mcg)				15	55	13	52	NA	NA	NA	NA	NA	NA
Howarth 1996	Vaginal PGE2 (gel)	Vaginal misoprostol (≥50mcg)				15	36	6	36	NA	NA	NA	NA	NA	NA
Hudon 1999	Intracervical PGE2	Foley catheter				37	55	39	56	NA	NA	NA	NA	NA	NA
Hutchon 1980	Placebo	Intracervical PGE2				13	35	11	32	NA	NA	NA	NA	NA	NA
Incerpi 2001	Placebo	Vaginal misoprostol (<50mcg)				11	63	14	57	NA	NA	NA	NA	NA	NA
Irion 1998	Vaginal PGE2 (gel)	Intracervical PGE2				31	125	39	122	NA	NA	NA	NA	NA	NA
Iskander 1978	Extra-amniotic	IV prostaglandin				1	20	0	20	NA	NA	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
	prostaglandins														
Jackson 1994	Vaginal PGE2 (gel)	IV oxytocin				17	83	16	75	NA	NA	NA	NA	NA	NA
Jagani 1982	No treatment	IV oxytocin	Amniotomy	Foley catheter	Laminaria	0	10	3	10	4	10	1	10	3	10
Jagani 1984	No treatment	Vaginal PGE2 pessary (normal release)	IV oxytocin			2	16	5	15	5	16	NA	NA	NA	NA
Janakiraman 2011	No treatment	Membrane sweeping				16	62	9	61	NA	NA	NA	NA	NA	NA
Jeeva 1982	Vaginal PGE2 (tablet)	Laminaria				3	10	4	10	NA	NA	NA	NA	NA	NA
Jindal 2019	Vaginal PGE2 (gel)	Mifepristone				2	44	6	46	NA	NA	NA	NA	NA	NA
Johnson 1985	Vaginal PGE2 (gel)	Laminaria				10	40	6	40	NA	NA	NA	NA	NA	NA
Jozwiak 2011	Vaginal PGE2 (gel)	Foley catheter				82	408	93	411	NA	NA	NA	NA	NA	NA
Jozwiak 2013	Vaginal PGE2 pessary (slow release)	Foley catheter				26	119	21	107	NA	NA	NA	NA	NA	NA

DRAFT FOR CONSULTATION

Evidence tables for pharmacological and mechanical methods for induction of labour

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
Jozwiak 2014	Vaginal misoprostol (<50mcg)	Foley catheter				11	64	14	56	NA	NA	NA	NA	NA	NA
Kadanali 1996	Intracervical PGE2	Vaginal misoprostol (≥50mcg)				22	112	12	112	NA	NA	NA	NA	NA	NA
Kadian 2008	Vaginal PGE2 (gel)	Nitric oxide				48	200	28	200	NA	NA	NA	NA	NA	NA
Kalkat 2008	Vaginal PGE2 (gel)	Vaginal PGE2 pessary (slow release)				8	60	14	60	NA	NA	NA	NA	NA	NA
Kaminski 1994	PGF2 gel	IV oxytocin				5	150	8	146	NA	NA	NA	NA	NA	NA
Kandil 2012	Vaginal misoprostol (<50mcg)	Foley catheter				8	50	9	50	NA	NA	NA	NA	NA	NA
Karatas 2016	Vaginal PGE2 pessary (slow release)	Foley catheter				7	42	15	43	NA	NA	NA	NA	NA	NA
Kashanian 2006a	Vaginal misoprostol (<50mcg)	Foley catheter				40	100	37	100	NA	NA	NA	NA	NA	NA
Kashanian 2006b	No treatment	Membrane sweeping				6	51	6	50	NA	NA	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
Kashanian 2008	Placebo	Corticosteroids				14	61	10	61	NA	NA	NA	NA	NA	NA
Kashanian 2020	Titrated (low dose) oral misoprostol solution	IV oxytocin				6	40	5	40	NA	NA	NA	NA	NA	NA
Katz 1983	No treatment	IV oxytocin plus amniotomy				7	78	16	78	NA	NA	NA	NA	NA	NA
Kaul 2004	Intracervical PGE2	Membrane sweeping				7	30	2	30	NA	NA	NA	NA	NA	NA
Keirse 1995	Vaginal PGE2 (gel)	Intracervical PGE2				9	140	12	142	NA	NA	NA	NA	NA	NA
Kennedy 1978	Intracervical PGE2	IV oxytocin plus amniotomy				4	30	1	30	NA	NA	NA	NA	NA	NA
Kennedy 1982	Vaginal PGE2 (tablet)	IV oxytocin plus amniotomy				1	50	2	50	NA	NA	NA	NA	NA	NA
Khatib 2019	Vaginal PGE2 pessary (slow release)	Double balloon/Cook's catheter				4	21	5	21	NA	NA	NA	NA	NA	NA
Khazardoost 2011	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)				6	30	3	30	NA	NA	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
Khoury 2001	Vaginal PGE2 pessary (slow release)	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)			11	39	15	39	11	40	NA	NA	NA	NA
Kidanto 2007	Vaginal misoprostol (<50mcg)	IV oxytocin				7	71	23	71	NA	NA	NA	NA	NA	NA
Kim 2000	Vaginal PGE2 (tablet)	Vaginal misoprostol (≥50mcg)				5	74	3	39	NA	NA	NA	NA	NA	NA
Kipikasa 2005	Oral misoprostol tablet (<50mcg)	Oral misoprostol tablet (≥50mcg)				5	23	6	29	NA	NA	NA	NA	NA	NA
Koc 2013	Vaginal PGE2 pessary (slow release)	IV oxytocin				14	89	7	79	NA	NA	NA	NA	NA	NA
Kolderup 1999	Intracervical PGE2	Vaginal misoprostol (≥50mcg)				21	78	23	81	NA	NA	NA	NA	NA	NA
Komala 2013	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)				14	100	6	100	NA	NA	NA	NA	NA	NA
Kovavisarach 1997	Vaginal PGE2 (tablet)	Vaginal misoprostol (≥50mcg)				7	30	4	30	NA	NA	NA	NA	NA	NA

DRAFT FOR CONSULTATION

Evidence tables for pharmacological and mechanical methods for induction of labour

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
Kovavisarach 1998	Vaginal PGE2 (tablet)	Vaginal misoprostol (≥50mcg)				4	40	6	40	NA	NA	NA	NA	NA	NA
Krammer 1995	Intracervical PGE2	Laminaria				47	202	68	214	NA	NA	NA	NA	NA	NA
Krishnamurthy 2015	Placebo	Nitric oxide				14	50	22	50	NA	NA	NA	NA	NA	NA
Krithika 2008	Intracervical PGE2	Vaginal misoprostol (<50mcg)				8	50	6	50	NA	NA	NA	NA	NA	NA
Kulshreshtha 2007	Intracervical PGE2	Vaginal misoprostol (≥50mcg)				3	20	1	20	NA	NA	NA	NA	NA	NA
Kumar 2001	Intracervical PGE2	Vaginal misoprostol (<50mcg)				23	100	18	100	NA	NA	NA	NA	NA	NA
Kwon 2001	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)				19	82	13	78	NA	NA	NA	NA	NA	NA
Lackritz 1979	Placebo	Laminaria				3	5	2	7	NA	NA	NA	NA	NA	NA
Laloha 2015	Placebo	Corticosteroids				7	86	8	86	NA	NA	NA	NA	NA	NA
Lange 1984	Vaginal PGE2 pessary	IV oxytocin				14	95	14	90	NA	NA	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
	(normal release)														
Langenegger 2005	Intracervical PGE2	Oral misoprostol tablet (≥50mcg)				22	95	22	96	NA	NA	NA	NA	NA	NA
Larmon 2002	Placebo	Intracervical PGE2	Oestrogens			10	43	5	41	13	44	NA	NA	NA	NA
Laube 1986	Placebo	Intracervical PGE2				1	15	8	30	NA	NA	NA	NA	NA	NA
Le Roux 2002	Vaginal PGE2 (gel)	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)			82	240	42	120	39	120	NA	NA	NA	NA
Lee 1997	Vaginal PGE2 (tablet)	Vaginal misoprostol (≥50mcg)				4	25	2	25	NA	NA	NA	NA	NA	NA
Legarth 1987	Vaginal PGE2 pessary (normal release)	IV oxytocin				1	49	4	49	NA	NA	NA	NA	NA	NA
Legarth 1988	Intracervical PGE2	Vaginal PGE2 pessary (normal release)				9	57	9	56	NA	NA	NA	NA	NA	NA

DRAFT FOR CONSULTATION

Evidence tables for pharmacological and mechanical methods for induction of labour

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
Lemancewicz 1999	Intracervical PGE2	Vaginal misoprostol (≥50mcg)	IV oxytocin			10	40	10	44	10	47	NA	NA	NA	NA
Levine 2016	Vaginal misoprostol (<50mcg)	Foley catheter				29	120	35	123	NA	NA	NA	NA	NA	NA
Lewis 1983	No treatment	Vaginal PGE2 pessary (normal release)	Foley catheter			6	22	3	22	7	22	NA	NA	NA	NA
Lien 1998	Placebo	Intracervical PGE2				8	47	6	46	NA	NA	NA	NA	NA	NA
Liggins 1979	Placebo	Vaginal PGE2 pessary (normal release)				9	32	7	52	NA	NA	NA	NA	NA	NA
Lim 2018	Vaginal PGE2 (tablet)	Double balloon/Cook's catheter				11	52	9	31	NA	NA	NA	NA	NA	NA
Lo 1994	Vaginal PGE2 (tablet)	IV oxytocin plus amniotomy				10	101	5	99	NA	NA	NA	NA	NA	NA
Lo 2006	IV oxytocin plus amniotomy	Buccal/sublingual misoprostol				4	25	3	25	NA	NA	NA	NA	NA	NA

DRAFT FOR CONSULTATION

Evidence tables for pharmacological and mechanical methods for induction of labour

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
Lokkegaard 2015	Vaginal PGE2 (tablet)	Double balloon/Cook's catheter				107	413	114	412	NA	NA	NA	NA	NA	NA
Lokugam age 2003	Vaginal PGE2 (gel)	Vaginal misoprostol (≥50mcg)				37	95	29	96	NA	NA	NA	NA	NA	NA
Lopes 1991	Vaginal PGE2 (gel)	Intracervical PGE2				2	22	2	28	NA	NA	NA	NA	NA	NA
Luther 1980	Placebo	Oestrogens				10	49	6	51	NA	NA	NA	NA	NA	NA
Lykkesfeldt 1979	IV oxytocin plus amniotomy	Oral prostaglandins				6	92	7	69	NA	NA	NA	NA	NA	NA
Lyndrup 1989	Vaginal PGE2 pessary (normal release)	IV oxytocin				3	19	4	24	NA	NA	NA	NA	NA	NA
Lyndrup 1991	Intracervical PGE2	Vaginal PGE2 pessary (normal release)				18	64	16	61	NA	NA	NA	NA	NA	NA
Lyndrup 1994	Vaginal PGE2 pessary (normal release)	Foley catheter + EASI				5	50	18	59	NA	NA	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
Macer 1984	Vaginal PGE2 pessary (normal release)	IV oxytocin				2	45	2	40	NA	NA	NA	NA	NA	NA
MacKenzie 1979	Placebo	Vaginal PGE2 (gel)	PGF2 gel			3	16	2	16	2	16	NA	NA	NA	NA
MacLennan 1979	Placebo	PGF2 gel				3	40	2	40	NA	NA	NA	NA	NA	NA
MacLennan 1980a	Placebo	Relaxin				3	30	1	30	NA	NA	NA	NA	NA	NA
MacLennan 1980b	Placebo	PGF2 gel				3	30	3	60	NA	NA	NA	NA	NA	NA
MacLennan 1986	Placebo	Relaxin				4	23	6	48	NA	NA	NA	NA	NA	NA
MacLennan 1989	Vaginal PGE2 (gel)	IV oxytocin plus amniotomy				19	165	14	155	NA	NA	NA	NA	NA	NA
Madaan 2014	Intracervical PGE2	Vaginal misoprostol (<50mcg)				12	50	9	50	NA	NA	NA	NA	NA	NA
Magann 1995	Intracervical PGE2	IV oxytocin	Oestrogens			19	33	20	33	19	33	NA	NA	NA	NA
Magann 1998a	No treatment	Membrane sweeping				5	32	4	33	NA	NA	NA	NA	NA	NA
Magann 1998b	No treatment	Intracervical PGE2	Membrane sweeping			5	35	8	35	5	35	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
Magann 1999	Vaginal PGE2 pessary (slow release)	Membrane sweeping				25	91	17	91	NA	NA	NA	NA	NA	NA
Magtibay 1998	Intracervical PGE2	Vaginal misoprostol (≥ 50 mcg)				5	19	3	17	NA	NA	NA	NA	NA	NA
Mahacakrai 2018	Vaginal misoprostol (<50mcg)	Titrate (low dose) oral misoprostol solution				0	15	1	14	NA	NA	NA	NA	NA	NA
Mahmood 1989	Vaginal PGE2 (tablet)	Vaginal PGE2 (gel)				12	40	6	40	NA	NA	NA	NA	NA	NA
Mahmood 1995	Vaginal PGE2 (gel)	Amniotomy				5	130	6	130	NA	NA	NA	NA	NA	NA
Majoko 2002a	Vaginal misoprostol (≥ 50 mcg)	Extra-amniotic prostaglandin				6	76	14	76	NA	NA	NA	NA	NA	NA
Majoko 2002b	Vaginal PGE2 pessary (normal release)	Vaginal misoprostol (≥ 50 mcg)	Titrate (low dose) oral misoprostol solution	Extra-amniotic prostaglandins		13	75	11	128	13	127	14	76	NA	NA
Manandhar 2017	IV oxytocin	Mifepristone				24	34	17	34	NA	NA	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
Martin 1989	No treatment	Laminaria				1	10	2	12	NA	NA	NA	NA	NA	NA
Mawire 1999	Foley catheter + EASI ^^	Extra-amniotic prostaglandin				7	81	10	81	NA	NA	NA	NA	NA	NA
McColgin 1990b	No treatment	Membrane sweeping				5	48	7	51	NA	NA	NA	NA	NA	NA
McKenna 1999	Placebo	Intracervical PGE2				3	31	4	30	NA	NA	NA	NA	NA	NA
McKenna 2004	Placebo	Vaginal misoprostol (<50mcg)				9	35	9	33	NA	NA	NA	NA	NA	NA
McLaren 1987	Vaginal PGE2 (tablet)	Vaginal PGE2 pessary (slow release)				2	12	1	12	NA	NA	NA	NA	NA	NA
Megalo 2004	Intracervical PGE2	Vaginal misoprostol (≥50mcg)				14	100	18	100	NA	NA	NA	NA	NA	NA
Mehrotra 2010	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)				11	68	10	60	NA	NA	NA	NA	NA	NA
Mei-Dan 2012	Foley catheter + EASI	Double balloon/Cook's catheter				18	88	20	100	NA	NA	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
Mei-Dan 2014	Foley catheter + EASI	Double balloon/Cook's catheter + EASI				25	126	5	60	NA	NA	NA	NA	NA	NA
Mercer 1995	IV oxytocin	IV oxytocin plus amniotomy				23	103	24	106	NA	NA	NA	NA	NA	NA
Meydanli 2003	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)				11	60	13	60	NA	NA	NA	NA	NA	NA
Meyer 2002	Intracervical PGE2	Vaginal misoprostol (<50mcg)				8	42	9	42	NA	NA	NA	NA	NA	NA
Miller 1991	Vaginal PGE2 (gel)	Vaginal PGE2 pessary (slow release)				6	20	4	20	NA	NA	NA	NA	NA	NA
Misra 1994	Intracervical PGE2	IV oxytocin				28	136	42	127	NA	NA	NA	NA	NA	NA
Modarres 2000	No treatment	Breast stimulation				11	50	3	50	NA	NA	NA	NA	NA	NA
Modlock 2010	Placebo	Acupuncture				11	58	11	60	NA	NA	NA	NA	NA	NA
Moini 2003	Intracervical PGE2	Foley catheter + EASI				8	35	2	35	NA	NA	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
Moldin 1996	Amniotomy	IV oxytocin plus amniotomy				1	98	1	98	NA	NA	NA	NA	NA	NA
Mollart 2016	No treatment	Acupuncture				4	22	7	22	NA	NA	NA	NA	NA	NA
Moodley 2003	Vaginal PGE2 (gel)	Vaginal misoprostol (<50mcg)	Titrated (low dose) oral misoprostol solution			80	193	40	100	41	103	NA	NA	NA	NA
Moraes Filho 2010	Vaginal misoprostol (<50mcg)	Foley catheter				32	119	44	121	NA	NA	NA	NA	NA	NA
Movahed 2016	Nitric oxide	Foley catheter	Laminaria			6	25	3	25	7	25	NA	NA	NA	NA
Mundle 2018	Oral misoprostol tablet (<50mcg)	Foley catheter				124	302	151	300	NA	NA	NA	NA	NA	NA
Murphy 1980	Placebo	PGF2 gel				9	100	10	165	NA	NA	NA	NA	NA	NA
Murray 1995	Vaginal PGE2 (tablet)	Vaginal PGE2 (gel)				25	100	24	100	NA	NA	NA	NA	NA	NA
Murthy 2006	Intracervical PGE2	Vaginal misoprostol (<50mcg)				13	35	8	37	NA	NA	NA	NA	NA	NA
Nager 1987	No treatment	Intracervical PGE2				7	15	5	19	NA	NA	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
Naismith 1973	IV oxytocin	IV prostaglandin				1	20	0	20	NA	NA	NA	NA	NA	NA
Nanda 2007	Intracervical PGE2	Vaginal misoprostol (<50mcg)				7	50	8	50	NA	NA	NA	NA	NA	NA
Nassar 2006	Vaginal misoprostol (≥50mcg)	Buccal/sublingual misoprostol				24	85	30	85	NA	NA	NA	NA	NA	NA
Nayak 2015	Vaginal PGE2 (tablet)	Intracervical PGE2				24	64	11	64	NA	NA	NA	NA	NA	NA
Neiger 2001	Intracervical PGE2	Vaginal misoprostol (≥50mcg)				4	29	7	32	NA	NA	NA	NA	NA	NA
Neilson 1983	Vaginal PGE2 (gel)	PGF2 gel				9	38	9	38	NA	NA	NA	NA	NA	NA
Newman 1997	No treatment	Vaginal PGE2 (gel)				9	30	8	28	NA	NA	NA	NA	NA	NA
Nicoll 2001	No treatment	Nitric oxide				4	12	8	24	NA	NA	NA	NA	NA	NA
Nigam 2004	Oral misoprostol tablet (≥50mcg)	IV oxytocin				3	36	2	34	NA	NA	NA	NA	NA	NA
Nigam 2010	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)				10	60	17	60	NA	NA	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
Nimrod 1984	Placebo	Intracervical PGE2				0	15	4	30	NA	NA	NA	NA	NA	NA
Niromanesh 2003	Vaginal PGE2 (tablet)	Foley catheter				12	44	11	45	NA	NA	NA	NA	NA	NA
Noah 1987	No treatment	Intracervical PGE2				84	403	67	413	NA	NA	NA	NA	NA	NA
Nongkhlaw 2015	Intracervical PGE2	Vaginal misoprostol (<50mcg)				6	135	5	135	NA	NA	NA	NA	NA	NA
Noor 2015	Vaginal misoprostol (<50mcg)	Foley catheter				14	60	19	44	NA	NA	NA	NA	NA	NA
Nopdonratkoon 2003	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)				7	53	3	53	NA	NA	NA	NA	NA	NA
Nunes 1999	Vaginal PGE2 (gel)	Vaginal misoprostol (≥50mcg)				12	94	13	95	NA	NA	NA	NA	NA	NA
Nuutila 1995	Placebo	Intracervical PGE2				10	21	4	24	NA	NA	NA	NA	NA	NA
Nuutila 1996	Vaginal PGE2 (gel)	Intracervical PGE2				17	71	6	39	NA	NA	NA	NA	NA	NA
Oboro 2005	No treatment	Vaginal misoprostol (<50mcg)				7	39	3	38	NA	NA	NA	NA	NA	NA
O'Brien 1995	Placebo	Vaginal PGE2 (gel)				10	50	7	50	NA	NA	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
Ohel 1996	No treatment	Vaginal PGE2 (tablet)				6	104	4	70	NA	NA	NA	NA	NA	NA
Omar 2013	No treatment	Sexual intercourse				116	576	101	574	NA	NA	NA	NA	NA	NA
Ophir 1992	Vaginal PGE2 (tablet)	Foley catheter				5	27	4	27	NA	NA	NA	NA	NA	NA
Orhue 1995	Vaginal PGE2 pessary (normal release)	IV oxytocin plus amniotomy	Foley catheter			6	34	7	30	3	30	NA	NA	NA	NA
Osman 2006	Vaginal PGE2 (gel)	Nitric oxide				61	198	65	197	NA	NA	NA	NA	NA	NA
Ottinger 1998	Vaginal PGE2 pessary (slow release)	Intracervical PGE2				13	45	11	45	NA	NA	NA	NA	NA	NA
Owen 1991	Placebo	Intracervical PGE2				16	53	13	47	NA	NA	NA	NA	NA	NA
Owolabi 2005	Vaginal misoprostol (≥ 50 mcg)	Foley catheter				11	60	17	60	NA	NA	NA	NA	NA	NA
Ozkan 2009	Vaginal PGE2 pessary	Vaginal misoprostol (≥ 50 mcg)				18	56	14	56	NA	NA	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
	(slow release)														
Paisarntaniwong 2005	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)				18	73	23	73	NA	NA	NA	NA	NA	NA
Pandis 2001	Vaginal PGE2 (gel)	Vaginal misoprostol (≥50mcg)				43	225	38	210	NA	NA	NA	NA	NA	NA
Papageorgiou 1992	Intracervical PGE2	IV oxytocin				6	83	7	82	NA	NA	NA	NA	NA	NA
Papanikolaou 2004	Vaginal PGE2 (tablet)	Vaginal misoprostol (≥50mcg)				11	83	6	80	NA	NA	NA	NA	NA	NA
Parazzini 1998	Vaginal PGE2 (gel)	IV oxytocin plus amniotomy				28	157	22	163	NA	NA	NA	NA	NA	NA
Parewijck 1986	Intracervical PGE2	Extra-amniotic prostaglandin				2	95	1	101	NA	NA	NA	NA	NA	NA
Parikh 2001	Intracervical PGE2	IV oxytocin				1	15	2	15	NA	NA	NA	NA	NA	NA
Parlakgumus 2014	No treatment	Membrane sweeping				14	71	12	69	NA	NA	NA	NA	NA	NA
Parimkayala 2019	Oral misoprostol tablet (≥50mcg)	Buccal/sublingual misoprostol				20	60	16	60	NA	NA	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
Patel 2016	Vaginal misoprostol (<50mcg)	Buccal/sublingual misoprostol				18	50	14	50	NA	NA	NA	NA	NA	NA
Patil 2005	Intracervical PGE2	Oral misoprostol tablet (≥50mcg)				19	95	17	95	NA	NA	NA	NA	NA	NA
Paungmora 2004	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)				28	76	33	75	NA	NA	NA	NA	NA	NA
Peccerillo 1995	Vaginal PGE2 (gel)	Intracervical PGE2				8	36	6	31	NA	NA	NA	NA	NA	NA
Pennell 2009	Vaginal PGE2 (gel)	Foley catheter	Double balloon/Cook's catheter			42	113	40	110	46	107	NA	NA	NA	NA
Pereira Alves Filho 2019	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)				3	21	4	16	NA	NA	NA	NA	NA	NA
Perry 2004	Vaginal PGE2 pessary (slow release)	Intracervical PGE2				7	30	9	33	NA	NA	NA	NA	NA	NA
Perryman 1992	Vaginal PGE2 (gel)	Vaginal PGE2 pessary				11	45	15	45	NA	NA	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
		(normal release)													
Pinto 1967	Placebo	Oestrogens				5	50	6	50	NA	NA	NA	NA	NA	NA
Pollnow 1996	Intracervical PGE2	IV oxytocin				7	100	4	100	NA	NA	NA	NA	NA	NA
Pongsathana 2005	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)				7	84	8	82	NA	NA	NA	NA	NA	NA
PonMalar 2017	Placebo	Vaginal misoprostol (<50mcg)				18	63	8	63	NA	NA	NA	NA	NA	NA
Poulsen 1991	Intracervical PGE2	Vaginal PGE2 pessary (normal release)				21	116	22	110	NA	NA	NA	NA	NA	NA
Prager 2008	Vaginal PGE2 (gel)	Vaginal misoprostol (<50mcg)	Foley catheter			50	191	56	199	45	198	NA	NA	NA	NA
Prasad 1989	Placebo	Vaginal PGE2 pessary (slow release)				11	36	8	33	NA	NA	NA	NA	NA	NA
Prins 1983	Placebo	Vaginal PGE2 (gel)				7	15	4	15	NA	NA	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
Pulle 1986	Intracervical PGE2	IV oxytocin				3	25	3	25	NA	NA	NA	NA	NA	NA
Putnam 2011	No treatment	Membrane sweeping				33	116	58	234	NA	NA	NA	NA	NA	NA
Qazi 2019	Vaginal PGE2 (gel)	Vaginal misoprostol ($\geq 50\text{mcg}$)				7	58	14	58	NA	NA	NA	NA	NA	NA
Quinn 1981	Foley catheter + EASI ^^	Extra-amniotic prostaglandin				2	10	1	15	NA	NA	NA	NA	NA	NA
Rabl 2001	No treatment	Acupuncture				2	20	2	25	NA	NA	NA	NA	NA	NA
Rabl 2002	Vaginal PGE2 (tablet)	Vaginal PGE2 pessary (slow release)				27	100	30	100	NA	NA	NA	NA	NA	NA
Rahman 2013	Vaginal misoprostol ($< 50\text{mcg}$)	Oral misoprostol tablet ($\geq 50\text{mcg}$)				32	110	34	110	NA	NA	NA	NA	NA	NA
Rameez 2007	Placebo	Nitric oxide				12	78	11	78	NA	NA	NA	NA	NA	NA
Ramsey 2003	Vaginal PGE2 pessary (slow release)	Intracervical PGE2	Vaginal misoprostol ($\geq 50\text{mcg}$)			4	38	5	35	5	38	NA	NA	NA	NA

DRAFT FOR CONSULTATION

Evidence tables for pharmacological and mechanical methods for induction of labour

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
Ratnam 1974	IV oxytocin	IV oxytocin plus amniotomy	Oral prostaglandins			2	50	3	50	6	54	NA	NA	NA	NA
Rayburn 1988	Placebo	Vaginal PGE2 (gel)				21	63	10	55	NA	NA	NA	NA	NA	NA
Razaq 2011	Vaginal misoprostol (≥50mcg)	Nitric oxide				39	75	45	75	NA	NA	NA	NA	NA	NA
Reinhard 2014	Vaginal PGE2 (tablet)	Intracervical PGE2				8	19	5	20	NA	NA	NA	NA	NA	NA
Rezaie 2016	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)				15	60	15	120	NA	NA	NA	NA	NA	NA
Richardson 1991	Placebo	Intracervical PGE2				5	27	6	21	NA	NA	NA	NA	NA	NA
Rix 1996	Vaginal PGE2 (tablet)	Intracervical PGE2				18	98	16	110	NA	NA	NA	NA	NA	NA
Roach 1997	No treatment	Vaginal PGE2 pessary (normal release)				18	105	16	96	NA	NA	NA	NA	NA	NA
Roberts 1986	No treatment	Vaginal PGE2 (gel)	IV oxytocin	Laminaria		8	24	3	27	6	25	5	28	NA	NA

DRAFT FOR CONSULTATION

Evidence tables for pharmacological and mechanical methods for induction of labour

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
Rouben 1993	Vaginal PGE2 (gel)	Foley catheter + EASI				26	56	26	56	NA	NA	NA	NA	NA	NA
Rouzi 2014	Vaginal PGE2 pessary (slow release)	Titrated (low dose) oral misoprostol solution				18	80	9	80	NA	NA	NA	NA	NA	NA
Rouzi 2017	Oral misoprostol tablet (<50mcg)	Titrated (low dose) oral misoprostol solution				6	73	17	73	NA	NA	NA	NA	NA	NA
Rowlands 2001	Vaginal PGE2 pessary (normal release)	Vaginal misoprostol (≥50mcg)				16	63	13	62	NA	NA	NA	NA	NA	NA
Roy 2015	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)	Buccal/sublingual misoprostol			82	400	38	400	79	400	NA	NA	NA	NA
Rozenberg 2001	Vaginal PGE2 (gel)	Vaginal misoprostol (≥50mcg)				30	185	33	184	NA	NA	NA	NA	NA	NA
Rozenberg 2004	Vaginal PGE2 pessary (slow release)	Vaginal misoprostol (≥50mcg)				16	70	13	70	NA	NA	NA	NA	NA	NA

DRAFT FOR CONSULTATION

Evidence tables for pharmacological and mechanical methods for induction of labour

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
Roztocil 1998	Vaginal PGE2 (gel)	Oestrogens	Laminaria			20	83	9	82	20	82	NA	NA	NA	NA
Russell 2007	Vaginal misoprostol (<50mcg)	Buccal/sublingual misoprostol				104	364	111	374	NA	NA	NA	NA	NA	NA
Saad 2019	Foley catheter	Laminaria				50	209	39	208	NA	NA	NA	NA	NA	NA
Sadi 2016	Placebo	Herbal supplements				3	25	0	25	NA	NA	NA	NA	NA	NA
Saggaf 2001	Vaginal PGE2 (gel)	Vaginal misoprostol (≥50mcg)				5	27	1	30	NA	NA	NA	NA	NA	NA
Sahu 2004	Intracervical PGE2	Vaginal misoprostol (≥50mcg)				5	25	2	25	NA	NA	NA	NA	NA	NA
Salamalekis 2000	No treatment	IV oxytocin	Membrane sweeping			1	35	3	35	2	34	NA	NA	NA	NA
Saleem 2006	Vaginal PGE2 pessary (normal release)	Vaginal misoprostol (≥50mcg)	Foley catheter			11	75	9	73	11	78	NA	NA	NA	NA
Saleh 1975	Amniotomy	IV oxytocin plus amniotomy				4	50	1	50	NA	NA	NA	NA	NA	NA
Salim 2011	Foley catheter	Double balloon/Co				15	145	26	148	NA	NA	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
		ok's catheter													
Sanchez-Ramos 1992	Vaginal PGE2 (gel)	Laminaria				8	38	7	36	NA	NA	NA	NA	NA	NA
Sanchez-Ramos 1998	Vaginal PGE2 pessary (slow release)	Vaginal misoprostol ($\geq 50\text{mcg}$)				15	115	24	108	NA	NA	NA	NA	NA	NA
Savithri 2018	Intracervical PGE2	Oral misoprostol tablet ($< 50\text{mcg}$)				12	50	13	50	NA	NA	NA	NA	NA	NA
Sawai 1991	Placebo	Vaginal PGE2 (gel)				4	26	6	24	NA	NA	NA	NA	NA	NA
Sawai 1994	Placebo	Vaginal PGE2 pessary (normal release)				6	42	1	38	NA	NA	NA	NA	NA	NA
Saxena 2011	Intracervical PGE2	Vaginal misoprostol ($< 50\text{mcg}$)	Vaginal misoprostol ($\geq 50\text{mcg}$)			22	70	21	70	21	70	NA	NA	NA	NA
Sayed 2016	Foley catheter	Double balloon/Cook's catheter				11	37	8	37	NA	NA	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
Schmitz 2014	Placebo	Nitric oxide				186	684	185	678	NA	NA	NA	NA	NA	NA
Schneider 2004	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)				41	134	59	162	NA	NA	NA	NA	NA	NA
Sciscione 1999	Intracervical PGE2	Foley catheter				21	72	21	77	NA	NA	NA	NA	NA	NA
Secher 1981	IV oxytocin	Oral prostaglandins				4	119	10	125	NA	NA	NA	NA	NA	NA
Seeras 1995	Vaginal PGE2 (gel)	Intracervical PGE2				3	31	5	37	NA	NA	NA	NA	NA	NA
Selo-Ojeme 2009	Amniotomy	IV oxytocin plus amniotomy				17	62	12	61	NA	NA	NA	NA	NA	NA
Shaheen 2013	Vaginal PGE2 (gel)	Buccal/sublingual misoprostol				11	53	10	53	NA	NA	NA	NA	NA	NA
Shakya 2010	Intracervical PGE2	Vaginal misoprostol (≥50mcg)				10	31	10	35	NA	NA	NA	NA	NA	NA
Sharami 2014	Vaginal misoprostol (≥50mcg)	Buccal/sublingual misoprostol				18	63	10	63	NA	NA	NA	NA	NA	NA
Sharma 2005	Intracervical PGE2	Vaginal misoprostol (≥50mcg)	Nitric oxide			11	21	11	23	9	21	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
Shechter-Maor 2015	Vaginal PGE2 pessary (slow release)	Double balloon/Coak's catheter				4	26	2	26	NA	NA	NA	NA	NA	NA
Sheela 2007	Intracervical PGE2	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)			7	50	7	50	5	50	NA	NA	NA	NA
Sheela 2015	Vaginal misoprostol (<50mcg)	Buccal/sublingual misoprostol				8	100	6	100	NA	NA	NA	NA	NA	NA
Sheikher 2009	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)	Foley catheter			4	30	8	30	8	30	NA	NA	NA	NA
Shepherd 1976	Placebo	Extra-amniotic prostaglandin				1	15	1	15	NA	NA	NA	NA	NA	NA
Sherman 2001	Foley catheter + EASI ^^	Extra-amniotic prostaglandin				10	58	6	58	NA	NA	NA	NA	NA	NA
Shetty 2001	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)				28	123	30	122	NA	NA	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
Shetty 2002a	Oral misoprostol tablet (≥50mcg)	Buccal/sublingual misoprostol				15	50	8	50	NA	NA	NA	NA	NA	NA
Shetty 2002b	Oral misoprostol tablet (≥50mcg)	Buccal/sublingual misoprostol				32	124	31	125	NA	NA	NA	NA	NA	NA
Shetty 2003	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)				14	50	13	51	NA	NA	NA	NA	NA	NA
Shetty 2004	Vaginal PGE2 (tablet)	Oral misoprostol tablet (≥50mcg)				27	100	25	100	NA	NA	NA	NA	NA	NA
Sifakis 2007	Vaginal PGE2 (tablet)	Vaginal misoprostol (≥50mcg)				55	211	51	204	NA	NA	NA	NA	NA	NA
Silva-Cruz 1988	Vaginal PGE2 (gel)	IV oxytocin				5	25	7	25	NA	NA	NA	NA	NA	NA
Singh 2014	No treatment	Breast stimulation				20	99	8	100	NA	NA	NA	NA	NA	NA
Smith 1990	Vaginal PGE2 (gel)	Vaginal PGE2 pessary (normal release)				4	34	5	35	NA	NA	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
Smith 1994	Vaginal PGE2 (gel)	Vaginal PGE2 pessary (slow release)				4	55	3	66	NA	NA	NA	NA	NA	NA
Smith 2008	Placebo	Acupuncture				42	180	34	180	NA	NA	NA	NA	NA	NA
Soliman 2013	Vaginal misoprostol (≥ 50 mcg)	Nitric oxide				19	65	22	65	NA	NA	NA	NA	NA	NA
Solis Ruiz 2015	Vaginal PGE2 pessary (slow release)	Vaginal misoprostol (< 50 mcg)				24	49	7	42	NA	NA	NA	NA	NA	NA
Solt 2019	Foley catheter	Double balloon or Cook's catheter				26	91	11	85	NA	NA	NA	NA	NA	NA
Somirathne 2017	Oral misoprostol tablet (≥ 50 mcg)	Foley catheter				11	32	14	47	NA	NA	NA	NA	NA	NA
Souzi 2018	Vaginal misoprostol (< 50 mcg)	Nitric oxide	Laminaria			7	32	0	32	5	32	NA	NA	NA	NA
Souza 2013	Vaginal misoprostol (< 50 mcg)	Titrated (low dose) oral				37	100	41	100	NA	NA	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
		misoprostol solution													
Spallicci 2007	Placebo	Hyaluronidase				42	85	15	83	NA	NA	NA	NA	NA	NA
Spellacy 1973	IV oxytocin	IV prostaglandin				0	107	9	115	NA	NA	NA	NA	NA	NA
Srisomboon 1996	Placebo	Vaginal misoprostol ($\geq 50\text{mcg}$)				8	30	6	32	NA	NA	NA	NA	NA	NA
St Onge 1995	Intracervical PGE2	Foley catheter				7	28	6	34	NA	NA	NA	NA	NA	NA
Stampe Sorensen 1992	Vaginal PGE2 (tablet)	Vaginal PGE2 pessary (normal release)				17	135	15	132	NA	NA	NA	NA	NA	NA
Stempel 1997	Vaginal PGE2 (gel)	Intracervical PGE2				7	44	7	39	NA	NA	NA	NA	NA	NA
Stenlund 1999	Placebo	Mifepristone				3	12	4	24	NA	NA	NA	NA	NA	NA
Stewart 1983	Vaginal PGE2 (tablet)	Extra-amniotic prostaglandin				5	30	5	32	NA	NA	NA	NA	NA	NA
Stitely 2000	Placebo	Vaginal misoprostol ($< 50\text{mcg}$)				8	33	4	27	NA	NA	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
Strobelt 2006	Vaginal PGE2 pessary (slow release)	Intracervical PGE2				12	56	11	51	NA	NA	NA	NA	NA	NA
Suffecool 2014	Vaginal PGE2 pessary (slow release)	Double balloon/Cook's catheter				16	31	17	31	NA	NA	NA	NA	NA	NA
Sultana 2006	Vaginal misoprostol (≥ 50 mcg)	Oral misoprostol tablet (≥ 50 mcg)				17	50	15	50	NA	NA	NA	NA	NA	NA
Surita 2005	Hyaluronidase	Foley catheter				40	70	28	70	NA	NA	NA	NA	NA	NA
Suvobrata 2011	IV oxytocin	Buccal/sublingual misoprostol				12	50	10	45	NA	NA	NA	NA	NA	NA
Suzuki 2000	No treatment	Oral prostaglandins				6	19	3	17	NA	NA	NA	NA	NA	NA
Tabasi 2007	Vaginal misoprostol (≥ 50 mcg)	IV oxytocin				15	55	25	55	NA	NA	NA	NA	NA	NA
Tabor 1995	Intracervical PGE2	Vaginal misoprostol (≥ 50 mcg)				15	59	17	68	NA	NA	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
Tabowei 2003	Vaginal misoprostol (<50mcg)	Foley catheter				8	60	10	61	NA	NA	NA	NA	NA	NA
Taechakraichana 1996	Intracervical PGE2	Vaginal PGE2 pessary (normal release)				5	9	1	10	NA	NA	NA	NA	NA	NA
Taher 2011	Vaginal PGE2 (tablet)	Vaginal PGE2 (gel)				28	83	29	82	NA	NA	NA	NA	NA	NA
Tan 2007	No treatment	Sexual intercourse				21	102	27	108	NA	NA	NA	NA	NA	NA
Tan 2010	Vaginal PGE2 pessary (normal release)	Vaginal misoprostol (<50mcg)				10	57	23	112	NA	NA	NA	NA	NA	NA
Tan 2013	Amniotomy	IV oxytocin plus amniotomy				7	101	9	105	NA	NA	NA	NA	NA	NA
Tandon 2014	Intracervical PGE2	Vaginal misoprostol (≥50mcg)				8	50	6	50	NA	NA	NA	NA	NA	NA
Tannirandorn 1999	No treatment	Membrane sweeping				7	39	6	41	NA	NA	NA	NA	NA	NA
Ten Eikelder 2016	Oral misoprostol	Foley catheter				155	924	185	921	NA	NA	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
	tablet (≥50mcg)														
Tessier 1997	Vaginal PGE2 (gel)	Oral misoprostol tablet (≥50mcg)				29	132	34	135	NA	NA	NA	NA	NA	NA
Tey 1995	No treatment	Intracervical PGE2				8	19	6	21	NA	NA	NA	NA	NA	NA
Thaisomboon 2012	Oral misoprostol tablet (≥50mcg)	Titrated (low dose) oral misoprostol solution				13	32	17	32	NA	NA	NA	NA	NA	NA
Thakur 2005	Placebo	Mifepristone				13	25	10	25	NA	NA	NA	NA	NA	NA
Thavarasah 1990	Vaginal PGE2 (tablet)	Intracervical PGE2				15	112	9	88	NA	NA	NA	NA	NA	NA
Thiery 1984	Placebo	Vaginal PGE2 (tablet)	Intracervical PGE2			0	40	0	41	1	40	NA	NA	NA	NA
Thomas 1986	PGF2 gel	Foley catheter				7	25	7	32	NA	NA	NA	NA	NA	NA
Tomlinson 2001	Vaginal PGE2 (gel)	Vaginal PGE2 pessary (slow release)				6	34	4	35	NA	NA	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
Toppozada 1997	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)				2	20	4	20	NA	NA	NA	NA	NA	NA
Torkzaharani 2017	No treatment	Placebo	Acupuncture			24	50	26	50	22	50	NA	NA	NA	NA
Triglia 2010	Vaginal PGE2 (gel)	Vaginal PGE2 pessary (slow release)				20	65	16	65	NA	NA	NA	NA	NA	NA
Trofatter 1985	Placebo	Intracervical PGE2				9	29	8	30	NA	NA	NA	NA	NA	NA
Trofatter 1993	No treatment	Intracervical PGE2				26	236	26	252	NA	NA	NA	NA	NA	NA
Tromans 1981	Vaginal PGE2 (gel)	Oestrogens				7	30	8	30	NA	NA	NA	NA	NA	NA
Troostwijk 1992	Placebo	Intracervical PGE2				7	68	6	71	NA	NA	NA	NA	NA	NA
Tulek 2018	IV oxytocin	Double balloon or Cook's catheter				11	40	8	40	NA	NA	NA	NA	NA	NA
Ugwu 2013	Vaginal misoprostol (<50mcg)	Foley catheter				5	45	12	45	NA	NA	NA	NA	NA	NA
Ugwu 2014	No treatment	Membrane sweeping				11	61	11	62	NA	NA	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
Ulmsten 1979	Intracervical PGE2	IV oxytocin				1	50	0	50	NA	NA	NA	NA	NA	NA
Ulmsten 1982	Placebo	Intracervical PGE2				0	25	0	25	NA	NA	NA	NA	NA	NA
Ulmsten 1985	Placebo	Intracervical PGE2	Vaginal PGE2 pessary (normal release)			6	20	3	19	7	19	NA	NA	NA	NA
Uludag 2005	Vaginal misoprostol (≥ 50 mcg)	Oral misoprostol tablet (≥ 50 mcg)				12	48	6	51	NA	NA	NA	NA	NA	NA
Vahid Roudsari 2011	Vaginal misoprostol (< 50 mcg)	Foley catheter				5	49	22	59	NA	NA	NA	NA	NA	NA
Vakhariya 1972	IV oxytocin	IV prostaglandin				1	75	1	75	NA	NA	NA	NA	NA	NA
Valadan 2005	Vaginal PGE2 (tablet)	IV oxytocin				14	46	16	45	NA	NA	NA	NA	NA	NA
Valentine 1977	No treatment	IV oxytocin	Oral prostaglandins			7	15	4	15	7	30	NA	NA	NA	NA
van Gemund 2004	Vaginal PGE2 (gel)	Vaginal misoprostol (< 50 mcg)				70	340	53	341	NA	NA	NA	NA	NA	NA

DRAFT FOR CONSULTATION

Evidence tables for pharmacological and mechanical methods for induction of labour

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
Varaklis 1995	Intracervical PGE2	Vaginal misoprostol (<50mcg)				3	33	8	36	NA	NA	NA	NA	NA	NA
Vayssiere 2018	Vaginal PGE2 pessary (slow release)	Vaginal misoprostol (<50mcg)				166	838	184	836	NA	NA	NA	NA	NA	NA
Veena 2016	Intracervical PGE2	Buccal/sublingual misoprostol				31	95	15	95	NA	NA	NA	NA	NA	NA
Wang 2016	Vaginal PGE2 pessary (normal release)	Titrated (low dose) oral misoprostol solution				36	199	30	212	NA	NA	NA	NA	NA	NA
Wallstrom 2019	Titrated (low dose) oral misoprostol solution	Sustained release misoprostol insert				14	99	19	97	NA	NA	NA	NA	NA	NA
Weiss 2016	Placebo	Relaxin				5	32	9	29	NA	NA	NA	NA	NA	NA
Wieland 1999	Vaginal PGE2 pessary (slow release)	Intracervical PGE2				11	31	9	35	NA	NA	NA	NA	NA	NA
Wielgos 2007	Vaginal PGE2	Intracervical PGE2				24	66	22	62	NA	NA	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
	pessary (slow release)														
Wilson 1978	Vaginal PGE2 (tablet)	IV oxytocin	Extra-amniotic prostaglandins	Oral prostaglandins		3	15	5	15	1	15	4	15	NA	NA
Wing 1995a	Intracervical PGE2	Vaginal misoprostol (≥50mcg)				13	67	10	68	NA	NA	NA	NA	NA	NA
Wing 1995b	Intracervical PGE2	Vaginal misoprostol (<50mcg)				38	137	28	138	NA	NA	NA	NA	NA	NA
Wing 1997	Vaginal PGE2 pessary (slow release)	Vaginal misoprostol (<50mcg)				20	98	18	99	NA	NA	NA	NA	NA	NA
Wing 1999	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)				25	110	15	110	NA	NA	NA	NA	NA	NA
Wing 2000a	Placebo	Mifepristone				18	83	9	97	NA	NA	NA	NA	NA	NA
Wing 2000b	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)				25	113	15	121	NA	NA	NA	NA	NA	NA

DRAFT FOR CONSULTATION

Evidence tables for pharmacological and mechanical methods for induction of labour

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
Wing 2004	Oral misoprostol tablet (≥50mcg)	IV oxytocin				9	110	8	88	NA	NA	NA	NA	NA	NA
Wing 2008	Vaginal PGE2 pessary (slow release)	Sustained release misoprostol insert				115	436	243	871	NA	NA	NA	NA	NA	NA
Wing 2013	Vaginal PGE2 pessary (slow release)	Sustained release misoprostol insert				184	680	176	678	NA	NA	NA	NA	NA	NA
Wingerup 1978	Placebo	Intracervical PGE2				3	10	0	10	NA	NA	NA	NA	NA	NA
Wiriyasirivaj 1996	No treatment	Membrane sweeping				3	59	6	61	NA	NA	NA	NA	NA	NA
Witter 1987	No treatment	IV oxytocin				27	97	30	103	NA	NA	NA	NA	NA	NA
Witter 1992	Placebo	Vaginal PGE2 pessary (slow release)				13	33	9	39	NA	NA	NA	NA	NA	NA
Wong 2002	No treatment	Membrane sweeping				10	60	8	60	NA	NA	NA	NA	NA	NA
Yazdizadeh 2013	Placebo	Nitric oxide				10	39	10	41	NA	NA	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
Yelikar 2015	Placebo	Mifepristone				8	50	6	50	NA	NA	NA	NA	NA	NA
Yenuberi 2016	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)				81	380	95	383	NA	NA	NA	NA	NA	NA
Yildirim 2010	No treatment	Membrane sweeping				32	167	38	179	NA	NA	NA	NA	NA	NA
Young 2020	Vaginal PGE2 (gel)	Vaginal misoprostol (< 50mcg)	Oral misoprostol tablet (≥50mcg)			47	172	54	172	55	167	NA	NA	NA	NA
Yuen 1996	Intracervical PGE2	Vaginal PGE2 pessary (normal release)	Double balloon/Cook's catheter			6	39	5	39	10	36	NA	NA	NA	NA
Zahran 2009	Vaginal misoprostol (≥50mcg)	Buccal/sublingual misoprostol				80	240	71	240	NA	NA	NA	NA	NA	NA
Zanconato 2011	Vaginal PGE2 (gel)	Vaginal PGE2 pessary (slow release)				10	26	9	26	NA	NA	NA	NA	NA	NA
Zanini 1990	Vaginal PGE2 (gel)	Intracervical PGE2				5	48	9	52	NA	NA	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 5 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total	Arm 5 event	Arm 5 total
Zeteroglu 2004	Vaginal misoprostol (≥50mcg)	IV oxytocin				6	52	11	52	NA	NA	NA	NA	NA	NA
Zeteroglu 2006a	Vaginal misoprostol (≥50mcg)	IV oxytocin				5	32	4	32	NA	NA	NA	NA	NA	NA
Zeteroglu 2006b	Vaginal misoprostol (≥50mcg)	IV oxytocin				8	50	10	50	NA	NA	NA	NA	NA	NA
Zhang 2015	Placebo	Vaginal misoprostol (<50mcg)				24	49	68	173	NA	NA	NA	NA	NA	NA
Ziaei 2003	No treatment	Corticosteroids				5	33	1	32	NA	NA	NA	NA	NA	NA
Zvandasara 2008	Vaginal misoprostol (≥50mcg)	Titrated (low dose) oral misoprostol solution				3	65	5	69	NA	NA	NA	NA	NA	NA

1 Caesarean birth

2 NA: not available; EASI: extra amniotic saline infusion

3 ^^ used Foley in both intervention groups

4

5

6

1 D6 - Perinatal mortality

2 **Table 6: Evidence table for perinatal mortality**

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 events	Arm 1 total	Arm 2 events	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Aalami-Harandi 2013	Titrated (low dose) oral misoprostol solution	IV oxytocin			0	128	0	128	NA	NA	NA	NA
Abdul 2007	Vaginal misoprostol (≥50mcg)	IV oxytocin			3	34	2	28	NA	NA	NA	NA
Adair 1998	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)			0	85	0	93	NA	NA	NA	NA
Adeniji 2005	Vaginal misoprostol (≥50mcg)	Foley catheter			0	50	0	46	NA	NA	NA	NA
Aduloju 2019	Oral misoprostol tablet (< 50 mcg)	Titrated (low dose) oral misoprostol solution			0	75	0	75	NA	NA	NA	NA
Al-Taani 2004	Vaginal PGE2 (tablet)	Foley catheter			0	75	0	72	NA	NA	NA	NA
Ayaz 2010	Vaginal PGE2 (tablet)	Vaginal misoprostol (≥50mcg)			1	60	0	60	NA	NA	NA	NA
Azubuike 2015	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)			0	40	1	43	NA	NA	NA	NA
Bagratee 1990	Vaginal PGE2 (tablet)	Laminaria			0	40	0	40	NA	NA	NA	NA
Bakos 1987	IV oxytocin	Amniotomy			0	113	0	110	NA	NA	NA	NA
Balci 2010	Vaginal misoprostol (≥50mcg)	IV oxytocin			0	50	0	50	NA	NA	NA	NA
Barkai 1994	No treatment	Placebo	Intracervical PGE2		0	175	0	91	0	174	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 events	Arm 1 total	Arm 2 events	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Bartha 2000	Intracervical PGE2	Oral misoprostol tablet (≥50mcg)			0	100	0	100	NA	NA	NA	NA
Bell 1993	Placebo	Relaxin			0	22	0	18	NA	NA	NA	NA
Bollapragada 2009	Placebo	Nitric oxide			1	173	0	177	NA	NA	NA	NA
Brennand 1997	Placebo	Relaxin			0	23	0	73	NA	NA	NA	NA
Buser 1997	Intracervical PGE2	Vaginal misoprostol (≥50mcg)			0	79	2	76	NA	NA	NA	NA
Chanrachakul 2003	No treatment	IV oxytocin plus amniotomy			0	125	0	124	NA	NA	NA	NA
Chua 1997	Intracervical PGE2	Laminaria			0	95	1	90	NA	NA	NA	NA
Cromi 2011	Vaginal PGE2 pessary (slow release)	Foley catheter			0	132	0	265	NA	NA	NA	NA
Damania 1992	No treatment	IV oxytocin	Breast stimulation		0	20	1	20	3	17	NA	NA
De Miranda 2006	No treatment	Membrane sweeping			2	367	2	375	NA	NA	NA	NA
Deshmukh 2011	Intracervical PGE2	Foley catheter			9	200	7	200	NA	NA	NA	NA
Deshmukh 2013	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)			1	100	0	100	NA	NA	NA	NA
Dodd 2006	Vaginal PGE2 (gel)	Titrated (low dose) oral misoprostol solution			0	376	0	365	NA	NA	NA	NA
Dogra 2019	No treatment	IV oxytocin			0	25	0	25	NA	NA	NA	NA
Domisse 1980	Placebo	Vaginal PGE2 (tablet)			0	28	0	28	NA	NA	NA	NA
El-Torkey 1992	No treatment	Membrane sweeping			0	32	0	33	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 events	Arm 1 total	Arm 2 events	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Ezechukwu 2015	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)			0	70	0	70	NA	NA	NA	NA
Frass 2011	No treatment	Vaginal misoprostol (≥50mcg)			0	57	1	56	NA	NA	NA	NA
Gattas 2020	Vaginal misoprostol (<50 mcg)	Buccal/sublingual misoprostol			0	100	0	98	NA	NA	NA	NA
Gelisen 2005	No treatment	Vaginal misoprostol (≥50mcg)	IV oxytocin	Foley catheter	1	300	0	100	0	100	0	100
Gupta 1998	No treatment	Membrane sweeping			0	50	1	50	NA	NA	NA	NA
Herabutya 1993	Vaginal PGE2 (tablet)	Intracervical PGE2			0	26	0	22	NA	NA	NA	NA
Hofmeyr 2001	Vaginal PGE2 (gel)	Titrated (low dose) oral misoprostol solution	Foley catheter		1	349	1	345	1	171	NA	NA
Kaminski 1994	PGF2 gel	IV oxytocin			0	150	0	150	NA	NA	NA	NA
Katz 1983	No treatment	IV oxytocin plus amniotomy			1	78	1	78	NA	NA	NA	NA
Kennedy 1982	Vaginal PGE2 (tablet)	IV oxytocin plus amniotomy			0	50	0	50	NA	NA	NA	NA
Khoury 2001	Vaginal PGE2 pessary (slow release)	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)		0	39	0	39	0	40	NA	NA
Kipikasa 2005	Oral misoprostol tablet (<50mcg)	Oral misoprostol tablet (≥50mcg)			0	23	0	29	NA	NA	NA	NA
Komala 2013	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)			0	100	0	100	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 events	Arm 1 total	Arm 2 events	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Lange 1984	Vaginal PGE2 pessary (normal release)	IV oxytocin			0	80	0	90	NA	NA	NA	NA
Langenegger 2005	Intracervical PGE2	Oral misoprostol tablet (≥ 50 mcg)			0	95	0	96	NA	NA	NA	NA
Liggins 1979	Placebo	Vaginal PGE2 pessary (normal release)			0	32	1	52	NA	NA	NA	NA
Lyndrup 1991	Intracervical PGE2	Vaginal PGE2 pessary (normal release)			0	64	1	61	NA	NA	NA	NA
MacLennan 1980b	Placebo	PGF2 gel			0	30	0	60	NA	NA	NA	NA
MacLennan 1989	Vaginal PGE2 (gel)	IV oxytocin plus amniotomy			0	165	0	155	NA	NA	NA	NA
Madaan 2014	Intracervical PGE2	Vaginal misoprostol (< 50 mcg)			0	50	0	50	NA	NA	NA	NA
Mahacakri 2018	Vaginal misoprostol (< 50 mcg)	Titrated (low dose) oral misoprostol solution			1	15	0	14	NA	NA	NA	NA
Majoko 2002a	Vaginal misoprostol (≥ 50 mcg)	Extra-amniotic prostaglandin			1	76	1	76	NA	NA	NA	NA
Majoko 2002b	Vaginal PGE2 pessary (normal release)	Vaginal misoprostol (≥ 50 mcg)	Titrated (low dose) oral misoprostol solution	Extra-amniotic prostaglandins	1	75	2	128	1	127	1	76
Manandhar 2017	IV oxytocin	Mifepristone			0	34	0	34	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 events	Arm 1 total	Arm 2 events	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Martin 1989	No treatment	Laminaria			0	10	0	12	NA	NA	NA	NA
Mawire 1999	Foley catheter + EASI ^{^^}	Extra-amniotic prostaglandin			3	81	2	81	NA	NA	NA	NA
McColgin 1990a	No treatment	Membrane sweeping			0	90	1	90	NA	NA	NA	NA
Misra 1994	Intracervical PGE2	IV oxytocin			1	136	0	127	NA	NA	NA	NA
Modarres 2000	No treatment	Breast stimulation			0	50	0	50	NA	NA	NA	NA
Mollart 2016	No treatment	Acupuncture			0	22	1	22	NA	NA	NA	NA
Moodley 2003	Vaginal PGE2 (gel)	Vaginal misoprostol (<50mcg)	Titrated (low dose) oral misoprostol solution		1	193	2	100	0	103	NA	NA
Mundle 2018	Oral misoprostol tablet (<50mcg)	Foley catheter			6	302	5	300	NA	NA	NA	NA
Naismith 1973	IV oxytocin	IV prostaglandin			0	20	0	20	NA	NA	NA	NA
Noah 1987	No treatment	Intracervical PGE2			2	403	0	413	NA	NA	NA	NA
Nuutila 1995	Placebo	Intracervical PGE2			0	21	0	24	NA	NA	NA	NA
Nuutila 1996	Vaginal PGE2 (gel)	Intracervical PGE2			0	71	0	39	NA	NA	NA	NA
Oboro 2005	No treatment	Vaginal misoprostol (<50mcg)			1	39	0	38	NA	NA	NA	NA
Omar 2013	No treatment	Sexual intercourse			2	576	1	574	NA	NA	NA	NA
Ophir 1992	Vaginal PGE2 (tablet)	Foley catheter			0	27	0	27	NA	NA	NA	NA
Ozkan 2009	Vaginal PGE2 pessary (slow release)	Vaginal misoprostol (≥50mcg)			0	56	0	56	NA	NA	NA	NA
Papageorgiou 1992	Intracervical PGE2	IV oxytocin			0	83	0	82	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 events	Arm 1 total	Arm 2 events	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Papanikolaou 2004	Vaginal PGE2 (tablet)	Vaginal misoprostol (≥50mcg)			1	83	0	80	NA	NA	NA	NA
Parazzini 1998	Vaginal PGE2 (gel)	IV oxytocin plus amniotomy			0	157	0	163	NA	NA	NA	NA
Patel 2016	Vaginal misoprostol (<50mcg)	Buccal/sublingual misoprostol			0	50	0	50	NA	NA	NA	NA
Prasad 1989	Placebo	Vaginal PGE2 pessary (slow release)			0	36	0	33	NA	NA	NA	NA
Prins 1983	Placebo	Vaginal PGE2 (gel)			0	15	0	15	NA	NA	NA	NA
Quinn 1981	Foley catheter + EASI ^{^^}	Extra-amniotic prostaglandin			0	10	1	15	NA	NA	NA	NA
Rahman 2013	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)			1	110	0	110	NA	NA	NA	NA
Ratnam 1974	IV oxytocin	IV oxytocin plus amniotomy	Oral prostaglandins		1	50	0	50	0	54	NA	NA
Rayburn 1992	Placebo	Vaginal PGE2 pessary (slow release)			0	114	0	101	NA	NA	NA	NA
Rouzi 2014	Vaginal PGE2 pessary (slow release)	Titrated (low dose) oral misoprostol solution			1	80	1	80	NA	NA	NA	NA
Rouzi 2017	Oral misoprostol tablet (<50mcg)	Titrated (low dose) oral misoprostol solution			0	73	0	73	NA	NA	NA	NA
Saleh 1975	Amniotomy	IV oxytocin plus amniotomy			0	50	0	50	NA	NA	NA	NA
Salmon 1986	No treatment	Breast stimulation			0	50	0	50	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 events	Arm 1 total	Arm 2 events	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Schmitz 2014	Placebo	Nitric oxide			0	684	3	678	NA	NA	NA	NA
Seeras 1995	Vaginal PGE2 (gel)	Intracervical PGE2			0	31	0	37	NA	NA	NA	NA
Shaheen 2013	Vaginal PGE2 (gel)	Buccal/sublingual misoprostol			0	53	0	53	NA	NA	NA	NA
Shakya 2010	Intracervical PGE2	Vaginal misoprostol (≥50mcg)			0	31	0	35	NA	NA	NA	NA
Sharma 2005	Intracervical PGE2	Vaginal misoprostol (≥50mcg)	Nitric oxide		0	21	0	23	0	21	NA	NA
Silva-Cruz 1988	Vaginal PGE2 (gel)	IV oxytocin			0	25	0	25	NA	NA	NA	NA
Singh 2014	No treatment	Breast stimulation			1	99	1	100	NA	NA	NA	NA
Smith 2008	Placebo	Acupuncture			0	183	0	181	NA	NA	NA	NA
Somirathne 2017	Oral misoprostol tablet (≥50mcg)	Foley catheter			0	91	1	89	NA	NA	NA	NA
Souza 2013	Vaginal misoprostol (<50mcg)	Titrated (low dose) oral misoprostol solution			0	100	0	100	NA	NA	NA	NA
Spellacy 1973	IV oxytocin	IV prostaglandin			0	107	1	115	NA	NA	NA	NA
Stenlund 1999	Placebo	Mifepristone			0	12	0	24	NA	NA	NA	NA
Sultana 2006	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)			0	50	0	50	NA	NA	NA	NA
Suzuki 2000	No treatment	Oral prostaglandins			0	38	0	34	NA	NA	NA	NA
Tabowei 2003	Vaginal misoprostol (<50mcg)	Foley catheter			0	60	0	61	NA	NA	NA	NA
Ten Eikelder 2016	Oral misoprostol tablet (≥50mcg)	Foley catheter			1	924	3	921	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 events	Arm 1 total	Arm 2 events	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Tessier 1997	Vaginal PGE2 (gel)	Oral misoprostol tablet (≥50mcg)			0	132	0	135	NA	NA	NA	NA
Tromans 1981	Vaginal PGE2 (gel)	Oestrogens			0	30	0	30	NA	NA	NA	NA
Ulmsten 1979	Intracervical PGE2	IV oxytocin			0	50	0	50	NA	NA	NA	NA
Varaklis 1995	Intracervical PGE2	Vaginal misoprostol (<50mcg)			0	33	0	36	NA	NA	NA	NA
Wallstrom 2019	Titrated (low dose) oral misoprostol solution	Sustained release misoprostol insert			0	99	0	97	NA	NA	NA	NA
Wang 2016	Vaginal PGE2 pessary (normal release)	Titrated (low dose) oral misoprostol solution			0	199	0	212	NA	NA	NA	NA
Weiss 2016	Placebo	Relaxin			0	32	0	40	NA	NA	NA	NA
Wing 2008	Vaginal PGE2 pessary (slow release)	Sustained release misoprostol insert			0	436	0	871	NA	NA	NA	NA
Wing 2013	Vaginal PGE2 pessary (slow release)	Sustained release misoprostol insert			0	680	0	678	NA	NA	NA	NA
Wong 2002	No treatment	Membrane sweeping			0	60	0	60	NA	NA	NA	NA
Yelikar 2015	Placebo	Mifepristone			0	50	1	50	NA	NA	NA	NA
Yildirim 2010	No treatment	Membrane sweeping			1	167	0	179	NA	NA	NA	NA
Young 2020	Vaginal PGE2 (gel)	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)		0	172	0	172	0	167	NA	NA
Zeteroglu 2006a	Vaginal misoprostol (≥50mcg)	IV oxytocin			0	NA	0	32	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 events	Arm 1 total	Arm 2 events	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Zeteroglu 2006b	Vaginal misoprostol (≥50mcg)	IV oxytocin			0	50	0	50	NA	NA	NA	NA
Zvandasara 2008	Vaginal misoprostol (≥50mcg)	Titrated (low dose) oral misoprostol solution			0	65	0	69	NA	NA	NA	NA

1 NA: not available; EASI: extra-amniotic saline infusion

2 ^^Foley used in both interventions

3

4

5

6

7 D7 - Maternal morbidity (uterine rupture) and mortality

8 Table 7: Evidence tables for maternal morbidity and mortality

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 1 events	Arm 1 total	Arm 2 events	Arm 2 total	Arm 3 events	Arm 3 total
Aalami-Harandi 2013	Titrated (low dose) oral misoprostol solution	IV oxytocin		0	128	0	128	NA	NA
Abdelaziz 2018	Vaginal PGE2 (tablet)	Vaginal PGE2 pessary (slow release)		0	100	0	100	NA	NA
Abdul 2007	Vaginal misoprostol (≥50mcg)	IV oxytocin		1	34	0	28	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 1 events	Arm 1 total	Arm 2 events	Arm 2 total	Arm 3 events	Arm 3 total
Adeniji 2005	Vaginal misoprostol (≥50mcg)	Foley catheter		0	50	0	46	NA	NA
Aduloju 2016	Vaginal misoprostol (<50mcg)	Foley catheter		0	70	0	70	NA	NA
Aduloju 2019	Oral misoprostol tablet (< 50 mcg)	Titrated (low dose) oral misoprostol solution		0	75	0	75	NA	NA
Akay 2012	Vaginal PGE2 pessary (slow release)	IV oxytocin		0	72	0	72	NA	NA
Al-Taani 2004	Vaginal PGE2 (tablet)	Foley catheter		0	75	0	72	NA	NA
Azubuike 2015	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)		0	40	0	43	NA	NA
Balci 2010	Vaginal misoprostol (≥50mcg)	IV oxytocin		0	50	0	50	NA	NA
Balci 2011	Vaginal misoprostol (≥50mcg)	IV oxytocin		0	50	0	51	NA	NA
Barkai 1994	No treatment	Placebo	Intracervical PGE2	0	175	0	91	0	174
Berkane 2005	Placebo	Mifepristone		0	57	3	289	NA	NA
Carlan 2001	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)		0	501	0	503	NA	NA
Chanrachakul 2003	No treatment	IV oxytocin plus amniotomy		0	125	0	124	NA	NA
Chitrakar 2012	Intracervical PGE2	Vaginal misoprostol (<50mcg)		0	100	1	100	NA	NA
Chua 1997	Intracervical PGE2	Laminaria		1	95	0	95	NA	NA
Dällenbach 2003	Vaginal PGE2 (gel)	Oral misoprostol tablet (<50mcg)		0	100	0	100	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 1 events	Arm 1 total	Arm 2 events	Arm 2 total	Arm 3 events	Arm 3 total
Dodd 2006	Vaginal PGE2 (gel)	Titrated (low dose) oral misoprostol solution		0	376	0	365	NA	NA
Dogra 2019	No treatment	IV oxytocin		0	25	0	25	NA	NA
Dulger 2018	Placebo	Nitric oxide		0	34	0	36	NA	NA
Elhassan 2005b	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)		0	31	0	32	NA	NA
Ezechukwu 2015	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)		0	70	0	70	NA	NA
Fisher 2001	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)		0	64	1	62	NA	NA
Gattas 2020	Vaginal misoprostol (<50 mcg)	Buccal/sublingual misoprostol		0	100	0	98	NA	NA
Girija 2009	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)		0	50	1	50	NA	NA
Greybush 2001	Vaginal misoprostol (<50mcg)	Foley catheter		0	65	0	71	NA	NA
Gupta 2006	Intracervical PGE2	Vaginal misoprostol (<50mcg)		0	100	0	100	NA	NA
Gupta 2010	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)		0	80	0	80	NA	NA
Haas 2019	Vaginal misoprostol (<50 mcg)	Buccal/sublingual misoprostol		0	152	0	148	NA	NA
Has 2002	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)		1	58	0	56	NA	NA
Herabutya 1993	Vaginal PGE2 (tablet)	Intracervical PGE2		0	26	1	22	NA	NA
Hofmeyr 2001	Vaginal PGE2 (gel)	Titrated (low dose) oral misoprostol solution	Foley catheter	0	349	0	346	0	174
Irion 1998	Vaginal PGE2 (gel)	Intracervical PGE2		0	125	1	122	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 1 events	Arm 1 total	Arm 2 events	Arm 2 total	Arm 3 events	Arm 3 total
Jozwiak 2011	Vaginal PGE2 (gel)	Foley catheter		1	408	0	411	NA	NA
Jozwiak 2013	Vaginal PGE2 pessary (slow release)	Foley catheter		0	119	0	107	NA	NA
Jozwiak 2014	Vaginal misoprostol (<50mcg)	Foley catheter		0	64	0	56	NA	NA
Kaminski 1994	PGF2 gel	IV oxytocin		0	150	0	146	NA	NA
Kipikasa 2005	Oral misoprostol tablet (<50mcg)	Oral misoprostol tablet (≥50mcg)		0	23	0	29	NA	NA
Krithika 2008	Intracervical PGE2	Vaginal misoprostol (<50mcg)		0	50	0	50	NA	NA
Langenegger 2005	Intracervical PGE2	Oral misoprostol tablet (≥50mcg)		0	95	0	96	NA	NA
Le Roux 2002	Vaginal PGE2 (gel)	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)	0	240	0	120	0	120
MacLennan 1989	Vaginal PGE2 (gel)	IV oxytocin plus amniotomy		0	165	0	155	NA	NA
Mahacakri 2018	Vaginal misoprostol (<50mcg)	Titrated (low dose) oral misoprostol solution		0	15	0	14	NA	NA
Majoko 2002a	Vaginal misoprostol (≥50mcg)	Extra-amniotic prostaglandin		0	76	0	76	NA	NA
Manandhar 2017	IV oxytocin	Mifepristone		0	34	0	34	NA	NA
Mawire 1999	Foley catheter + EASI ^^	Extra-amniotic prostaglandin		0	81	0	81	NA	NA
Mehrotra 2010	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)		0	68	0	60	NA	NA
Moraes Filho 2010	Vaginal misoprostol (<50mcg)	Foley catheter		0	119	0	121	NA	NA
Mundle 2018	Oral misoprostol tablet (<50mcg)	Foley catheter		0	302	0	300	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 1 events	Arm 1 total	Arm 2 events	Arm 2 total	Arm 3 events	Arm 3 total
Noah 1987	No treatment	Intracervical PGE2		1	403	0	413	NA	NA
Noor 2015	Vaginal misoprostol (<50mcg)	Foley catheter		0	60	0	44	NA	NA
Orhue 1995	Vaginal PGE2 pessary (normal release)	IV oxytocin plus amniotomy	Foley catheter	0	34	0	30	0	30
Ozkan 2009	Vaginal PGE2 pessary (slow release)	Vaginal misoprostol (≥50mcg)		0	56	0	56	NA	NA
Papanikolaou 2004	Vaginal PGE2 (tablet)	Vaginal misoprostol (≥50mcg)		0	83	0	80	NA	NA
PonMalar 2017	Placebo	Vaginal misoprostol (<50mcg)		0	63	0	63	NA	NA
Prager 2008	Vaginal PGE2 (gel)	Vaginal misoprostol (<50mcg)	Foley catheter	0	191	0	199	0	198
Prasad 1989	Placebo	Vaginal PGE2 pessary (slow release)		0	36	0	33	NA	NA
Rabl 2002	Vaginal PGE2 (tablet)	Vaginal PGE2 pessary (slow release)		1	100	0	100	NA	NA
Rahman 2013	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)		0	110	0	110	NA	NA
Saeed 2011	Vaginal PGE2 (tablet)	Vaginal misoprostol (≥50mcg)		0	100	0	100	NA	NA
Salmon 1986	No treatment	Breast stimulation		0	50	0	50	NA	NA
Schmitz 2014	Placebo	Nitric oxide		0	684	0	678	NA	NA
Shakya 2010	Intracervical PGE2	Vaginal misoprostol (≥50mcg)		0	31	0	35	NA	NA
Somirathne 2017	Oral misoprostol tablet (≥50mcg)	Foley catheter		0	91	0	89	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 1 events	Arm 1 total	Arm 2 events	Arm 2 total	Arm 3 events	Arm 3 total
Souza 2013	Vaginal misoprostol (<50mcg)	Titrated (low dose) oral misoprostol solution		0	100	0	100	NA	NA
Spellacy 1973	IV oxytocin	IV prostaglandin		0	107	0	115	NA	NA
Suvobrata 2011	IV oxytocin	Buccal/sublingual misoprostol		0	50	0	45	NA	NA
Tandon 2014	Intracervical PGE2	Vaginal misoprostol (≥50mcg)		0	50	0	50	NA	NA
Ten Eikelder 2016	Oral misoprostol tablet (≥50mcg)	Foley catheter		0	924	0	921	NA	NA
Thaisomboon 2012	Oral misoprostol tablet (≥50mcg)	Titrated (low dose) oral misoprostol solution		0	32	0	32	NA	NA
Triglia 2010	Vaginal PGE2 (gel)	Vaginal PGE2 pessary (slow release)		0	65	0	65	NA	NA
Ugwu 2013	Vaginal misoprostol (<50mcg)	Foley catheter		0	45	0	45	NA	NA
van Gemund 2004	Vaginal PGE2 (gel)	Vaginal misoprostol (<50mcg)		1	340	1	341	NA	NA
Wang 2016	Vaginal PGE2 pessary (normal release)	Titrated (low dose) oral misoprostol solution		0	199	0	212	NA	NA
Wing 2008	Vaginal PGE2 pessary (slow release)	Sustained release misoprostol insert		0	436	0	871	NA	NA
Wing 2013	Vaginal PGE2 pessary (slow release)	Sustained release misoprostol insert		0	680	0	678	NA	NA
Young 2020	Vaginal PGE2 (gel)	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)	0	172	0	172	0	167
Zeteroglu 2006a	Vaginal misoprostol (≥50mcg)	IV oxytocin		0	32	0	32	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 1 events	Arm 1 total	Arm 2 events	Arm 2 total	Arm 3 events	Arm 3 total
Zeteroglu 2006b	Vaginal misoprostol (≥50mcg)	IV oxytocin		0	50	0	50	NA	NA
Zhang 2015	Placebo	Vaginal misoprostol (<50mcg)		0	50	0	175	NA	NA
Zvandasara 2008	Vaginal misoprostol (≥50mcg)	Titrated (low dose) oral misoprostol solution		0	65	0	69	NA	NA

1 NA: not available EASI: extra-amniotic saline infusion

2 ^ Foley used in both interventions

3

4

5

6

7 D8a - Maternal satisfaction – GRADED studies

8 Table 8: Evidence table for maternal satisfaction GRADED studies

Author/s study	Arm 1 treatment code	Arm 2 treatment code	Maternal satisfaction outcome measure, when/how collected	Arm 1	Arm 2	Study notes
N=total randomised	N= no. randomised	N= no. randomised	Questions and scoring			
Abdelaziz 2018	Vaginal PGE2 (tablet)	Vaginal PGE2 (pessary)	Patient acceptability was assessed after delivery via answering a questionnaire investigating the discomfort caused by the insertion of dinoprostone	Satisfactory: 44/70 (63%)	Satisfactory: 61/75 (81%)	100 per group analysed; not all questionnaires were

Author/s study	Arm 1 treatment code	Arm 2 treatment code	Maternal satisfaction outcome measure, when/how collected			
N=total randomised	N= no. randomised	N= no. randomised	Questions and scoring	Arm 1	Arm 2	Study notes
N=217	N=109	– slow release) N=108	preparation; rate of dissatisfaction was higher in dinoprostone vaginal tablets group than in dinoprostone vaginal insert group (37% versus 19% respectively) Questions and scoring Questionnaire was rated as either strongly agree, agree, disagree, or strongly disagree; a total score of ≤ 50 was categorized as unsatisfactory: (1) you are satisfied with the pharmaceutical preparation used in pre-induction cervical ripening; (2) if you need to have pre-induction cervical ripening in the future, you do not mind using the same pharmaceutical preparation again; (3) you are fully satisfied about the frequency of application of the used pharmaceutical preparation; (4) you did not experience any discomfort during the insertion or application of the used pharmaceutical preparation			completed for analysis satisfactory: p=0.016 RevMan: RR=0.77 [0.63, 0.95], p=0.02 (favours pessary)
Ashrafunnessa 1997 N=98	Intracervical PGE2 N=49	IV oxytocin N=49	It was not clear when women were asked about their opinions. Questions and scoring Women's opinions regarding acceptability of methods (rated recommendable, acceptable, unsatisfactory or no answer)	Positive result: N=33/49 (67.3%) 16/49 rated as recommendable, 17/49 acceptable, 11/49 unsatisfactory 5/49 no answer	Positive result: N=41/49 (83.7%) 22/49 rated as recommendable, 19/49 acceptable, 4/49 unsatisfactory 4/49 no answer	Study in India; not clear when the study was carried out. It was stated that there was no significant difference between

Author/s study	Arm 1 treatment code	Arm 2 treatment code	Maternal satisfaction outcome measure, when/how collected			
N=total randomised	N= no. randomised	N= no. randomised	Questions and scoring	Arm 1	Arm 2	Study notes
						groups for rating of labour induction method positive acceptability: RevMan: RR=0.80 [0.64, 1.01], p=0.07 (favours oxytocin)
Bollapragada 2009 N=350	Placebo N=173	Nitric oxide N=177	Outcomes measured on admission to hospital General satisfaction measured post delivery Questions and scoring Women's experience of induction of labour; pain and anxiety Discomfort and anxiety measured on a 10-point scale General satisfaction; six questions Likert scale 1–10 (1 best) 1. Labour [from very easy (1) to very difficult (10)]. 2. Experience of taking tablets (1 extremely good, 10 not at all good). 3. Pain (1 not at all painful, 10 very painful). 4. Anxiety (1 not at all anxious, 10 very anxious). 5. Same treatment again (1 definitely, 10 definitely not).	1. Labour 6.52 (2.16); p=0.26 (ns) 2. Experience of taking tablets 3.23 (2.15) ; p=0.043 3. Pain 2.18 (2.18); p=0.056 (ns) 4. Anxiety 2.39 (1.88); p=0.67 (ns) 5. Same treatment again 2.77 (2.19); p=0.063 (ns) 6. Advise friend to have same 2.69 (2.07); p=0.17 (ns)	1. Labour 6.18 (2.46) 2. Experience of taking tablets 3.84 (2.3) 3. Pain 2.76 (2.3) 4. Anxiety 2.5 (1.96) 5. Same treatment again 3.39 (2.74) 6. Advise friend to have same 3.1 (2.38)	Study in UK. Response rates for satisfaction outcomes approximately 63%. Overall, most women expressed positive views about home treatment. Women in the placebo group had slightly more positive views, and women in the ISMN group who suffered headache had significantly fewer

Author/s study	Arm 1 treatment code	Arm 2 treatment code	Maternal satisfaction outcome measure, when/how collected			
N=total randomised	N= no. randomised	N= no. randomised	Questions and scoring	Arm 1	Arm 2	Study notes
			6. Advise friend to have same (1 definitely, 10 definitely not)			positive views (data not shown). (5) RevMan: MD=0.62 [0.10, 1.14], p=0.02 (favours placebo) (6) RevMan: MD=0.41 [-0.06, 0.88], p=0.09 (favours placebo)
Bullarbo 2007 N=200	Placebo N=100	Nitric oxide N=100	Opinion of outpatient procedure and whether or not women would recommend this treatment Questions and scoring NR	Would recommend: N=93/99 (93.9%)	Would recommend: N=89/94 (94.7%)	Study in Sweden; 94% of women in intervention group and 99% controls responded; significance not reported "Most women in both groups were either positive or very positive to the treatment." RevMan: RR=1.01 [0.94, 1.308], no difference

Author/s study	Arm 1 treatment code	Arm 2 treatment code	Maternal satisfaction outcome measure, when/how collected			
N=total randomised	N= no. randomised	N= no. randomised	Questions and scoring	Arm 1	Arm 2	Study notes
Cardozo 1986 N=402	No treatment N=207	Vaginal PGE2 pessary (normal release) N=195	NR Questions and scoring Satisfaction with management (pleased, no comment, disappointed)	Pleased with management: N=110/207 (53%)	Pleased with management: N=97/195 (49.7%)	Study in UK significance not reported RevMan: RR=0.94 [0.77, 1.13], p=0.50 (favours no treatment)
Chavakula 2015 N=100	Vaginal misoprostol (Dose less than 50 mcg) N=46	Mechanical methods – Foley catheter N=54	Patient satisfaction score assessed by a visual analogue score ranging from zero to five (0 = very poor; 5 = very good). Questions and scoring Total range 0–5 (0 = very poor; 5 = very good).	satisfaction mean 4.48 (range 3-5)	satisfaction mean 4.5 (range 4-5)	satisfaction p=0.488 (ns) backcalculated using mean, N, p-value: MD=0.02 [95%CI - 0.036, 0.076]
Colon 2005 N=204	Vaginal misoprostol (Dose less than 50 mcg) N=111	Oral misoprostol tablet (dose 50mcg or more) N=93	Not clear how satisfaction was measured post delivery Questions and scoring NR	Satisfied with overall experience: 98% (109/111) Dissatisfied with misoprostol: 14% (N=16/111)	Satisfied with overall experience: 98% (91/93) Dissatisfied with misoprostol: 7.5% (N=7/93)	Study in USA; 153/204 responded to survey significance not reported Satisfied with experience: RevMan: RR=1.00 [0.96, 1.04], p=0.86

Author/s study	Arm 1 treatment code	Arm 2 treatment code	Maternal satisfaction outcome measure, when/how collected			
N=total randomised	N= no. randomised	N= no. randomised	Questions and scoring	Arm 1	Arm 2	Study notes
						(no difference) Dissatisfied with misoprostol: RevMan: RR=1.92 [0.82, 4.46], p=0.13 (favours oral)
Ezechukwu 2015 N=140	Vaginal misoprostol (Dose 50 mcg or more) N=70	Oral misoprostol tablet (dose 50mcg or more) N=70	Structured interviewer-administered questionnaire was given to each of the participants as soon as possible after delivery to assess the acceptance and satisfaction with the received method of induction of labor. To ensure consistency, the questionnaire was administered by the same interviewer throughout the study Questions and scoring Maternal satisfaction questionnaire; A method is said to be acceptable to a participant if the participant is pleased or happy with the method, and vice versa (answers: acceptable, not acceptable, and indifferent). Maternal satisfaction with a particular method of induction of labor was defined as patient's expression of preference and willingness to consent to the same method if induction of labor is indicated in any subsequent pregnancies (answers: satisfied, not satisfied)	Perception of method: "acceptable": 61/70 (87.1%) "unacceptable": 8/70 (11.4%) satisfaction with method "satisfied": 56/70 (80%)	Perception of method "acceptable": 53/70 (75.7%) "Unacceptable": 16/70 (22.9%) satisfaction with method "satisfied": 49/70 (70%)	perception of method "acceptable": p=0.12 (ns) RevMan: RR=1.15 [0.98, 1.35], p=0.09 (favours vaginal) "unacceptable": p=0.11 (ns) satisfaction with method "satisfied": p=0.17 (ns) RevMan: RR=1.14 [0.94, 1.39], p=0.18 (favours vaginal)

Author/s study	Arm 1 treatment code	Arm 2 treatment code	Maternal satisfaction outcome measure, when/how collected			
N=total randomised	N= no. randomised	N= no. randomised	Questions and scoring	Arm 1	Arm 2	Study notes
Haas 2019 N=319	Vaginal misoprostol (Dose less than 50 mcg) N=158	Buccal/sublingual misoprostol N=161	Questionnaire completed the first or second day following the birth including questions on induction method Questions and scoring How did you feel about your experience with your induction of labor? (It was a great experience/ It was a terrible experience / It was neither great nor terrible/ I'm not sure / Missing), If you were to have induction of labor in the future, which one would you prefer? (Vagina/ Cheek/ Unsure/ Missing)	Great experience with induction: 79/149 (53.0) Preferred same induction of labour in the future: 56/145 (38.6)	Great experience with induction: 77/141 (54.6) Preferred same induction of labour in the future: 69/139 (49.6)	Study in USA 2015-17; 284/300 responded to all questions on the post-delivery satisfaction questionnaire. No significant differences in participant satisfaction responses. Great experience with induction: RevMan RR=0.97 [0.78, 1.20], p=0.07 (no difference) Preferred same induction of labour in the future: RevMan: RR=0.78 [0.60, 1.01], p<0.01 (favours buccal/sublingual)

Author/s study	Arm 1 treatment code	Arm 2 treatment code	Maternal satisfaction outcome measure, when/how collected			
N=total randomised	N= no. randomised	N= no. randomised	Questions and scoring	Arm 1	Arm 2	Study notes
Henry 2013 N=101	Vaginal PGE2 (gel) N=51	Mechanical methods – Foley catheter N=50	<p>Patient acceptability was assessed through the patient satisfaction questionnaire, and rate of unplanned (not in labour) hospital readmission. Women were followed-up and satisfaction surveys administered on the Postnatal Ward 24–48 hours post birth</p> <p>Questions and scoring (1a) A lot of discomfort at insertion (agree or strongly agree) (1b) A lot of discomfort at 4-6hours later (agree or strongly agree) (1c) A lot of discomfort at cervical ripening (agree or strongly agree) (2a) Able to cope with discomfort at insertion (agree or strongly agree) (2b) Able to cope with discomfort at 4-6 hours later (agree or strongly agree) (2c) Able to cope with discomfort at cervical ripening (agree or strongly agree) (3) Would choose this method again (always or most times) (4) Worried the IOL not safe *Only answers represented in brackets were reported in the study*</p>	1a. N=13/45 (29%) p=0.014 1b. N=16/45 (36%) p=ns 1c. N=25/43 (58%) p=0.003 2a. N=39/45 (87%) p=ns 2b. N=34/45 (76%) p=ns 2c. N=29/43 (67%) p=0.002 3. N=19/45 (42%) p=0.031 4. N=12/43 (28%) p=0.006	1a. N=26/48 (55%) 1b. N=11/48 (23%) 1c. N=10/39 (26%) 2a. N=43/48 (92%) 2b. N=37/48 (77%) 2c. N=37/39 (95%) 3. N=31/48 (65%) 4. N=2/39 (5%)	93 of 101 women completed the satisfaction survey (3) OR=2.5 (95%CI 1.1-5.8), p=0.031 (if swapping event and non-event) RevMan (no swap): OR=0.40 [0.17,0.93], p=0.03, favour Foley) RR=0.65 [0.44, 0.98], p=0.04 (favours Foley)
Kennedy 1978	Intracervical PGE2	IV oxytocin	NR	Reaction unfavourable: 1/27	Reaction unfavourable: 1/27	UK study. Brief report. Most women

Author/s study	Arm 1 treatment code	Arm 2 treatment code	Maternal satisfaction outcome measure, when/how collected			
N=total randomised	N= no. randomised	N= no. randomised	Questions and scoring	Arm 1	Arm 2	Study notes
N=55	N=28	plus amniotomy N=27	Questions and scoring Maternal reactions to method (favourable vs. unfavourable) and whether labour was better or worse than previous labours (for multiparous women only)	Labour worse than previous: 2/14	Labour worse than previous: 2/11	55/60 responded to survey but data on experience of labour for multiparous women only; significance not reported reaction unfavourable: RevMan: RR=1.00 [0.07, 15.18], p=1.0 (no difference)
Kennedy 1982 N=100	Vaginal PGE2 (tablet) N=50	IV oxytocin plus amniotomy N=50	NR Questions and scoring Maternal reactions to method (favourable vs. unfavourable)	Reaction unfavourable: 0/50	Reaction unfavourable: 26/50	Study carried out in the UK significance not reported Peto OR used as zero cases in one group RevMan: POR=0.07 [0.03, 0.17], p<00001 (favours vaginal PGE2 tablet)

Author/s study	Arm 1 treatment code	Arm 2 treatment code	Maternal satisfaction outcome measure, when/how collected			
N=total randomised	N= no. randomised	N= no. randomised	Questions and scoring	Arm 1	Arm 2	Study notes
Legarth 1987 N=98	Vaginal PGE2 pessary (normal release) N=49	IV oxytocin N=49	Women's perceptions of pain and view of method of induction used Questions and scoring NR	Intense pain: 19/47 Unsatisfactory: 1/47	Intense pain: 11/45 Unsatisfactory: 7/45	Study in Denmark significance not reported RevMan: RR=0.14 [0.02, 1.07], p=0.06 (favours Vaginal PGE2 pessary normal release)
Lim 2018 (main trial: Tan 2015) N=87	Vaginal PGE2 (tablet) N=54	Mechanical methods – Double balloon or Cook's catheter N=33	After delivery, a member of the study team interviewed the patients. Questions and scoring Information collected included patients' views on pain felt during the induction process, overall satisfaction, comments and whether they would recommend their mode of induction to other women (yes/no) Satisfaction scored on a scale of 0 (unhappy) to 5 (very happy)	Satisfaction: mean 3.2 SD 1.4 recommend: N=36/52 (69.2%)	Satisfaction: mean 3.4 SD 1.5 recommend: N=22/31 (71.0%)	No significant difference between groups Satisfaction. RevMan: MD=-0.20 [-0.83, 0.43], p=0.54 (no difference) Recommend. RevMan: RR=0.98 [0.73, 1.30], p=0.87 (favours Vaginal)
Lo 1994 N=200	Vaginal PGE2 (tablet) N=101	IV oxytocin plus amniotomy	Maternal acceptance of method Questions and scoring It was not clear what women were asked	Rated positively: 63/101	Rated positively: 77/99	Study in Hong Kong 1991–2; results stratified by parity; significance not reported

Author/s study	Arm 1 treatment code	Arm 2 treatment code	Maternal satisfaction outcome measure, when/how collected			
N=total randomised	N= no. randomised	N= no. randomised	Questions and scoring	Arm 1	Arm 2	Study notes
		N=99				RevMan: RR=0.80 [0.67, 0.96], p=0.02 (favours IV oxytocin+amniotomy)
Lyndrup 1994 (EASI) N=109	Vaginal PGE2 pessary (normal release) N=50	Mechanical methods – Foley catheter N=59	After delivery, patients who had delivered vaginally within the study period were asked to comment on the induction procedure by one of three expressions: recommendable, satisfactory, and unsatisfactory. Questions and scoring recommendable, satisfactory, unsatisfactory	N=39/50 responded Recommendable N=23/39 Acceptable N=12/39 Unsatisfactory N=3/39 no answer N=1/39	N=32/59 responded Recommendable N=24/32 Acceptable N=6/32 Unsatisfactory N=2/32	p=ns RevMan: RR=0.96 [0.83, 1.10], p=0.54 (no difference)
Mei Dan 2012 (EASI) N=188	Mechanical methods – Foley catheter N=88	Mechanical methods – Double balloon or Cook's catheter N=100	NR Questions and scoring Satisfaction scale 1-10	7 ± 2.8	6.5 ± 3.2	p=0.64 (mean and SD) MA'd with Sayed 2016 and Mei-Dan 2014; RevMan MD=-0.22 [-0.95, 0.51], p=0.55, i2=52% (RE model) (no difference)

Author/s study	Arm 1 treatment code	Arm 2 treatment code	Maternal satisfaction outcome measure, when/how collected			
N=total randomised	N= no. randomised	N= no. randomised	Questions and scoring	Arm 1	Arm 2	Study notes
Mei Dan 2014 (EASI) N=186	Mechanical methods – Foley catheter N=126	Mechanical methods – Double balloon or Cook's catheter N=60	Satisfaction data were collected by research students on direct interview with participants and/or from the clinical chart after delivery Questions and scoring All participants rated their satisfaction with the induction process using a Likert scale (0–10, with higher numbers indicating greater satisfaction)	7.0±2.8	7.7±2.8	p=0.42 (mean and SD) MA'd with Sayed 2016 and Mei-Dan 2012; RevMan MD=-0.22 [-0.95, 0.51], p=0.55, i2=52% (RE model) (no difference)
Mundle 2018 N=602	Oral misoprostol tablet (Dose less than 50 mcg) N=302	Mechanical methods – Foley catheter N=300	Women's expectations about labour were assessed before the induction process and 48 h after the birth Questions and scoring Would use same method for future induction? (answer: yes/no/no preference)	Yes: N=250/302 (82.8%) No: N=35/302 (11.6%) no pref: N=17/302 (6%)	Yes: N=216/300 (72%) No: N=59/300 (19.7%) no pref: N=25/300 (8.3%)	significance reported for "no" only: p=0.0063 RevMan: RR=1.15 [1.05, 1.25], m p=0.002 (favours Oral misoprostol) (also Mundle 2017 and Leigh 2018 (no additional data from these))
Nassar 2006	Vaginal misoprostol (Dose	Buccal/sublingual	Questionnaire completed following the birth including questions on induction method	Opt for same "route" again: 18/72	Opt for same "route" again: 59/76	Study in Beirut 2004–6;

Author/s study	Arm 1 treatment code	Arm 2 treatment code	Maternal satisfaction outcome measure, when/how collected			
N=total randomised	N= no. randomised	N= no. randomised	Questions and scoring	Arm 1	Arm 2	Study notes
N=170	50 mcg or more)	misoprostol	Questions and scoring Views of induction in subsequent/future pregnancy	Favourable view of induction: 27/72	Favourable view of induction: 46/76	significance not reported Same route: RevMan: RR=0.32 [0.21, 0.49], p<0.00001 (favours buccal/sublingual misoprostol) Favourable view: RevMan: RR=0.62 [0.44, 0.88], p=0.007 (favours Buccal/sublingual misoprostol)
	N=85	N=85				
Osman 2006 N=387	Vaginal PGE2 (gel) N=194	Nitric oxide N=193	Maternal satisfaction with cervical ripening treatment was measured by a visual analogue score (VAS) before discharge from hospital. Preference for inpatient or outpatient cervical ripening was also recorded Questions and scoring (1) How happy were you with your cervical ripening treatment? (VAS 1-10) (2) Would you prefer to have been at home during cervical ripening and then come into hospital for labour induction?	(1) mean 5.8 SD 3.1 median 7 IQR 3-8 (2) N=33/194 (17%) (3) N=133/194 (68.6%)	(1) mean 7.0 SD 2.7 median 8 IQR 5-9 (2) N=106/193 (54.9%) (3) N=161/193 (83.4%)	(1) p<0.0001 RevMan: MD=-1.20 [-1.78, -0.62], p<0.0001 (favours Nitrix oxide) (2) p<0.0001 (3) p=0.0006

Author/s study	Arm 1 treatment code	Arm 2 treatment code	Maternal satisfaction outcome measure, when/how collected			
N=total randomised	N= no. randomised	N= no. randomised	Questions and scoring	Arm 1	Arm 2	Study notes
			(3) Next time, would you prefer to go home for cervical ripening if a safe, pain-free method was available with the option of coming into hospital if contractions start?			
Sayed 2016 N=78	Mechanical methods – Foley catheter N=39	Mechanical methods – Double balloon or Cook's catheter N=39	After delivery, all participants rated their satisfaction with the whole induction process using VAS Questions and scoring VAS (0–10: 0 = not satisfied, 10 = maximum satisfaction)	Pain: mean 4.7 SD 3.1 Satisfaction: mean 5.7 SD 2.01 (range 2-9)	Pain: mean 4.3 SD 2.7 Satisfaction: mean 6.17 SD 1.98 (range 1-10)	Pain: p=0.55 (ns) Satisfaction: p=0.86 (ns) RevMan: MD=-0.47 [-1.36, 0.42], p=0.30 (favours Cook's/double balloon)
Schmitz 2014 N=1373	Placebo N=689	Nitric oxide N=684	Maternal satisfaction was assessed by a self-administered questionnaire on day 2 postpartum Questions and scoring Would you recommend the same treatment? (answer: yes/no) Felt satisfied with treatment? (answer: not at all, a little, moderately, very, extremely)	Completed forms: N=524/684 (76.6%) Recommend: N=405/524 (81.2%) Felt satisfied: N=415/524 extremely N=49 (9.6%) very N=154 (30.2%) moderately N=136 (26.7%) a little N=76 (14.9%)	Completed forms: N=525/678 (77.4%) Recommend: N=339/525 (67.3%) Felt satisfied: N=418/525 extremely N=25 (4.8%) very N=137 (26.5%) moderately N=153 (29.5%)	Almost 25% of the women in each group did not answer the satisfaction questionnaire. Completed: p=0.76 (ns) recommend: p<0.001 RevMan: RR=0.84 [0.77, 0.90], p<0.00001 (favours placebo)

Author/s study	Arm 1 treatment code	Arm 2 treatment code	Maternal satisfaction outcome measure, when/how collected			
N=total randomised	N= no. randomised	N= no. randomised	Questions and scoring	Arm 1	Arm 2	Study notes
				not at all N=95 (18.6%)	a little N=103 (19.9%) not at all N=100 (19.3%)	satisfied: p=0.008 RevMan: RR=1.01 [0.95, 1.07], p=0.87 (no difference) "maternal satisfaction rate: 23%"
Selo-Ojeme 2009 N=123	Amniotomy N=62	IV oxytocin plus amniotomy N=61	Following delivery or on admission to the post-natal ward, a self-administered questionnaire was given to the women to complete. Participants were asked to put their completed questionnaire in a specially placed box at the ward reception before leaving the hospital. Measures overall satisfaction with the whole induction process as well as the degree of satisfaction with specific components of the induction process Questions and scoring The questionnaire comprised a seven-point Likert-type scale ranging from 'very dissatisfied' (-3) to 'very satisfied' (+3) (1) overall experience of induction of labour (satisfied/neither/dissatisfied) (2) would you have it again? (yes/no/no response)	N=36/62 (1) satisfied: N=27/36 (75%) (2) Yes: N=23/36 (63.9%)	N=39/61 (1) satisfied: N=36/39 (92.3%) (2) Yes: N=26/39 (66.7%)	(1) RR= 4 (95%CI 1.1–16.1), p=0.03 RevMan: RR=1.23 [1.0, 1.52], p=0.05 (favours IV oxytocin +amniotomy) (2) RR= 1.1 (95%CI 0.4–2.9), p=0.18 (ns) RevMan: RR=1.04 [0.75, 1.45], p=0.80 (no difference) (not in HTA maternal satisfaction table)

Author/s study	Arm 1 treatment code	Arm 2 treatment code	Maternal satisfaction outcome measure, when/how collected			
N=total randomised	N= no. randomised	N= no. randomised	Questions and scoring	Arm 1	Arm 2	Study notes
Shechter-Maor 2015 N=52	Vaginal PGE2 (pessary – slow release) N=26	Mechanical methods – Double balloon or Cook's catheter N=26	Questionnaires regarding the patients' personal impressions were completed after delivery, all by the same recorder Questions and scoring Maternal impression (scale 1-5): Fearful of induction Uncomfortable with induction Satisfaction with induction process	fearful: mean 2.33 SD 1.3 uncomfortable: mean 2.33 SD 1.3 satisfaction: mean 3.33 SD 1.2	fearful: mean 3.76 SD 1.2 uncomfortable: mean 3.59 SD 1.1 satisfaction: mean 3.41 SD 1.3	"Maternal fear and inconvenience were reported less often with PGE2. Higher maternal satisfaction rates were reported with PGE2 " fearful: p=0.002 uncomfortable: p=0.004 satisfaction: p=0.860 (ns) RevMan: MD=-0.08 [-0.76, 0.60], p=0.82 (no difference)
Shetty 2001 N=245	Vaginal misoprostol (Dose 50 mcg or more) N=123	Oral misoprostol tablet (dose 50mcg or more) N=122	Questionnaire returned before discharge Questions and scoring (1) satisfaction rate (2) pain (3) speed of induction (4) preferred method if induced again	N=81 questionnaires returned satisfaction rate 89.1% (N=72/81) preferred mode for next induction: 15.8% of the vaginal group said they would prefer it	N=98 questionnaires returned satisfaction rate 74.5% (N=73/98) preferred mode: 49% of oral group would prefer oral administration	189/245 returned completed questionnaires (77.1%) while on the postnatal wards before discharge from hospital. Satisfaction higher in vaginal group RR

Author/s study	Arm 1 treatment code	Arm 2 treatment code	Maternal satisfaction outcome measure, when/how collected			
N=total randomised	N= no. randomised	N= no. randomised	Questions and scoring	Arm 1	Arm 2	Study notes
				orally. Unsure of preference: 35.3%	Unsure of preference: 41.8%	1.2 (95% CI 1.04-1.4) RevMan: RR=1.19 [1.04, 1.37], p=0.01 (favours vaginal misoprostol)
Surita 2005 (N=140	Hyaluronidase N=70	Mechanical methods – Foley catheter N=70	Women reported satisfaction with and discomfort associated with each method Questions and scoring NR	Satisfaction: 49/70 Very or relatively uncomfortable: 10/70	Satisfaction: 56/70 Very or relatively uncomfortable: 12/70	Study in Brazil 2000–2 significance not reported Satisfaction: RevMan: RR=1.14 [0.94, 1.39], p=0.18 (favours Foley catheter)
Tan 2013 N=206	Amniotomy N=101	IV oxytocin plus amniotomy N=105	24 hours after the birth Questions and scoring Satisfaction with the birth process on a 1–10 scale (lower score better)	mean 3 (3-5)	mean 3 (3-4)	Study in Malaysia 2010–12 p=0.36 (ns) Backcalculated using MD, N, p-value: MD= 0 [0, 0]

Author/s study	Arm 1 treatment code	Arm 2 treatment code	Maternal satisfaction outcome measure, when/how collected			
N=total randomised	N= no. randomised	N= no. randomised	Questions and scoring	Arm 1	Arm 2	Study notes
						(in HTA this is IV oxytocin Vs placebo - here it is amniotomy (instead of placebo), and IV oxy+amnio)
Ten Eikelder 2016 N=1859	Oral misoprostol tablet (dose 50mcg or more) N=932	Mechanical methods – Foley catheter N=927	When consent to participation was given and randomization had taken place, women received the questionnaire within 24 hours after delivery. Thereafter, they were asked to complete the questionnaire within the following 24 hours. Questions and scoring Set of 11 questions regarding moods and experiences with answers on a scale of 1 to 5 (“Much worse than expected,” “Worse than expected,” “As expected,” “Better than expected,” and “Much better than expected”) and an option to fill in “Don’t know.” To evaluate the preference for the induction method, we asked if they felt like the alternative procedure of induction of labor would have been better for them: "are you satisfied with the procedure?" (answer: worse than expected, as expected, better than expected)	Completed forms: N=273 Satisfied: N=166/273 (60.8%) worse: N=81/273 (32.8%) as expected: N=123/273 (49.8%) better: N=43/273 (17.4%)	Completed forms: N=229 Satisfied: N=136/229 (59.3%) worse: N=74/229 (35.2%) as expected: N=108/229 (46.8%) better: N=28/229 (13.3%)	Only 18 hospitals approached for questionnaire; 695 women eligible to fill out the questionnaire. Completed by N=502/695 satisfied: p=0.48 (ns) RevMan: RR=1.02 [0.89, 1.18], p=0.75 (no difference) (also TenEikelder 2013 (protocol), 2017 (maternal satisfaction), 2016 (editorial comment),

Author/s study	Arm 1 treatment code	Arm 2 treatment code	Maternal satisfaction outcome measure, when/how collected			
N=total randomised	N= no. randomised	N= no. randomised	Questions and scoring	Arm 1	Arm 2	Study notes
						2016 (Lancet, main trial, full)
van Gemund 2004 N=681	Vaginal PGE2 (gel) N=340	Vaginal misoprostol (Dose less than 50 mcg) N=341	Preference for subsequent labour Questions and scoring NR	164/286 would choose the same method again (57.3%)	179/291 would choose same method again (61.5%)	Study in the Netherlands significance not reported RevMan: RR=0.93 [0.81, 1.07], p=0.31 (favours Vaginal misoprostol)
Wallstrom 2019 N=199	Titrated (low dose) oral misoprostol solution N=99	Sustained release misoprostol insert N=100	Women's delivery experience measured by a visual analogue score (VAS) Questions and scoring VAS (0–10: 0 = not satisfied, 10 = maximum satisfaction)	Delivery experience satisfaction: mean 6.8 SD 2.4 (N=99)	Delivery experience satisfaction: mean 7.0 SD 2.3 (N=97)	Study in Sweden 2016-18 Delivery experience satisfaction: p=0.55 (not significant) RevMan: MD = -0.20 [-0.86,0.46], p=0.55 (not significant)
Young 2019 N=511	Vaginal PGE2 (gel) N=172	Vaginal misoprostol (Dose less than 50 mcg)	Questionnaire regarding maternal satisfaction with labour. Questions and scoring	Arm 1 Want same induction method N=102/139 (73.4%)	Arm 2 Want same induction method N=108/139 (77.7%)	Canada 1999-2000 No differences found between groups in maternal satisfaction.

Author/s study	Arm 1 treatment code	Arm 2 treatment code	Maternal satisfaction outcome measure, when/how collected			
N=total randomised	N= no. randomised	N= no. randomised	Questions and scoring	Arm 1	Arm 2	Study notes
		N=172 Arm 3 Oral misoprostol tablet (Dose 50mcg or more) N=167	If you needed an labour induction in another pregnancy, would you want to have the same induction method?		Arm 3 Want same induction method N=112/145 (77.2%)	Canada 1999-2000 No differences found between groups in maternal satisfaction Vaginal PGE2 (gel) versus vaginal misoprostol (<50mcg): RevMan: RR = 0.94 [0.83,1.08], p=0.40 (not significant) Vaginal PGE2 (gel) versus oral misoprostol (≥50mcg): RevMan: RR = 0.95 [0.83,1.09],p=0.45 (not significant) Vaginal misoprostol (<50mcg) versus

Author/s study	Arm 1 treatment code	Arm 2 treatment code	Maternal satisfaction outcome measure, when/how collected			
N=total randomised	N= no. randomised	N= no. randomised	Questions and scoring	Arm 1	Arm 2	Study notes
						oral misoprostol (≥50mcg): RevMan: RR=1.01 [0.89,1.14], p=0.93 (not significant)
Zahran 2009 N=480	Vaginal misoprostol (Dose 50 mcg or more) N=240 (80 CS)	Buccal/sublingual misoprostol N=240 (71 CS)	After delivery, used the VAS to assess patients' satisfaction Questions and scoring Satisfaction with induction experience (VAS): (VB) vaginal birth (CD) caesarean deliveries	VB: mean 5.6 SD 2.9 (N=160) CD: mean 5.6 SD 2.9 (N=80)	VB: mean 5.2 SD 2.4 (N=169) CD: mean 4.2 SD 1.7 (N=71)	No significant difference between groups, or delivery methods for satisfaction with induction experience. "The sublingual route, whether that of placebo or the drug, was the preferred route of administration in all subgroups. These differed significantly within each group (P=0.03 and 0.02 for satisfaction differences in vaginally and abdominally

Author/s study	Arm 1 treatment code	Arm 2 treatment code	Maternal satisfaction outcome measure, when/how collected			
N=total randomised	N= no. randomised	N= no. randomised	Questions and scoring	Arm 1	Arm 2	Study notes
						delivered patients of the sublingual group" RevMan: MD=0.77 [0.32, 1.23], p=0.0009 (favours vaginal misoprostol <50mcg) (not in HTA maternal satisfaction table)

1
2
3

1 D8b – Maternal satisfaction – Narrative studies

2 Table 9: Evidence table for maternal satisfaction narrative studies

Author/study	Arm 1 treatment code	Arm 2 treatment code	Maternal satisfaction outcome measure, when/how collected, Questions and scoring	Results (Arm 1, Arm 2)	Study notes
Adeniji 2005 N=96	Vaginal misoprostol (Dose 50 mcg or more) N=50	Mechanical methods – foley catheter N=46	It was not clear when women completed questionnaires or how outcomes were measured. Questions and scoring: Maternal discomfort (NC) Maternal questionnaires	Intravaginal Misoprostol was well received by the patients . . . showing 85% acceptance of Misoprostol with average expression of minimal discomfort at insertion, in contrast to 35% acceptance, moderate discomfort and resentment of 'something between thighs' in the Foley catheters group (p < 0.05)	Study in Nigeria, 2003. The number of women responding to questionnaires was not stated
Dodd 2006 N=741	Vaginal PGE2 (gel) N=376	Titrated (low dose) oral misoprostol solution N=365	Women's preferences Questions and scoring: NR	Overall 58.5% said that that they would prefer an oral induction agent: "Women in the misoprostol group were more likely to say they 'liked everything' with their labour and birth"	Study in Australia; significance not reported
Ferraiolo 2010 N=151	Vaginal PGE2 (gel) N=72	Vaginal PGE2 (pessary – slow release) N=79	Pre and post-delivery maternal questionnaires Questions and scoring: NR	It was reported that in the post-induction questionnaires there was no significant difference in anxiety (p = 0.073) or discomfort (0.073). A burning sensation on application was experienced by 31.9% of women in the vaginal	Study in Italy 2007–8; 173 recruited but 22 excluded as they did not complete questionnaires or did not complete them correctly

Author/study	Arm 1 treatment code	Arm 2 treatment code	Maternal satisfaction outcome measure, when/how collected, Questions and scoring	Results (Arm 1, Arm 2)	Study notes
N=total randomised	N= no. randomised	N= no. randomised			
				gel group and 26.6% in the sustained-release pessary group	
Girija 2009 N=100	Vaginal misoprostol (Dose less than 50 mcg) N=50	Vaginal misoprostol (Dose 50 mcg or more) N=50	Not clear when or how satisfaction was measured Questions and scoring: NR	"Eighty percent (22/25) women in the 25 µg group and 100% 23/23 of women in the 50 µg group had a satisfaction level of more than 50% (p = 0.23)"	Study in India 2004–5; data on satisfaction available for only 48/100 randomised
Girija 2011 N=320	Intracervical PGE2 N=161	Vaginal misoprostol (Dose less than 50 mcg) N=159	Not clear when or how satisfaction was measured Questions and scoring: NR	"More than 50% satisfaction of (sic) was observed in 107 (89.2%) mothers in misoprostol group and 109 (91.6%) which was not statistically significant p = 0.6762"	Study in India 2006–8; 239/320 responded to satisfaction questionnaire
Guha 2015 N=200	Vaginal misoprostol (Dose 50 mcg or more) N=100	Nitric oxide N=100	NR Questions and scoring: NR	ARM1: Very happy 35.7% Happy 46.7% Unhappy 63% Very unhappy 55.6% ARM2: Very happy 64.3% Happy 53.3% Unhappy 37% Very unhappy 44.4%	"Maternal satisfaction was higher in nitric oxide group"; significance not reported Results do not add up, so cannot GRADE (Numerator and denominators were not reported)

Author/study	Arm 1 treatment code	Arm 2 treatment code	Maternal satisfaction outcome measure, when/how collected, Questions and scoring	Results (Arm 1, Arm 2)	Study notes
N=total randomised	N= no. randomised	N= no. randomised			
Kennel 2018 N=50	Vaginal misoprostol (Dose less than 50 mcg) N=22	Titrated (low dose) oral misoprostol solution N=28	NR Questions and scoring: NR	Approximately 80% of all participants preferred oral administration because they disliked vaginal placement, while 20% preferred the vaginal administration because it “worked better” and they “dislike pills.”	Abstract only; significance not reported
Shetty 2002a N=100	Oral misoprostol tablet (dose 50mcg or more) N=50	Buccal/sublingual misoprostol N=50	Not clear how satisfaction was measured Questions and scoring: NR	ARM1: Satisfaction rate: 82.5% ARM2: Satisfaction rate: 85.7%	UK study 2000; 82% returned postnatal questionnaires; significance not reported Cannot calculate numerator and denominator based on information available
Shetty 2002b N=249	Oral misoprostol tablet (dose 50mcg or more) N=124	Buccal/sublingual misoprostol N=125	Brief satisfaction questionnaire about satisfaction and preferences for the future Questions and scoring: NR	High levels of satisfaction with induction method in both groups (87–88%); significance not reported	UK study 2000–1; 78% of women responded to satisfaction questionnaire
Thomlinson 2001	Vaginal PGE2 (gel)	Vaginal PGE2 (pessary – slow release)	NR Questions and scoring: Outcomes measured on a Likert scale	ARM1: Pain on insertion: 2.7 (0–8)	Study in UK (difference not significant)

Author/study	Arm 1 treatment code	Arm 2 treatment code	Maternal satisfaction outcome measure, when/how collected, Questions and scoring	Results (Arm 1, Arm 2)	Study notes
N=total randomised	N= no. randomised	N= no. randomised			
N=69	N=34	N=35		Satisfaction with induction score: 3.9 (1–6) ARM2: Pain on insertion: 3.0 (0–10) Satisfaction with induction score: 4.3 (1–6)	Cannot calculate based on available data
Ugwu 2013 N=90	Vaginal misoprostol (Dose less than 50 mcg) N=45	Mechanical methods – foley catheter N=45	A structured interviewer-administered questionnaire was given to each of the participants upon conclusion of the cervical ripening process or as soon as possible in the postpartum period in those who developed spontaneous labour or delivered by emergency caesarean section, to assess their acceptance and perception of the received method. Questions and scoring: NR	there was no significant difference in the women's perception of the methods in terms of acceptability (Foley group (n=40) and misoprostol group (n=45); p=0.19)	not in original HTA report's maternal satisfaction table

1

2

3

1 D9 - Instrumental birth

2 **Table 10: Evidence table for instrumental birth**

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Ar m 1 eve nt	Ar m 1 tota l	Ar m 2 eve nt	Ar m 2 tota l	Ar m 3 eve nt	Ar m 3 tota l	Ar m 4 eve nt	Ar m 4 tota l
Aalami-Harandi 2013	Titrated (low dose) oral misoprostol solution	IV oxytocin			0	128	0	128	NA	NA	NA	NA
Abdelaziz 2018	Vaginal PGE2 (tablet)	Vaginal PGE2 pessary (slow release)			4	100	6	100	NA	NA	NA	NA
Abdul 2007	Vaginal misoprostol (≥ 50 mcg)	IV oxytocin			3	34	5	28	NA	NA	NA	NA
Adam 2005	Vaginal misoprostol (≥ 50 mcg)	Oral misoprostol tablet (≥ 50 mcg)			7	40	8	40	NA	NA	NA	NA
Adeniji 2005	Vaginal misoprostol (≥ 50 mcg)	Foley catheter			3	50	2	46	NA	NA	NA	NA
Alcoseba-Lim 1992	No treatment	Membrane sweeping			4	65	7	65	NA	NA	NA	NA
Allott 1993	No treatment	Membrane sweeping			12	96	11	99	NA	NA	NA	NA
Al-Taani 2004	Vaginal PGE2 (tablet)	Foley catheter			8	75	8	72	NA	NA	NA	NA
Anand 2012	Intracervical PGE2	Vaginal misoprostol (< 50 mcg)			6	100	10	100	NA	NA	NA	NA
Andersen 2013	No treatment	Membrane sweeping	Acupuncture		9	100	13	103	22	104	NA	NA
Ashrafunnesa 1997	Intracervical PGE2	IV oxytocin			9	49	5	49	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Ayaz 2010	Vaginal PGE2 (tablet)	Vaginal misoprostol (≥50mcg)			16	60	14	60	NA	NA	NA	NA
Azubuikwe 2015	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)			1	40	1	43	NA	NA	NA	NA
Bakos 1987	IV oxytocin	Amniotomy			9	113	7	110	NA	NA	NA	NA
Balci 2010	Vaginal misoprostol (≥50mcg)	IV oxytocin			1	50	1	50	NA	NA	NA	NA
Balci 2011	Vaginal misoprostol (≥50mcg)	IV oxytocin			0	50	1	51	NA	NA	NA	NA
Barda 2018	Vaginal PGE2 (tablet)	Foley catheter			10	150	9	150	NA	NA	NA	NA
Bartha 2000	Intracervical PGE2	Oral misoprostol tablet (≥50mcg)			27	100	23	100	NA	NA	NA	NA
Bartusevicius 2006	Vaginal misoprostol (<50mcg)	Buccal/sublingual misoprostol			2	70	5	70	NA	NA	NA	NA
Bell 1993	Placebo	Relaxin			6	22	6	18	NA	NA	NA	NA
Bennett 1998	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)			23	102	30	104	NA	NA	NA	NA
Berghella 1996	No treatment	Membrane sweeping			7	69	7	73	NA	NA	NA	NA
Berkane 2005	Placebo	Mifepristone			9	57	80	289	NA	NA	NA	NA
Bollapragada 2009	Placebo	Nitric oxide			54	173	47	177	NA	NA	NA	NA
Boulvain 1998	No treatment	Membrane sweeping			27	99	36	99	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Bounyasong 2000	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)			9	83	10	83	NA	NA	NA	NA
Brennand 1997	Placebo	Relaxin			2	23	15	73	NA	NA	NA	NA
Buchanan 1984	Placebo	Vaginal PGE2 pessary (normal release)			2	35	1	38	NA	NA	NA	NA
Cahill 1988	Vaginal PGE2 (tablet)	Laminaria			5	22	5	20	NA	NA	NA	NA
Caliskan 2005	Vaginal misoprostol (≥50mcg)	Buccal/sublingual misoprostol			1	80	2	80	NA	NA	NA	NA
Cammu 1998	No treatment	Membrane sweeping			18	138	23	140	NA	NA	NA	NA
Campbell 1984	Placebo	Vaginal PGE2 pessary (normal release)			14	95	13	104	NA	NA	NA	NA
Cardozo 1986	No treatment	Vaginal PGE2 pessary (normal release)			49	207	35	195	NA	NA	NA	NA
Carlan 2001	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)			66	501	56	503	NA	NA	NA	NA
Carlan 2002	Vaginal misoprostol (≥50mcg)	Buccal/sublingual misoprostol			9	79	3	79	NA	NA	NA	NA
Chang 1997	Vaginal PGE2 (tablet)	Vaginal misoprostol (≥50mcg)			3	30	2	30	NA	NA	NA	NA
Chua 1988	Vaginal PGE2 (tablet)	IV oxytocin plus amniotomy			4	40	4	40	NA	NA	NA	NA
Chua 1997	Intracervical PGE2	Laminaria			13	95	14	90	NA	NA	NA	NA
Chuck 1995	Intracervical PGE2	Vaginal misoprostol (≥50mcg)			3	50	1	49	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Chung 2003	Vaginal misoprostol (<50mcg)	Foley catheter			3	49	7	54	NA	NA	NA	NA
Chyu 1997	Vaginal PGE2 pessary (slow release)	Intracervical PGE2			10	37	6	36	NA	NA	NA	NA
Colon 2005	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)			7	111	4	93	NA	NA	NA	NA
Crane 1997	No treatment	Membrane sweeping			12	74	15	76	NA	NA	NA	NA
Cromi 2011	Vaginal PGE2 pessary (slow release)	Foley catheter			7	132	9	265	NA	NA	NA	NA
Cromi 2012	Vaginal PGE2 pessary (slow release)	Double balloon/Cook's catheter			1	103	6	105	NA	NA	NA	NA
Dällenbach 2003	Vaginal PGE2 (gel)	Oral misoprostol tablet (<50mcg)			27	100	20	100	NA	NA	NA	NA
Dalui 2005	Intracervical PGE2	Foley catheter			10	50	4	50	NA	NA	NA	NA
Danielian 1999	Vaginal PGE2 (gel)	Vaginal misoprostol (≥50mcg)			18	106	20	105	NA	NA	NA	NA
Davey 1979	Vaginal PGE2 (gel)	Oral prostaglandins			2	17	2	16	NA	NA	NA	NA
De Bonrosto Torralba 2019	Vaginal PGE2 pessary (slow release)	Vaginal misoprostol (<50mcg)			28	99	37	99	NA	NA	NA	NA
De la Torre 2001	Vaginal misoprostol (≥50mcg)	IV oxytocin			25	168	23	192	NA	NA	NA	NA
De Miranda 2006	No treatment	Membrane sweeping			53	367	55	375	NA	NA	NA	NA
Denguezli 2007	Intracervical PGE2	Vaginal misoprostol (≥50mcg)			3	65	4	65	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Deo 2012	Vaginal PGE2 (gel)	Vaginal misoprostol (<50mcg)	Foley catheter		3	52	6	54	1	52	NA	NA
Deshmukh 2011	Intracervical PGE2	Foley catheter			6	200	8	200	NA	NA	NA	NA
Deshmukh 2013	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)			10	100	6	100	NA	NA	NA	NA
Doany 1997	Placebo	Vaginal PGE2 (gel)	Membrane sweeping		1	28	1	37	9	50	NA	NA
Dodd 2006	Vaginal PGE2 (gel)	Titrated (low dose) oral misoprostol solution			63	376	65	365	NA	NA	NA	NA
Dogra 2019	No treatment	IV oxytocin			5	25	4	25	NA	NA	NA	NA
Dulger 2018	Placebo	Nitric oxide			0	34	1	36	NA	NA	NA	NA
Egarter 1989	Vaginal PGE2 (gel)	IV oxytocin			3	49	2	50	NA	NA	NA	NA
Elhassan 2004	Vaginal PGE2 (tablet)	Vaginal misoprostol (≥50mcg)			8	60	6	60	NA	NA	NA	NA
Elhassan 2005a	Vaginal misoprostol (≥50mcg)	IV oxytocin			6	70	12	70	NA	NA	NA	NA
Elhassan 2005b	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)			2	31	1	32	NA	NA	NA	NA
El-Mardi 1991	Vaginal PGE2 (tablet)	Vaginal PGE2 pessary (normal release)			10	100	9	100	NA	NA	NA	NA
El-Shawarby 2006	Vaginal PGE2 (gel)	Vaginal PGE2 pessary (slow release)			10	38	4	34	NA	NA	NA	NA
El-Sherbiny 2001	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)			9	93	10	92	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
El-Torkey 1992	No treatment	Membrane sweeping			3	32	2	33	NA	NA	NA	NA
Eroglu 2007	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)			5	73	4	74	NA	NA	NA	NA
Escudero 1997	Vaginal misoprostol (≥50mcg)	IV oxytocin			2	53	2	63	NA	NA	NA	NA
Ezechukwu 2015	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)			1	70	0	70	NA	NA	NA	NA
Farah 1997	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)			50	192	59	207	NA	NA	NA	NA
Fisher 2001	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)			6	64	8	62	NA	NA	NA	NA
Fletcher 1993	Placebo	Vaginal misoprostol (≥50mcg)			1	21	1	24	NA	NA	NA	NA
Fletcher 1994	Vaginal PGE2 (tablet)	Vaginal misoprostol (≥50mcg)			0	31	4	32	NA	NA	NA	NA
Frydman 1991	Placebo	Mifepristone			17	60	20	60	NA	NA	NA	NA
Gagnon-Gervais 2012	IV oxytocin	IV oxytocin plus amniotomy			9	72	9	71	NA	NA	NA	NA
Gaudet 2008	Placebo	Acupuncture			2	7	2	9	NA	NA	NA	NA
Giocalone 1998	Placebo	Mifepristone			6	42	9	41	NA	NA	NA	NA
Gilad 2018	Placebo	Castor oil			5	43	2	38	NA	NA	NA	NA
Girija 2009	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)			2	50	2	50	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Ar m 1 eve nt	Ar m 1 tota l	Ar m 2 eve nt	Ar m 2 tota l	Ar m 3 eve nt	Ar m 3 tota l	Ar m 4 eve nt	Ar m 4 tota l
Girija 2011	Intracervical PGE2	Vaginal misoprostol (<50mcg)			12	161	11	159	NA	NA	NA	NA
Greer 1989	Vaginal PGE2 (tablet)	Extra-amniotic prostaglandin			8	25	8	25	NA	NA	NA	NA
Gregson 2005	Vaginal PGE2 (gel)	Vaginal misoprostol (<50mcg)			26	129	29	139	NA	NA	NA	NA
Gregson 2015	Placebo	Acupuncture			13	60	17	70	NA	NA	NA	NA
Gribel 2011	Vaginal misoprostol (<50mcg)	Acupuncture			1	32	2	35	NA	NA	NA	NA
Gupta 1998	No treatment	Membrane sweeping			9	50	13	50	NA	NA	NA	NA
Gupta 2006	Intracervical PGE2	Vaginal misoprostol (<50mcg)			6	100	2	100	NA	NA	NA	NA
Hall 2002	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)			3	48	7	59	NA	NA	NA	NA
Haugland 2012	Foley catheter	Double balloon/Cook's catheter			20	90	24	88	NA	NA	NA	NA
Heden 1991	No treatment	IV oxytocin plus amniotomy			20	129	3	109	NA	NA	NA	NA
Hemlin 1998	Intracervical PGE2	Foley catheter + EASI			3	42	1	43	NA	NA	NA	NA
Henry 2013	Vaginal PGE2 (gel)	Foley catheter			11	51	18	50	NA	NA	NA	NA
Herabutya 1988	Intracervical PGE2	Oral prostaglandins			4	25	5	25	NA	NA	NA	NA
Hofmeyr 2001	Vaginal PGE2 (gel)	Titrated (low dose) oral misoprostol solution	Foley catheter		28	347	24	345	4	174	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Hokkila 2019	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)			27	133	18	135	NA	NA	NA	NA
Hosli 2008	Vaginal PGE2 (gel)	Vaginal misoprostol (≥50mcg)			13	55	5	52	NA	NA	NA	NA
Irion 1998	Vaginal PGE2 (gel)	Intracervical PGE2			32	125	24	122	NA	NA	NA	NA
Iskander 1978	Extra-amniotic prostaglandins	IV prostaglandin			1	20	2	20	NA	NA	NA	NA
Jackson 1994	Vaginal PGE2 (gel)	IV oxytocin			15	83	16	75	NA	NA	NA	NA
Jindal 2019	Vaginal PGE2 (gel)	Mifepristone			3	44	2	46	NA	NA	NA	NA
Johnson 1985	Vaginal PGE2 (gel)	Laminaria			21	40	15	40	NA	NA	NA	NA
Jozwiak 2011	Vaginal PGE2 (gel)	Foley catheter			54	408	45	411	NA	NA	NA	NA
Jozwiak 2013	Vaginal PGE2 pessary (slow release)	Foley catheter			20	119	13	107	NA	NA	NA	NA
Jozwiak 2014	Vaginal misoprostol (<50mcg)	Foley catheter			18	64	8	56	NA	NA	NA	NA
Kadanali 1996	Intracervical PGE2	Vaginal misoprostol (≥50mcg)			5	112	4	112	NA	NA	NA	NA
Kalkat 2008	Vaginal PGE2 (gel)	Vaginal PGE2 pessary (slow release)			9	60	10	60	NA	NA	NA	NA
Kandil 2012	Vaginal misoprostol (<50mcg)	Foley catheter			2	50	3	50	NA	NA	NA	NA
Kashanian 2020	Titrated (low dose) oral misoprostol solution	IV oxytocin			5	40	5	40	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Keirse 1995	Vaginal PGE2 (gel)	Intracervical PGE2			17	140	16	140	NA	NA	NA	NA
Kennedy 1978	Intracervical PGE2	IV oxytocin plus amniotomy			6	30	10	30	NA	NA	NA	NA
Kennedy 1982	Vaginal PGE2 (tablet)	IV oxytocin plus amniotomy			4	50	7	50	NA	NA	NA	NA
Khatib 2019	Vaginal PGE2 pessary (slow release)	Double balloon/Cook's catheter			1	21	2	21	NA	NA	NA	NA
Kim 2000	Vaginal PGE2 (tablet)	Vaginal misoprostol (≥ 50 mcg)			21	74	12	39	NA	NA	NA	NA
Koc 2013	Vaginal PGE2 pessary (slow release)	IV oxytocin			5	89	3	79	NA	NA	NA	NA
Kolderup 1999	Intracervical PGE2	Vaginal misoprostol (≥ 50 mcg)			9	78	16	81	NA	NA	NA	NA
Kovavisarac h 1997	Vaginal PGE2 (tablet)	Vaginal misoprostol (≥ 50 mcg)			3	30	2	30	NA	NA	NA	NA
Kovavisarac h 1998	Vaginal PGE2 (tablet)	Vaginal misoprostol (≥ 50 mcg)			8	40	3	40	NA	NA	NA	NA
Krishnamurthy 2015	Placebo	Nitric oxide			1	50	4	50	NA	NA	NA	NA
Kulshreshtha 2007	Intracervical PGE2	Vaginal misoprostol (≥ 50 mcg)			1	20	0	20	NA	NA	NA	NA
Lange 1984	Vaginal PGE2 pessary (normal release)	IV oxytocin			26	95	29	90	NA	NA	NA	NA
Larmon 2002	Placebo	Intracervical PGE2	Oestrogens		14	43	17	41	12	44	NA	NA
Lee 1997	Vaginal PGE2 (tablet)	Vaginal misoprostol (≥ 50 mcg)			2	25	3	25	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Legarth 1987	Vaginal PGE2 pessary (normal release)	IV oxytocin			13	49	7	49	NA	NA	NA	NA
Legarth 1988	Intracervical PGE2	Vaginal PGE2 pessary (normal release)			8	56	9	57	NA	NA	NA	NA
Lien 1998	Placebo	Intracervical PGE2			3	47	6	46	NA	NA	NA	NA
Liggins 1979	Placebo	Vaginal PGE2 pessary (normal release)			5	32	11	52	NA	NA	NA	NA
Lo 1994	Vaginal PGE2 (tablet)	IV oxytocin plus amniotomy			26	101	18	99	NA	NA	NA	NA
Lo 2006	IV oxytocin plus amniotomy	Buccal/sublingual misoprostol			4	25	5	25	NA	NA	NA	NA
Lokkegaard 2015	Vaginal PGE2 (tablet)	Double balloon/Cook's catheter			45	413	45	412	NA	NA	NA	NA
Lokugamage 2003	Vaginal PGE2 (gel)	Vaginal misoprostol (≥ 50 mcg)			24	95	36	96	NA	NA	NA	NA
Lopes 1991	Vaginal PGE2 (gel)	Intracervical PGE2			5	22	4	28	NA	NA	NA	NA
Lughmani 2009	Vaginal misoprostol (<50mcg)	IV oxytocin			4	25	6	23	NA	NA	NA	NA
Lykkesfeldt 1979	IV oxytocin plus amniotomy	Oral prostaglandins			23	92	11	69	NA	NA	NA	NA
Lyndrup 1989	Vaginal PGE2 pessary (normal release)	IV oxytocin			5	19	4	24	NA	NA	NA	NA
Lyndrup 1991	Intracervical PGE2	Vaginal PGE2 pessary (normal release)			10	64	9	61	NA	NA	NA	NA
Lyndrup 1994	Vaginal PGE2 pessary (normal release)	Foley catheter + EASI			16	50	11	59	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Macer 1984	Vaginal PGE2 pessary (normal release)	IV oxytocin			3	45	3	40	NA	NA	NA	NA
MacLennan 1979	Placebo	PGF2 gel			16	40	12	40	NA	NA	NA	NA
MacLennan 1980a	Placebo	Relaxin			15	30	14	30	NA	NA	NA	NA
MacLennan 1980b	Placebo	PGF2 gel			15	30	19	60	NA	NA	NA	NA
MacLennan 1989	Vaginal PGE2 (gel)	IV oxytocin plus amniotomy			31	165	45	155	NA	NA	NA	NA
Madaan 2014	Intracervical PGE2	Vaginal misoprostol (<50mcg)			1	50	0	50	NA	NA	NA	NA
Magann 1995	Intracervical PGE2	IV oxytocin	Oestrogens		2	33	2	33	2	33	NA	NA
Magann 1998b	No treatment	Intracervical PGE2	Membrane sweeping		5	35	3	35	4	35	NA	NA
Magann 1999	Vaginal PGE2 pessary (slow release)	Membrane sweeping			7	91	7	91	NA	NA	NA	NA
Mahacakri 2018	Vaginal misoprostol (<50mcg)	Titrated (low dose) oral misoprostol solution			0	15	1	14	NA	NA	NA	NA
Mahmood 1995	Vaginal PGE2 (gel)	Amniotomy			19	130	17	130	NA	NA	NA	NA
Martin 1989	No treatment	Laminaria			2	10	3	12	NA	NA	NA	NA
Mawire 1999	Foley catheter + EASI ^{^^}	Extra-amniotic prostaglandin			1	81	1	81	NA	NA	NA	NA
McColgin 1990b	No treatment	Membrane sweeping			4	48	2	51	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
McKenna 2004	Placebo	Vaginal misoprostol (<50mcg)			6	35	3	33	NA	NA	NA	NA
McLaren 1987	Vaginal PGE2 (tablet)	Vaginal PGE2 pessary (slow release)			0	12	1	12	NA	NA	NA	NA
Megalo 2004	Intracervical PGE2	Vaginal misoprostol (≥50mcg)			13	100	18	100	NA	NA	NA	NA
Mei-Dan 2012	Foley catheter + EASI	Double balloon/Cook's catheter			18	88	13	100	NA	NA	NA	NA
Mei-Dan 2014	Foley catheter + EASI	Double balloon/Cook's catheter + EASI			22	126	7	60	NA	NA	NA	NA
Meydanli 2003	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)			2	60	3	60	NA	NA	NA	NA
Misra 1994	Intracervical PGE2	IV oxytocin			3	136	6	127	NA	NA	NA	NA
Modlock 2010	Placebo	Acupuncture			8	58	8	60	NA	NA	NA	NA
Mundle 2018	Oral misoprostol tablet (<50mcg)	Foley catheter			2	302	3	300	NA	NA	NA	NA
Murphy 1980	Placebo	PGF2 gel			33	100	32	165	NA	NA	NA	NA
Murray 1995	Vaginal PGE2 (tablet)	Vaginal PGE2 (gel)			40	100	35	100	NA	NA	NA	NA
Murthy 2006	Intracervical PGE2	Vaginal misoprostol (<50mcg)			2	35	1	37	NA	NA	NA	NA
Naismith 1973	IV oxytocin	IV prostaglandin			10	20	14	20	NA	NA	NA	NA
Nassar 2006	Vaginal misoprostol (≥50mcg)	Buccal/sublingual misoprostol			12	85	5	85	NA	NA	NA	NA
Nicoll 2001	No treatment	Nitric oxide			3	12	7	24	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Nongkhlaw 2015	Intracervical PGE2	Vaginal misoprostol (<50mcg)			13	135	12	135	NA	NA	NA	NA
Nopdonrattakoon 2003	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)			1	53	3	53	NA	NA	NA	NA
Oboro 2005	No treatment	Vaginal misoprostol (<50mcg)			11	39	12	38	NA	NA	NA	NA
Omar 2013	No treatment	Sexual intercourse			46	576	52	574	NA	NA	NA	NA
Ophir 1992	Vaginal PGE2 (tablet)	Foley catheter			2	27	1	27	NA	NA	NA	NA
Orhue 1995	Vaginal PGE2 pessary (normal release)	IV oxytocin plus amniotomy	Foley catheter		4	34	5	30	6	30	NA	NA
Osman 2006	Vaginal PGE2 (gel)	Nitric oxide			60	198	61	197	NA	NA	NA	NA
Owolabi 2005	Vaginal misoprostol (≥50mcg)	Foley catheter			3	60	3	60	NA	NA	NA	NA
Paisarntantiwong 2005	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)			1	73	5	73	NA	NA	NA	NA
Papageorgiou 1992	Intracervical PGE2	IV oxytocin			7	83	9	82	NA	NA	NA	NA
Papanikolaou 2004	Vaginal PGE2 (tablet)	Vaginal misoprostol (≥50mcg)			20	83	28	83	NA	NA	NA	NA
Parazzini 1998	Vaginal PGE2 (gel)	IV oxytocin plus amniotomy			4	157	2	163	NA	NA	NA	NA
Patil 2005	Intracervical PGE2	Oral misoprostol tablet (≥50mcg)			6	95	9	95	NA	NA	NA	NA
Pennell 2009	Vaginal PGE2 (gel)	Foley catheter	Double balloon/Cook's catheter		28	113	25	110	23	107	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Pongsatha 2005	Vaginal misoprostol ($\geq 50\text{mcg}$)	Oral misoprostol tablet ($\geq 50\text{mcg}$)			12	84	11	82	NA	NA	NA	NA
Prager 2008	Vaginal PGE2 (gel)	Vaginal misoprostol ($< 50\text{mcg}$)	Foley catheter		31	191	33	199	29	198	NA	NA
Prasad 1989	Placebo	Vaginal PGE2 pessary (slow release)			7	36	10	33	NA	NA	NA	NA
Qazi 2019	Vaginal PGE2 (gel)	Vaginal misoprostol ($\geq 50\text{mcg}$)			11	58	7	58	NA	NA	NA	NA
Quinn 1981	Foley catheter + EASI ^{^^}	Extra-amniotic prostaglandin			7	10	6	15	NA	NA	NA	NA
Rabl 2001	No treatment	Acupuncture			3	20	3	25	NA	NA	NA	NA
Rabl 2002	Vaginal PGE2 (tablet)	Vaginal PGE2 pessary (slow release)			17	100	9	100	NA	NA	NA	NA
Rahman 2013	Vaginal misoprostol ($< 50\text{mcg}$)	Oral misoprostol tablet ($\geq 50\text{mcg}$)			14	110	12	110	NA	NA	NA	NA
Rayburn 1988	Placebo	Vaginal PGE2 (gel)			7	63	3	55	NA	NA	NA	NA
Reinhard 2014	Vaginal PGE2 (tablet)	Intracervical PGE2			2	19	2	20	NA	NA	NA	NA
Rezaie 2016	Vaginal misoprostol ($< 50\text{mcg}$)	Oral misoprostol tablet ($\geq 50\text{mcg}$)			2	60	8	120	NA	NA	NA	NA
Rouzi 2014	Vaginal PGE2 pessary (slow release)	Titrated (low dose) oral misoprostol solution			2	80	1	80	NA	NA	NA	NA
Rouzi 2017	Oral misoprostol tablet ($< 50\text{mcg}$)	Titrated (low dose) oral misoprostol solution			5	73	2	73	NA	NA	NA	NA
Rowlands 2001	Vaginal PGE2 pessary (normal release)	Vaginal misoprostol ($\geq 50\text{mcg}$)			23	63	19	62	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Rozenberg 2001	Vaginal PGE2 (gel)	Vaginal misoprostol (≥50mcg)			56	185	47	184	NA	NA	NA	NA
Saad 2019	Foley catheter	Laminaria			6	209	10	208	NA	NA	NA	NA
Saggaf 2001	Vaginal PGE2 (gel)	Vaginal misoprostol (≥50mcg)			3	27	0	30	NA	NA	NA	NA
Sahu 2004	Intracervical PGE2	Vaginal misoprostol (≥50mcg)			2	25	1	25	NA	NA	NA	NA
Saleh 1975	Amniotomy	IV oxytocin plus amniotomy			25	50	25	50	NA	NA	NA	NA
Salim 2011	Foley catheter	Double balloon/Cook's catheter			6	145	12	148	NA	NA	NA	NA
Sanchez-Ramos 1992	Vaginal PGE2 (gel)	Laminaria			10	38	9	36	NA	NA	NA	NA
Sanchez-Ramos 1998	Vaginal PGE2 pessary (slow release)	Vaginal misoprostol (≥50mcg)			18	115	21	108	NA	NA	NA	NA
Schmitz 2014	Placebo	Nitric oxide			221	684	211	678	NA	NA	NA	NA
Secher 1981	IV oxytocin	Oral prostaglandins			20	119	10	125	NA	NA	NA	NA
Seeras 1995	Vaginal PGE2 (gel)	Intracervical PGE2			9	31	14	37	NA	NA	NA	NA
Selo-Ojeme 2009	Amniotomy	IV oxytocin plus amniotomy			10	62	12	61	NA	NA	NA	NA
Shaheen 2013	Vaginal PGE2 (gel)	Buccal/sublingual misoprostol			4	53	5	53	NA	NA	NA	NA
Sharma 2005	Intracervical PGE2	Vaginal misoprostol (≥50mcg)	Nitric oxide		1	21	1	23	1	21	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Shechter-Maor 2015	Vaginal PGE2 pessary (slow release)	Double balloon/Cook's catheter			1	26	1	26	NA	NA	NA	NA
Shepherd 1976	Placebo	Extra-amniotic prostaglandin			7	15	8	15	NA	NA	NA	NA
Sherman 2001	Foley catheter + EASI ^^	Extra-amniotic prostaglandin			5	58	5	58	NA	NA	NA	NA
Shetty 2001	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)			30	123	28	122	NA	NA	NA	NA
Shetty 2002a	Oral misoprostol tablet (≥50mcg)	Buccal/sublingual misoprostol			7	50	11	50	NA	NA	NA	NA
Shetty 2002b	Oral misoprostol tablet (≥50mcg)	Buccal/sublingual misoprostol			28	124	34	125	NA	NA	NA	NA
Shetty 2003	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)			7	50	18	51	NA	NA	NA	NA
Shetty 2004	Vaginal PGE2 (tablet)	Oral misoprostol tablet (≥50mcg)			26	100	29	100	NA	NA	NA	NA
Silva-Cruz 1988	Vaginal PGE2 (gel)	IV oxytocin			11	25	2	25	NA	NA	NA	NA
Sitthiwattana wong 1999	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)			15	66	14	65	NA	NA	NA	NA
Smith 2008	Placebo	Acupuncture			25	180	27	180	NA	NA	NA	NA
Somirathne 2017	Oral misoprostol tablet (≥50mcg)	Foley catheter			1	32	0	47	NA	NA	NA	NA
Souza 2013	Vaginal misoprostol (<50mcg)	Titrated (low dose) oral misoprostol solution			2	100	2	100	NA	NA	NA	NA
Srisomboon 1996	Placebo	Vaginal misoprostol (≥50mcg)			9	30	10	32	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Srisomboon 1998	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)			5	24	3	24	NA	NA	NA	NA
St Onge 1995	Intracervical PGE2	Foley catheter			8	28	13	34	NA	NA	NA	NA
Steer 1976	IV oxytocin	IV oxytocin plus amniotomy			2	8	4	12	NA	NA	NA	NA
Stenlund 1999	Placebo	Mifepristone			1	12	8	24	NA	NA	NA	NA
Stewart 1983	Vaginal PGE2 (tablet)	Extra-amniotic prostaglandin			12	30	11	30	NA	NA	NA	NA
Suffecool 2014	Vaginal PGE2 pessary (slow release)	Double balloon/Cook's catheter			4	31	2	31	NA	NA	NA	NA
Sultana 2006	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)			1	50	2	50	NA	NA	NA	NA
Tabowei 2003	Vaginal misoprostol (<50mcg)	Foley catheter			13	60	15	61	NA	NA	NA	NA
Taher 2011	Vaginal PGE2 (tablet)	Vaginal PGE2 (gel)			20	83	13	82	NA	NA	NA	NA
Tan 2013	Amniotomy	IV oxytocin plus amniotomy			2	101	2	105	NA	NA	NA	NA
Tannirandorn 1999	No treatment	Membrane sweeping			9	39	4	41	NA	NA	NA	NA
Ten Eikelder 2016	Oral misoprostol tablet (≥50mcg)	Foley catheter			125	924	88	921	NA	NA	NA	NA
Tessier 1997	Vaginal PGE2 (gel)	Oral misoprostol tablet (≥50mcg)			24	132	23	135	NA	NA	NA	NA
Thomas 1986	PGF2 gel	Foley catheter			3	25	4	32	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Tomlinson 2001	Vaginal PGE2 (gel)	Vaginal PGE2 pessary (slow release)			7	34	5	35	NA	NA	NA	NA
Topozada 1997	Vaginal misoprostol (≥ 50 mcg)	Oral misoprostol tablet (≥ 50 mcg)			4	20	2	20	NA	NA	NA	NA
Triglia 2010	Vaginal PGE2 (gel)	Vaginal PGE2 pessary (slow release)			10	65	2	65	NA	NA	NA	NA
Trofatter 1985	Placebo	Intracervical PGE2			8	29	6	30	NA	NA	NA	NA
Troostwijk 1992	Placebo	Intracervical PGE2			3	68	3	71	NA	NA	NA	NA
Tylleskar 1979	No treatment	IV oxytocin plus amniotomy			2	41	1	43	NA	NA	NA	NA
Ugwu 2013	Vaginal misoprostol (< 50 mcg)	Foley catheter			1	45	2	45	NA	NA	NA	NA
Ulmsten 1979	Intracervical PGE2	IV oxytocin			1	50	3	50	NA	NA	NA	NA
Ulmsten 1985	Placebo	Intracervical PGE2	Vaginal PGE2 pessary (normal release)		6	20	3	19	4	19	NA	NA
Valentine 1977	No treatment	IV oxytocin	Oral prostaglandins		4	15	7	15	11	30	NA	NA
Varaklis 1995	Intracervical PGE2	Vaginal misoprostol (< 50 mcg)			11	33	6	36	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Veena 2016	Intracervical PGE2	Buccal/sublingual misoprostol			6	95	7	95	NA	NA	NA	NA
Wang 2016	Vaginal PGE2 pessary (normal release)	Titrated (low dose) oral misoprostol solution			29	199	22	212	NA	NA	NA	NA
Wieland 1999	Vaginal PGE2 pessary (slow release)	Intracervical PGE2			4	31	12	35	NA	NA	NA	NA
Wilson 1978	Vaginal PGE2 (tablet)	IV oxytocin	Extra-amniotic prostaglandins	Oral prostaglandins	3	15	2	15	4	15	3	15
Wing 1995a	Intracervical PGE2	Vaginal misoprostol (≥ 50 mcg)			8	67	7	68	NA	NA	NA	NA
Wing 1995b	Intracervical PGE2	Vaginal misoprostol (< 50 mcg)			19	137	9	138	NA	NA	NA	NA
Wing 2004	Oral misoprostol tablet (≥ 50 mcg)	IV oxytocin			5	110	3	88	NA	NA	NA	NA
Wing 2013	Vaginal PGE2 pessary (slow release)	Sustained release misoprostol insert			35	680	43	678	NA	NA	NA	NA
Wingerup 1978	Placebo	Intracervical PGE2			1	10	0	10	NA	NA	NA	NA
Wiriyasirivaj 1996	No treatment	Membrane sweeping			11	59	10	61	NA	NA	NA	NA
Witter 1992	Placebo	Vaginal PGE2 pessary (slow release)			9	33	6	39	NA	NA	NA	NA
Wong 2002	No treatment	Membrane sweeping			13	60	12	60	NA	NA	NA	NA
Yelikar 2015	Placebo	Mifepristone			5	50	2	50	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Ar m 1 eve nt	Ar m 1 tota l	Ar m 2 eve nt	Ar m 2 tota l	Ar m 3 eve nt	Ar m 3 tota l	Ar m 4 eve nt	Ar m 4 tota l
Young 2020	Vaginal PGE2 (gel)	Vaginal misoprostol (< 50mcg)	Oral misoprostol tablet (≥50mcg)		15	172	24	172	24	167	NA	NA
Yuen 1996	Intracervical PGE2	Vaginal PGE2 pessary (normal release)	Double balloon/Cook's catheter		5	39	10	39	3	36	NA	NA
Zanini 1990	Vaginal PGE2 (gel)	Intracervical PGE2			1	48	2	52	NA	NA	NA	NA
Zeteroglu 2004	Vaginal misoprostol (≥50mcg)	IV oxytocin			1	52	2	52	NA	NA	NA	NA
Zeteroglu 2006a	Vaginal misoprostol (≥50mcg)	IV oxytocin			0	32	1	32	NA	NA	NA	NA
Zeteroglu 2006b	Vaginal misoprostol (≥50mcg)	IV oxytocin			0	50	2	50	NA	NA	NA	NA
Zhang 2015	Placebo	Vaginal misoprostol (<50mcg)			1	50	1	175	NA	NA	NA	NA
Zvandasara 2008	Vaginal misoprostol (≥50mcg)	Titrated (low dose) oral misoprostol solution			3	65	3	69	NA	NA	NA	NA

1 NA: not available; EASI: extra-amniotic saline infusion

2 ^^ used Foley in both interventions

1 D10 - NICU admission

2 Table 11: Evidence table for NICU admission

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Aalami-Harandi 2013	Titrated (low dose) oral misoprostol solution	IV oxytocin			1	128	5	128	NA	NA	NA	NA
Abdelaziz 2018	Vaginal PGE2 (tablet)	Vaginal PGE2 pessary (slow release)			6	100	3	100	NA	NA	NA	NA
Abedi-Asi 2007	Vaginal misoprostol (≥ 50 mcg)	IV oxytocin			9	60	12	60	NA	NA	NA	NA
Abotorabi 2019	Placebo	Nitric oxide			0	30	0	28	NA	NA	NA	NA
Adair 1998	Vaginal misoprostol (≥ 50 mcg)	Oral misoprostol tablet (≥ 50 mcg)			11	85	17	93	NA	NA	NA	NA
Aduloju 2016	Vaginal misoprostol (< 50 mcg)	Foley catheter			5	70	3	70	NA	NA	NA	NA
Aduloju 2019	Oral misoprostol tablet (< 50 mcg)	Titrated (low dose) oral misoprostol solution			6	75	7	75	NA	NA	NA	NA
Agarwal 2012	Placebo	Nitric oxide			14	100	5	100	NA	NA	NA	NA
Agarwal 2014	Intracervical PGE2	Nitric oxide			4	100	0	100	NA	NA	NA	NA
Ajori 2013	Placebo	Acupuncture			0	37	0	38	NA	NA	NA	NA
Akay 2012	Vaginal PGE2 pessary (slow release)	IV oxytocin			3	72	0	72	NA	NA	NA	NA
Al-Taani 2004	Vaginal PGE2 (tablet)	Foley catheter			5	75	6	72	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Andersen 2013	No treatment	Membrane sweeping	Acupuncture		5	100	3	103	1	104	NA	NA
Asher 2009	No treatment	Placebo	Acupuncture		1	30	0	29	0	30	NA	NA
Ayaz 2010	Vaginal PGE2 (tablet)	Vaginal misoprostol (≥ 50 mcg)			4	60	6	60	NA	NA	NA	NA
Azubuikwe 2015	Vaginal misoprostol (< 50 mcg)	Vaginal misoprostol (≥ 50 mcg)			2	40	8	43	NA	NA	NA	NA
Balci 2010	Vaginal misoprostol (≥ 50 mcg)	IV oxytocin			2	50	2	50	NA	NA	NA	NA
Barda 2018	Vaginal PGE2 (tablet)	Foley catheter			3	150	4	150	NA	NA	NA	NA
Bartha 2000	Intracervical PGE2	Oral misoprostol tablet (≥ 50 mcg)			11	100	12	100	NA	NA	NA	NA
Bartusevicius 2006	Vaginal misoprostol (< 50 mcg)	Buccal/sublingual misoprostol			2	70	2	70	NA	NA	NA	NA
Beigi 2003	Placebo	Oral misoprostol tablet (≥ 50 mcg)			2	78	2	78	NA	NA	NA	NA
Bollapragada 2009	Placebo	Nitric oxide			16	173	18	177	NA	NA	NA	NA
Boulvain 1998	No treatment	Membrane sweeping			6	99	6	99	NA	NA	NA	NA
Bullarbo 2007	Placebo	Nitric oxide			9	100	13	100	NA	NA	NA	NA
Caliskan 2005	Vaginal misoprostol (≥ 50 mcg)	Buccal/sublingual misoprostol			2	80	3	80	NA	NA	NA	NA
Cardozo 1986	No treatment	Vaginal PGE2 pessary (normal release)			3	207	6	195	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Carlan 2001	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)			37	501	43	503	NA	NA	NA	NA
Carlan 2002	Vaginal misoprostol (≥50mcg)	Buccal/sublingual misoprostol			10	79	11	79	NA	NA	NA	NA
Chanrachakul 2000a	Vaginal PGE2 (tablet)	Nitric oxide			1	56	0	54	NA	NA	NA	NA
Chanrachakul 2002	Vaginal misoprostol (≥50mcg)	Nitric oxide			3	52	0	55	NA	NA	NA	NA
Chanrachakul 2003	No treatment	IV oxytocin plus amniotomy			0	125	1	124	NA	NA	NA	NA
Charoenkul 2000	Vaginal PGE2 (tablet)	Vaginal misoprostol (≥50mcg)			1	71	0	72	NA	NA	NA	NA
Chavakula 2015	Vaginal misoprostol (<50mcg)	Foley catheter			1	46	4	54	NA	NA	NA	NA
Cheng 2008	Vaginal misoprostol (<50mcg)	Titrated (low dose) oral misoprostol solution			6	106	0	101	NA	NA	NA	NA
Chitrakar 2012	Intracervical PGE2	Vaginal misoprostol (<50mcg)			22	100	22	100	NA	NA	NA	NA
Chua 1997	Intracervical PGE2	Laminaria			3	95	7	90	NA	NA	NA	NA
Chuck 1995	Intracervical PGE2	Vaginal misoprostol (≥50mcg)			0	50	0	49	NA	NA	NA	NA
Chung 2003	Vaginal misoprostol (<50mcg)	Foley catheter			5	49	5	54	NA	NA	NA	NA
Colon 2005	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)			11	111	11	93	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Cromi 2011	Vaginal PGE2 pessary (slow release)	Foley catheter			7	132	11	265	NA	NA	NA	NA
Cromi 2012	Vaginal PGE2 pessary (slow release)	Double balloon/Cook's catheter			5	103	8	105	NA	NA	NA	NA
Dällenbach 2003	Vaginal PGE2 (gel)	Oral misoprostol tablet (<50mcg)			10	100	7	100	NA	NA	NA	NA
Danielian 1999	Vaginal PGE2 (gel)	Vaginal misoprostol (≥50mcg)			6	106	8	105	NA	NA	NA	NA
Dare 2002	No treatment	Membrane sweeping			11	68	9	69	NA	NA	NA	NA
De Bonrostro Torralba 2019	Vaginal PGE2 pessary (slow release)	Vaginal misoprostol (<50mcg)			2	99	2	99	NA	NA	NA	NA
De la Torre 2001	Vaginal misoprostol (≥50mcg)	IV oxytocin			15	168	13	192	NA	NA	NA	NA
De Miranda 2006	No treatment	Membrane sweeping			2	367	2	375	NA	NA	NA	NA
Denguezli 2007	Intracervical PGE2	Vaginal misoprostol (≥50mcg)			6	65	4	65	NA	NA	NA	NA
Deshmukh 2011	Intracervical PGE2	Foley catheter			42	200	37	200	NA	NA	NA	NA
Deshmukh 2013	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)			28	100	30	100	NA	NA	NA	NA
Doany 1997	Placebo	Vaginal PGE2 (gel)	Membrane sweeping		0	28	2	37	1	50	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Dodd 2006	Vaginal PGE2 (gel)	Titrated (low dose) oral misoprostol solution			2	376	5	365	NA	NA	NA	NA
Dogra 2019	No treatment	IV oxytocin			0	25	0	25	NA	NA	NA	NA
Edwards 2014	Vaginal PGE2 pessary (slow release)	Foley catheter			34	191	30	195	NA	NA	NA	NA
Elhassan 2004	Vaginal PGE2 (tablet)	Vaginal misoprostol (≥ 50 mcg)			6	60	6	60	NA	NA	NA	NA
Elhassan 2005b	Vaginal misoprostol (< 50 mcg)	Vaginal misoprostol (≥ 50 mcg)			3	31	2	32	NA	NA	NA	NA
El-Sherbiny 2001	Vaginal misoprostol (< 50 mcg)	Vaginal misoprostol (≥ 50 mcg)			11	93	13	92	NA	NA	NA	NA
Eroglu 2007	Vaginal misoprostol (< 50 mcg)	Vaginal misoprostol (≥ 50 mcg)			0	73	0	74	NA	NA	NA	NA
Ezechukwu 2015	Vaginal misoprostol (≥ 50 mcg)	Oral misoprostol tablet (≥ 50 mcg)			7	70	8	70	NA	NA	NA	NA
Farah 1997	Vaginal misoprostol (< 50 mcg)	Vaginal misoprostol (≥ 50 mcg)			11	192	23	207	NA	NA	NA	NA
Feitosa 2006	Vaginal misoprostol (< 50 mcg)	Buccal/sublingual misoprostol			1	75	1	75	NA	NA	NA	NA
Ferguson 2002	Vaginal misoprostol (≥ 50 mcg)	IV oxytocin			10	53	7	53	NA	NA	NA	NA
Fisher 2001	Vaginal misoprostol (≥ 50 mcg)	Oral misoprostol tablet (≥ 50 mcg)			9	64	9	62	NA	NA	NA	NA
Fonseca 2008	Vaginal misoprostol (< 50 mcg)	IV oxytocin			5	164	3	163	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Frass 2011	No treatment	Vaginal misoprostol (≥ 50 mcg)			3	57	5	56	NA	NA	NA	NA
Gaikwad 2014	Intracervical PGE2	Mifepristone			7	50	3	50	NA	NA	NA	NA
Garry 2003	Vaginal PGE2 pessary (slow release)	Vaginal misoprostol (≥ 50 mcg)			6	89	12	97	NA	NA	NA	NA
Gattas 2020	Vaginal misoprostol (<50 mcg)	Buccal/sublingual misoprostol			1	100	1	98	NA	NA	NA	NA
Gaudet 2008	Placebo	Acupuncture			0	7	3	9	NA	NA	NA	NA
Gelisen 2005	No treatment	Vaginal misoprostol (≥ 50 mcg)	IV oxytocin	Foley catheter	15	300	5	100	5	100	3	100
Ghanaie 2013	Intracervical PGE2	Foley catheter			11	118	10	121	NA	NA	NA	NA
Girija 2009	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥ 50 mcg)			7	50	8	50	NA	NA	NA	NA
Girija 2011	Intracervical PGE2	Vaginal misoprostol (<50mcg)			1	161	0	159	NA	NA	NA	NA
Gregson 2005	Vaginal PGE2 (gel)	Vaginal misoprostol (<50mcg)			2	129	1	139	NA	NA	NA	NA
Gregson 2015	Placebo	Acupuncture			0	60	0	70	NA	NA	NA	NA
Greybush 2001	Vaginal misoprostol (<50mcg)	Foley catheter			10	65	9	71	NA	NA	NA	NA
Guha 2015	Vaginal misoprostol (≥ 50 mcg)	Nitric oxide			19	100	4	100	NA	NA	NA	NA
Gupta 1998	No treatment	Membrane sweeping			2	50	0	50	NA	NA	NA	NA
Gupta 2006	Intracervical PGE2	Vaginal misoprostol (<50mcg)			10	100	14	100	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Haas 2019	Vaginal misoprostol (<50 mcg)	Buccal/sublingual misoprostol			20	152	21	148	NA	NA	NA	NA
Habib 2008	Placebo	Nitric oxide			1	51	0	51	NA	NA	NA	NA
Hall 2002	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)			3	48	0	59	NA	NA	NA	NA
Has 2002	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)			3	58	4	56	NA	NA	NA	NA
Heden 1991	No treatment	IV oxytocin plus amniotomy			8	129	10	109	NA	NA	NA	NA
Henry 2013	Vaginal PGE2 (gel)	Foley catheter			9	51	8	50	NA	NA	NA	NA
Herabutya 1992	No treatment	Intracervical PGE2			4	51	1	57	NA	NA	NA	NA
Hill 2008	No treatment	Membrane sweeping			2	138	3	162	NA	NA	NA	NA
Hofmeyr 2001	Vaginal PGE2 (gel)	Titrated (low dose) oral misoprostol solution	Foley catheter		14	346	9	345	2	171	NA	NA
Hokkila 2019	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)			4	133	4	135	NA	NA	NA	NA
Hoppe 2016	Foley catheter	Double balloon/Cook's catheter			6	48	4	50	NA	NA	NA	NA
Hosli 2008	Vaginal PGE2 (gel)	Vaginal misoprostol (≥50mcg)			6	55	0	52	NA	NA	NA	NA
Incerpi 2001	Placebo	Vaginal misoprostol (<50mcg)			20	63	18	57	NA	NA	NA	NA
Jozwiak 2011	Vaginal PGE2 (gel)	Foley catheter			4	408	3	411	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Jozwiak 2013	Vaginal PGE2 pessary (slow release)	Foley catheter			8	119	4	107	NA	NA	NA	NA
Jozwiak 2014	Vaginal misoprostol (<50mcg)	Foley catheter			1	64	2	56	NA	NA	NA	NA
Kandil 2012	Vaginal misoprostol (<50mcg)	Foley catheter			0	50	0	50	NA	NA	NA	NA
Keirse 1995	Vaginal PGE2 (gel)	Intracervical PGE2			27	140	25	142	NA	NA	NA	NA
Khazardoost 2011	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)			4	30	5	30	NA	NA	NA	NA
Khoury 2001	Vaginal PGE2 pessary (slow release)	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)		0	39	0	39	1	40	NA	NA
Kidanto 2007	Vaginal misoprostol (<50mcg)	IV oxytocin			17	71	32	71	NA	NA	NA	NA
Kipikasa 2005	Oral misoprostol tablet (<50mcg)	Oral misoprostol tablet (≥50mcg)			1	23	2	29	NA	NA	NA	NA
Koc 2013	Vaginal PGE2 pessary (slow release)	IV oxytocin			6	89	4	79	NA	NA	NA	NA
Kolderup 1999	Intracervical PGE2	Vaginal misoprostol (≥50mcg)			2	67	10	76	NA	NA	NA	NA
Krishnamurthy 2015	Placebo	Nitric oxide			3	50	1	50	NA	NA	NA	NA
Krithika 2008	Intracervical PGE2	Vaginal misoprostol (<50mcg)			6	50	6	50	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Kumar 2001	Intracervical PGE2	Vaginal misoprostol (<50mcg)			6	100	7	100	NA	NA	NA	NA
Langenegger 2005	Intracervical PGE2	Oral misoprostol tablet (≥50mcg)			0	95	0	96	NA	NA	NA	NA
Larmon 2002	Placebo	Intracervical PGE2	Oestrogens		1	43	1	41	1	44	NA	NA
Le Roux 2002	Vaginal PGE2 (gel)	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)		8	240	6	120	2	120	NA	NA
Levine 2016	Vaginal misoprostol (<50mcg)	Foley catheter			15	120	17	123	NA	NA	NA	NA
Lim 2018	Vaginal PGE2 (tablet)	Double balloon/Cook's catheter			2	52	0	31	NA	NA	NA	NA
Lo 2006	IV oxytocin plus amniotomy	Buccal/sublingual misoprostol			0	25	0	25	NA	NA	NA	NA
Lokkegaard 2015	Vaginal PGE2 (tablet)	Double balloon/Cook's catheter			73	413	56	412	NA	NA	NA	NA
Lokugamage 2003	Vaginal PGE2 (gel)	Vaginal misoprostol (≥50mcg)			4	95	11	96	NA	NA	NA	NA
Madaan 2014	Intracervical PGE2	Vaginal misoprostol (<50mcg)			3	50	2	50	NA	NA	NA	NA
Magann 1998a	No treatment	Membrane sweeping			2	32	2	33	NA	NA	NA	NA
Magann 1998b	No treatment	Intracervical PGE2	Membrane sweeping		0	35	3	35	2	35	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Magann 1999	Vaginal PGE2 pessary (slow release)	Membrane sweeping			5	91	1	91	NA	NA	NA	NA
Mahacakri 2018	Vaginal misoprostol (<50mcg)	Titrated (low dose) oral misoprostol solution			2	15	1	14	NA	NA	NA	NA
Mahmood 1995	Vaginal PGE2 (gel)	Amniotomy			6	130	7	130	NA	NA	NA	NA
Majoko 2002a	Vaginal misoprostol (≥50mcg)	Extra-amniotic prostaglandin			14	76	6	76	NA	NA	NA	NA
Majoko 2002b	Vaginal PGE2 pessary (normal release)	Vaginal misoprostol (≥50mcg)	Titrated (low dose) oral misoprostol solution	Extra-amniotic prostaglandins	8	75	19	128	16	127	6	76
Manandhar 2017	IV oxytocin	Mifepristone			0	34	0	34	NA	NA	NA	NA
Mawire 1999	Foley catheter + EASI ^^	Extra-amniotic prostaglandin			15	81	12	81	NA	NA	NA	NA
McKenna 1999	Placebo	Intracervical PGE2			2	31	1	30	NA	NA	NA	NA
McKenna 2004	Placebo	Vaginal misoprostol (<50mcg)			0	35	0	33	NA	NA	NA	NA
Megalo 2004	Intracervical PGE2	Vaginal misoprostol (≥50mcg)			4	100	10	100	NA	NA	NA	NA
Mehrotra 2010	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)			19	49	12	40	NA	NA	NA	NA
Meydanli 2003	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)			2	60	2	60	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Meyer 2002	Intracervical PGE2	Vaginal misoprostol (<50mcg)			5	42	4	42	NA	NA	NA	NA
Mollart 2016	No treatment	Acupuncture			5	22	3	22	NA	NA	NA	NA
Moodley 2003	Vaginal PGE2 (gel)	Vaginal misoprostol (<50mcg)	Titrated (low dose) oral misoprostol solution		29	193	21	100	12	103	NA	NA
Mundle 2018	Oral misoprostol tablet (<50mcg)	Foley catheter			28	302	19	298	NA	NA	NA	NA
Nanda 2007	Intracervical PGE2	Vaginal misoprostol (<50mcg)			0	50	0	50	NA	NA	NA	NA
Nassar 2006	Vaginal misoprostol (≥50mcg)	Buccal/sublingual misoprostol			3	85	3	85	NA	NA	NA	NA
Netta 2002	No treatment	Membrane sweeping			0	54	0	44	NA	NA	NA	NA
Nicoll 2001	No treatment	Nitric oxide			3	12	5	24	NA	NA	NA	NA
Nigam 2004	Oral misoprostol tablet (≥50mcg)	IV oxytocin			0	36	0	34	NA	NA	NA	NA
Nigam 2010	Vaginal misoprostol (<50mcg)	Vaginal misoprostol (≥50mcg)			0	60	0	60	NA	NA	NA	NA
Noor 2015	Vaginal misoprostol (<50mcg)	Foley catheter			8	60	6	44	NA	NA	NA	NA
Nunes 1999	Vaginal PGE2 (gel)	Vaginal misoprostol (≥50mcg)			0	94	0	95	NA	NA	NA	NA
Oboro 2005	No treatment	Vaginal misoprostol (<50mcg)			1	39	1	38	NA	NA	NA	NA
O'Brien 1995	Placebo	Vaginal PGE2 (gel)			5	50	1	50	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Omar 2013	No treatment	Sexual intercourse			12	576	5	574	NA	NA	NA	NA
Osman 2006	Vaginal PGE2 (gel)	Nitric oxide			14	198	13	197	NA	NA	NA	NA
Owolabi 2005	Vaginal misoprostol (≥50mcg)	Foley catheter			6	60	8	60	NA	NA	NA	NA
Ozkan 2009	Vaginal PGE2 pessary (slow release)	Vaginal misoprostol (≥50mcg)			3	56	2	56	NA	NA	NA	NA
Paisarntantiwong 2005	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)			0	73	0	73	NA	NA	NA	NA
Pandis 2001	Vaginal PGE2 (gel)	Vaginal misoprostol (≥50mcg)			3	225	6	210	NA	NA	NA	NA
Parazzini 1998	Vaginal PGE2 (gel)	IV oxytocin plus amniotomy			15	157	8	63	NA	NA	NA	NA
Parimkayala 2019	Oral misoprostol tablet (≥50mcg)	Buccal/sublingual misoprostol			0	60	1	60	NA	NA	NA	NA
Paungmora 2004	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)			0	76	1	75	NA	NA	NA	NA
Pennell 2009	Vaginal PGE2 (gel)	Foley catheter	Double balloon/Cook's catheter		21	113	22	110	13	107	NA	NA
PonMalar 2017	Placebo	Vaginal misoprostol (<50mcg)			0	63	0	63	NA	NA	NA	NA
Prager 2008	Vaginal PGE2 (gel)	Vaginal misoprostol (<50mcg)	Foley catheter		12	191	7	199	7	198	NA	NA
Prasad 1989	Placebo	Vaginal PGE2 pessary (slow release)			1	36	3	33	NA	NA	NA	NA
Putnam 2011	No treatment	Membrane sweeping			4	116	4	234	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Rahman 2013	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)			9	110	5	110	NA	NA	NA	NA
Ramsey 2003	Vaginal PGE2 pessary (slow release)	Intracervical PGE2	Vaginal misoprostol (≥50mcg)		1	38	3	35	1	38	NA	NA
Razaq 2011	Vaginal misoprostol (≥50mcg)	Nitric oxide			9	75	0	75	NA	NA	NA	NA
Rezaie 2016	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)			1	60	12	120	NA	NA	NA	NA
Roach 1997	No treatment	Vaginal PGE2 pessary (normal release)			20	105	22	96	NA	NA	NA	NA
Rouzi 2014	Vaginal PGE2 pessary (slow release)	Titrated (low dose) oral misoprostol solution			0	80	6	80	NA	NA	NA	NA
Rouzi 2017	Oral misoprostol tablet (<50mcg)	Titrated (low dose) oral misoprostol solution			2	73	4	73	NA	NA	NA	NA
Rowlands 2001	Vaginal PGE2 pessary (normal release)	Vaginal misoprostol (≥50mcg)			3	63	6	62	NA	NA	NA	NA
Rozenberg 2001	Vaginal PGE2 (gel)	Vaginal misoprostol (≥50mcg)			16	185	15	184	NA	NA	NA	NA
Rozenberg 2004	Vaginal PGE2 pessary (slow release)	Vaginal misoprostol (≥50mcg)			9	70	4	70	NA	NA	NA	NA
Sadi 2016	Placebo	Herbal supplements			6	25	1	25	NA	NA	NA	NA
Sahu 2004	Intracervical PGE2	Vaginal misoprostol (≥50mcg)			2	25	0	25	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Sanchez-Ramos 1992	Vaginal PGE2 (gel)	Laminaria			3	38	2	36	NA	NA	NA	NA
Sanchez-Ramos 1998	Vaginal PGE2 pessary (slow release)	Vaginal misoprostol (≥ 50 mcg)			8	115	8	108	NA	NA	NA	NA
Savithri 2018	Intracervical PGE2	Oral misoprostol tablet (< 50 mcg)			7	50	7	50	NA	NA	NA	NA
Sawai 1991	Placebo	Vaginal PGE2 (gel)			2	26	0	24	NA	NA	NA	NA
Sawai 1994	Placebo	Vaginal PGE2 pessary (normal release)			4	42	2	38	NA	NA	NA	NA
Schmitz 2014	Placebo	Nitric oxide			11	684	11	679	NA	NA	NA	NA
Seeras 1995	Vaginal PGE2 (gel)	Intracervical PGE2			5	31	4	37	NA	NA	NA	NA
Selo-Ojeme 2009	Amniotomy	IV oxytocin plus amniotomy			0	62	2	61	NA	NA	NA	NA
Shaheen 2013	Vaginal PGE2 (gel)	Buccal/sublingual misoprostol			0	53	1	53	NA	NA	NA	NA
Shakya 2010	Intracervical PGE2	Vaginal misoprostol (≥ 50 mcg)			0	31	0	35	NA	NA	NA	NA
Sharami 2014	Vaginal misoprostol (≥ 50 mcg)	Buccal/sublingual misoprostol			2	63	1	63	NA	NA	NA	NA
Sheela 2007	Intracervical PGE2	Vaginal misoprostol (< 50 mcg)	Oral misoprostol tablet (≥ 50 mcg)		0	50	1	50	0	50	NA	NA
Sheikher 2009	Vaginal misoprostol (< 50 mcg)	Oral misoprostol tablet (≥ 50 mcg)	Foley catheter		0	30	1	30	1	30	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Shetty 2001	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)			7	123	17	122	NA	NA	NA	NA
Shetty 2002a	Oral misoprostol tablet (≥50mcg)	Buccal/sublingual misoprostol			6	50	5	50	NA	NA	NA	NA
Shetty 2002b	Oral misoprostol tablet (≥50mcg)	Buccal/sublingual misoprostol			15	124	12	125	NA	NA	NA	NA
Shetty 2003	Vaginal misoprostol (<50mcg)	Oral misoprostol tablet (≥50mcg)			4	50	7	51	NA	NA	NA	NA
Shetty 2004	Vaginal PGE2 (tablet)	Oral misoprostol tablet (≥50mcg)			12	100	12	100	NA	NA	NA	NA
Silva-Cruz 1988	Vaginal PGE2 (gel)	IV oxytocin			0	25	0	25	NA	NA	NA	NA
Singh 2014	No treatment	Breast stimulation			4	99	6	100	NA	NA	NA	NA
Smith 2008	Placebo	Acupuncture			3	183	0	181	NA	NA	NA	NA
Soliman 2013	Vaginal misoprostol (≥50mcg)	Nitric oxide			4	65	2	65	NA	NA	NA	NA
Somirathne 2017	Oral misoprostol tablet (≥50mcg)	Foley catheter			3	91	2	89	NA	NA	NA	NA
Souzi 2018	Vaginal misoprostol (<50mcg)	Nitric oxide	Laminaria		0	32	0	32	0	32	NA	NA
Souza 2013	Vaginal misoprostol (<50mcg)	Titrated (low dose) oral misoprostol solution			4	100	5	100	NA	NA	NA	NA
Stitely 2000	Placebo	Vaginal misoprostol (<50mcg)			3	33	1	27	NA	NA	NA	NA
Tabowei 2003	Vaginal misoprostol (<50mcg)	Foley catheter			4	60	3	61	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Taher 2011	Vaginal PGE2 (tablet)	Vaginal PGE2 (gel)			2	83	1	82	NA	NA	NA	NA
Tan 2007	No treatment	Sexual intercourse			3	102	2	108	NA	NA	NA	NA
Tan 2010	Vaginal PGE2 pessary (normal release)	Vaginal misoprostol (<50mcg)			1	57	1	112	NA	NA	NA	NA
Tan 2013	Amniotomy	IV oxytocin plus amniotomy			0	101	1	105	NA	NA	NA	NA
Ten Eikelder 2016	Oral misoprostol tablet (≥50mcg)	Foley catheter			25	924	24	921	NA	NA	NA	NA
Tessier 1997	Vaginal PGE2 (gel)	Oral misoprostol tablet (≥50mcg)			5	132	3	135	NA	NA	NA	NA
Thaisomboon 2012	Oral misoprostol tablet (≥50mcg)	Titrated (low dose) oral misoprostol solution			0	32	0	32	NA	NA	NA	NA
Tulek 2018	IV oxytocin	Double balloon or Cook's catheter			4	40	1	40	NA	NA	NA	NA
Ugwu 2013	Vaginal misoprostol (<50mcg)	Foley catheter			2	45	3	45	NA	NA	NA	NA
Uludag 2005	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)			3	48	0	51	NA	NA	NA	NA
van Gemund 2004	Vaginal PGE2 (gel)	Vaginal misoprostol (<50mcg)			89	340	67	341	NA	NA	NA	NA
Wallstrom 2019	Titrated (low dose) oral misoprostol solution	Sustained release misoprostol insert			4	99	4	97	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Wang 2016	Vaginal PGE2 pessary (normal release)	Titrated (low dose) oral misoprostol solution			15	199	15	212	NA	NA	NA	NA
Weiss 2016	Placebo	Relaxin			4	32	4	40	NA	NA	NA	NA
Wing 1995a	Intracervical PGE2	Vaginal misoprostol (≥ 50 mcg)			11	67	13	68	NA	NA	NA	NA
Wing 1995b	Intracervical PGE2	Vaginal misoprostol (< 50 mcg)			23	137	17	138	NA	NA	NA	NA
Wing 1997	Vaginal PGE2 pessary (slow release)	Vaginal misoprostol (< 50 mcg)			27	98	30	99	NA	NA	NA	NA
Wing 1999	Vaginal misoprostol (< 50 mcg)	Oral misoprostol tablet (≥ 50 mcg)			31	110	29	110	NA	NA	NA	NA
Wing 2000a	Placebo	Mifepristone			11	83	13	97	NA	NA	NA	NA
Wing 2000b	Vaginal misoprostol (< 50 mcg)	Oral misoprostol tablet (≥ 50 mcg)			36	113	34	121	NA	NA	NA	NA
Wing 2004	Oral misoprostol tablet (≥ 50 mcg)	IV oxytocin			11	110	10	88	NA	NA	NA	NA
Wing 2008	Vaginal PGE2 pessary (slow release)	Sustained release misoprostol insert			33	436	50	871	NA	NA	NA	NA
Wing 2013	Vaginal PGE2 pessary (slow release)	Sustained release misoprostol insert			71	680	61	678	NA	NA	NA	NA
Yelikar 2015	Placebo	Mifepristone			2	50	4	50	NA	NA	NA	NA
Yenuberi 2016	Vaginal misoprostol (< 50 mcg)	Oral misoprostol tablet (≥ 50 mcg)			10	380	11	383	NA	NA	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 4 intervention	Arm 1 event	Arm 1 total	Arm 2 event	Arm 2 total	Arm 3 event	Arm 3 total	Arm 4 event	Arm 4 total
Yildirim 2010	No treatment	Membrane sweeping			5	167	10	179	NA	NA	NA	NA
Zahran 2009	Vaginal misoprostol (≥50mcg)	Buccal/sublingual misoprostol			5	240	4	240	NA	NA	NA	NA
Zeteroglu 2006a	Vaginal misoprostol (≥50mcg)	IV oxytocin			3	32	2	32	NA	NA	NA	NA
Zeteroglu 2006b	Vaginal misoprostol (≥50mcg)	IV oxytocin			2	50	2	50	NA	NA	NA	NA
Zvandasara 2008	Vaginal misoprostol (≥50mcg)	Titrated (low dose) oral misoprostol solution			15	65	11	69	NA	NA	NA	NA

1 NA: not available; EASI: extra-amniotic saline infusion

2 ^^ Foley used in both groups

3

4

5

6

7

8

9

10

1 D11 - Epidural outcome data

2 Table 12: Evidence table for epidural outcome

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 1 events	Arm 1 total	Arm 2 events	Arm 2 total	Arm 3 events	Arm 3 total
Allott 1993	No treatment	Membrane sweeping		20	96	19	99	NA	NA
Andersen 2013	No treatment	Membrane sweeping	Acupuncture	23	100	29	103	28	104
Bartusevicius 2006	Vaginal misoprostol (<50mcg)	Buccal/sublingual misoprostol		35	70	30	70	NA	NA
Bell 1993	Placebo	Relaxin		10	22	8	18	NA	NA
Bennett 1998	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)		61	102	65	104	NA	NA
Bollapragada 2009	Placebo	Nitric oxide		120	173	116	177	NA	NA
Boulvain 1998	No treatment	Membrane sweeping		69	99	75	99	NA	NA
Cahill 1988	Vaginal PGE2 (tablet)	Laminaria		3	22	2	20	NA	NA
Caliskan 2005	Vaginal misoprostol (≥50mcg)	Buccal/sublingual misoprostol		13	80	16	80	NA	NA
Cammu 1998	No treatment	Membrane sweeping		52	138	53	140	NA	NA
Cardozo 1986	No treatment	Vaginal PGE2 pessary (normal release)		68	207	68	195	NA	NA
Carlan 2001	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)		314	501	317	503	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 1 events	Arm 1 total	Arm 2 events	Arm 2 total	Arm 3 events	Arm 3 total
Carlan 2002	Vaginal misoprostol (≥ 50 mcg)	Buccal/sublingual misoprostol		59	80	57	77	NA	NA
Chuck 1995	Intracervical PGE2	Vaginal misoprostol (≥ 50 mcg)		22	50	14	49	NA	NA
Chung 2003	Vaginal misoprostol (< 50 mcg)	Foley catheter		39	49	38	54	NA	NA
Colon 2005	Vaginal misoprostol (< 50 mcg)	Oral misoprostol tablet (≥ 50 mcg)		95	111	79	93	NA	NA
Craft 1971	IV oxytocin	IV prostaglandin		15	15	15	15	NA	NA
Crane 1997	No treatment	Membrane sweeping		32	74	50	76	NA	NA
Cromi 2011	Vaginal PGE2 pessary (slow release)	Foley catheter		71	132	211	265	NA	NA
Cromi 2012	Vaginal PGE2 pessary (slow release)	Double balloon/Cook's catheter		63	103	87	105	NA	NA
Dällenbach 2003	Vaginal PGE2 (gel)	Oral misoprostol tablet (< 50 mcg)		80	100	76	100	NA	NA
Danielian 1999	Vaginal PGE2 (gel)	Vaginal misoprostol (≥ 50 mcg)		22	106	16	105	NA	NA
De Miranda 2006	No treatment	Membrane sweeping		14	367	17	375	NA	NA
Dodd 2006	Vaginal PGE2 (gel)	Titrated (low dose) oral misoprostol solution		229	376	243	365	NA	NA
El-Shawarby 2006	Vaginal PGE2 (gel)	Vaginal PGE2 pessary (slow release)		12	38	13	34	NA	NA
El-Torkey 1992	No treatment	Membrane sweeping		18	32	13	33	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 1 events	Arm 1 total	Arm 2 events	Arm 2 total	Arm 3 events	Arm 3 total
Ferguson 2002	Vaginal misoprostol (≥50mcg)	IV oxytocin		34	51	35	53	NA	NA
Ferraiolo 2010	Vaginal PGE2 (gel)	Vaginal PGE2 pessary (slow release)		35	72	52	79	NA	NA
Fonseca 2008	Vaginal misoprostol (<50mcg)	IV oxytocin		74	164	65	163	NA	NA
Frydman 1991	Placebo	Mifepristone		49	60	44	60	NA	NA
Gagnon-Gervais 2012	IV oxytocin	IV oxytocin plus amniotomy		63	72	66	71	NA	NA
Gattas 2020	Vaginal misoprostol (<50 mcg)	Buccal/sublingual misoprostol		1	100	2	98	NA	NA
Gaudet 2008	Placebo	Acupuncture		7	7	8	9	NA	NA
Gherman 2001	Vaginal PGE2 (gel)	Oral misoprostol tablet (≥50mcg)		26	30	23	28	NA	NA
Gilson 1996	No treatment	Laminaria		74	128	65	112	NA	NA
Greybush 2001	Vaginal misoprostol (<50mcg)	Foley catheter		56	65	54	71	NA	NA
Gribel 2011	Vaginal misoprostol (<50mcg)	Acupuncture		28	32	25	35	NA	NA
Haas 2019	Vaginal misoprostol (<50 mcg)	Buccal/sublingual misoprostol		127	152	122	148	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 1 events	Arm 1 total	Arm 2 events	Arm 2 total	Arm 3 events	Arm 3 total
Hokkila 2019	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)		102	133	114	135	NA	NA
Hoppe 2016	Foley catheter	Double balloon/Cook's catheter		38	48	43	50	NA	NA
Hosli 2008	Vaginal PGE2 (gel)	Vaginal misoprostol (≥50mcg)		34	55	31	52	NA	NA
Irion 1998	Vaginal PGE2 (gel)	Intracervical PGE2		87	125	90	122	NA	NA
Johnson 1985	Vaginal PGE2 (gel)	Laminaria		34	40	31	40	NA	NA
Jozwiak 2011	Vaginal PGE2 (gel)	Foley catheter		120	408	122	411	NA	NA
Jozwiak 2013	Vaginal PGE2 pessary (slow release)	Foley catheter		29	119	30	107	NA	NA
Jozwiak 2014	Vaginal misoprostol (<50mcg)	Foley catheter		17	64	19	56	NA	NA
Levine 2016	Vaginal misoprostol (<50mcg)	Foley catheter		111	120	114	123	NA	NA
Lim 2018	Vaginal PGE2 (tablet)	Double balloon/Cook's catheter		29	52	18	31	NA	NA
Lo 1994	Vaginal PGE2 (tablet)	IV oxytocin plus amniotomy		0	101	0	99	NA	NA
Lo 2006	IV oxytocin plus amniotomy	Buccal/sublingual misoprostol		5	25	6	25	NA	NA
MacKenzie 1979	Placebo	Vaginal PGE2 (gel)	PGF2 gel	13	16	7	16	11	16

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 1 events	Arm 1 total	Arm 2 events	Arm 2 total	Arm 3 events	Arm 3 total
MacLennan 1979	Placebo	PGF2 gel		15	40	12	40	NA	NA
MacLennan 1980b	Placebo	PGF2 gel		15	30	21	60	NA	NA
MacLennan 1989	Vaginal PGE2 (gel)	IV oxytocin plus amniotomy		42	164	52	154	NA	NA
Mahmood 1995	Vaginal PGE2 (gel)	Amniotomy		9	130	17	130	NA	NA
Martin 1989	No treatment	Laminaria		2	10	4	12	NA	NA
McKenna 2004	Placebo	Vaginal misoprostol (<50mcg)		22	26	20	24	NA	NA
McLaren 1987	Vaginal PGE2 (tablet)	Vaginal PGE2 pessary (slow release)		4	12	6	12	NA	NA
Mei-Dan 2014	Foley catheter + EASI	Double balloon/Cook's catheter + EASI		82	126	44	60	NA	NA
Mercer 1995	IV oxytocin	IV oxytocin plus amniotomy		78	103	86	106	NA	NA
Miller 1991	Vaginal PGE2 (gel)	Vaginal PGE2 pessary (slow release)		0	20	2	20	NA	NA
Modlock 2010	Placebo	Acupuncture		24	57	24	60	NA	NA
Mollart 2016	No treatment	Acupuncture		11	22	10	22	NA	NA
Mukhopadhyay 2002	Vaginal PGE2 (gel)	Vaginal PGE2 pessary (slow release)		40	50	36	45	NA	NA
Mundle 2018	Oral misoprostol tablet (<50mcg)	Foley catheter		124	302	150	300	NA	NA
Murphy 1980	Placebo	PGF2 gel		19	100	21	165	NA	NA
Murray 1995	Vaginal PGE2 (tablet)	Vaginal PGE2 (gel)		84	100	81	100	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 1 events	Arm 1 total	Arm 2 events	Arm 2 total	Arm 3 events	Arm 3 total
Nassar 2006	Vaginal misoprostol (≥50mcg)	Buccal/sublingual misoprostol		61	85	68	85	NA	NA
O'Brien 1995	Placebo	Vaginal PGE2 (gel)		35	50	29	50	NA	NA
Omar 2013	No treatment	Sexual intercourse		130	576	141	574	NA	NA
Osman 2006	Vaginal PGE2 (gel)	Nitric oxide		136	198	140	196	NA	NA
Pandis 2001	Vaginal PGE2 (gel)	Vaginal misoprostol (≥50mcg)		89	225	80	210	NA	NA
Pennell 2009	Vaginal PGE2 (gel)	Foley catheter	Double balloon/Cook's catheter	92	113	90	110	89	107
Prager 2008	Vaginal PGE2 (gel)	Vaginal misoprostol (<50mcg)	Foley catheter	117	191	120	199	145	198
Reinhard 2014	Vaginal PGE2 (tablet)	Intracervical PGE2		10	19	9	20	NA	NA
Rowlands 2001	Vaginal PGE2 pessary (normal release)	Vaginal misoprostol (≥50mcg)		29	47	21	49	NA	NA
Rozenberg 2001	Vaginal PGE2 (gel)	Vaginal misoprostol (≥50mcg)		173	185	169	184	NA	NA
Rozenberg 2004	Vaginal PGE2 pessary (slow release)	Vaginal misoprostol (≥50mcg)		65	70	63	70	NA	NA
Saad 2019	Foley catheter	Laminaria		188	209	174	208	NA	NA
Saleh 1975	Amniotomy	IV oxytocin plus amniotomy		50	50	50	50	NA	NA
Salim 2011	Foley catheter	Double balloon/Cook's catheter		66	145	78	148	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 1 events	Arm 1 total	Arm 2 events	Arm 2 total	Arm 3 events	Arm 3 total
Sciscione 1999	Intracervical PGE2	Foley catheter		67	72	65	77	NA	NA
Sciscione 2001	Vaginal misoprostol (≥50mcg)	Foley catheter		49	53	49	58	NA	NA
Seeras 1995	Vaginal PGE2 (gel)	Intracervical PGE2		11	30	15	35	NA	NA
Selo-Ojeme 2009	Amniotomy	IV oxytocin plus amniotomy		34	62	32	61	NA	NA
Shechter-Maor 2015	Vaginal PGE2 pessary (slow release)	Double balloon/Cook's catheter		22	26	23	26	NA	NA
Shetty 2001	Vaginal misoprostol (≥50mcg)	Oral misoprostol tablet (≥50mcg)		45	123	55	122	NA	NA
Smith 2008	Placebo	Acupuncture		83	158	89	163	NA	NA
Soliman 2013	Vaginal misoprostol (≥50mcg)	Nitric oxide		22	65	17	65	NA	NA
Souza 2013	Vaginal misoprostol (<50mcg)	Titrated (low dose) oral misoprostol solution		0	100	1	100	NA	NA
Steer 1976	IV oxytocin	IV oxytocin plus amniotomy		6	8	6	12	NA	NA
Taher 2011	Vaginal PGE2 (tablet)	Vaginal PGE2 (gel)		49	83	57	82	NA	NA
Tan 2007	No treatment	Sexual intercourse		26	102	35	108	NA	NA
Tan 2013	Amniotomy	IV oxytocin plus amniotomy		10	101	3	105	NA	NA

Trial Name	Arm 1 intervention	Arm 2 intervention	Arm 3 intervention	Arm 1 events	Arm 1 total	Arm 2 events	Arm 2 total	Arm 3 events	Arm 3 total
Ten Eikelder 2016	Oral misoprostol tablet ($\geq 50\text{mcg}$)	Foley catheter		386	924	421	921	NA	NA
Tomlinson 2001	Vaginal PGE2 (gel)	Vaginal PGE2 pessary (slow release)		11	34	10	35	NA	NA
Tromans 1981	Vaginal PGE2 (gel)	Oestrogens		24	30	24	30	NA	NA
van Gemund 2004	Vaginal PGE2 (gel)	Vaginal misoprostol ($< 50\text{mcg}$)		74	340	69	341	NA	NA
Wallstrom 2019	Titrated (low dose) oral misoprostol solution	Sustained release misoprostol insert		88	99	79	97	NA	NA
Wing 2013	Vaginal PGE2 pessary (slow release)	Sustained release misoprostol insert		628	680	607	678	NA	NA
Witter 1992	Placebo	Vaginal PGE2 pessary (slow release)		22	33	28	39	NA	NA
Wong 2002	No treatment	Membrane sweeping		11	60	11	60	NA	NA
Young 2020	Vaginal PGE2 (gel)	Vaginal misoprostol ($< 50\text{mcg}$)	Oral misoprostol tablet ($\geq 50\text{mcg}$)	101	172	89	172	90	167

1 NA: not available

2 EASI: extra-amniotic saline infusion

3